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ABSTRACT 
SYNTHESIS OF UNSYMMETRICAL PENDANT-ARMED AND PHOSPHONIC 
ACID-PENDANT-ARMED CROSS-BRIDGED TETRAAZAMACROCYCLES 
by 
Dannon Jason Stigers 
University of New Hampshire, December 2008 
The synthesis of a variety of cross-bridged tetraazamacrocycles bearing 
phosphonate pendant arms and their corresponding phosphonic acid derivatives as well as 
their Cu(II) complexes are presented. The half-life of decomplexation of Cu(II)-51 in 5M 
HC1 at 90 °C was found to be 3.8 hours. Ligand 51 showed faster complexation kinetics 
relative to known cross-bridged tetraazamacrocycles bearing ionizable pendant 
.ISL N f P-OH 
OH 
51 
arms. The biodistribution of 64Cu(II)-51 was studied in male rats and indicated an 
improved blood and liver clearance and higher bone retention of 64Cu(II)-51 relative to 
64Cu(II)-10. 
The formation of a single pendant-armed cross-bridged cyclam is presented 
through an unusual single alkylation of cross-bridged cyclam. Several experiments were 
xvm 
implemented to probe the origin of the selectivity of the reaction including computational 
studies, ID !H NMR and 2D NMR experiments. Monoamide ligand 64 was used as a 
r OcT N H 2 
NH N 
64 
springboard for the formation of several unsymmetrical pendant-armed cross-bridged 
cyclams. 
Attempts were made toward the synthesis of two potential bifunctional chelators 
for radiopharmaceuticals, each bearing only one phosphonic acid pendant arm and 
O C T 0 " r-'s NCT^I ° 
^ T l - P ^ N N O - P ^ N N N °
H 
78 86 
one free carboxylate for conjugation to somatostatin analogues. 
xix 
Chapter I 
SYNTHESIS OF CROSS-BRIDGED TETRAAZAMACROCYCLES BEARING 
PHOSPHONIC ACID PENDANT ARMS 
I. Introduction 
Cyclic polyamines are an interesting class of compounds that have attracted a 
great deal of attention in recent years. Specifically, the coordination chemistry 
community has been interested in the study of such compounds due to the increased 
kinetic inertness and thermodynamic stability of their small metal cation complexes 
compared to their acyclic analogues. " These effects have allowed many variations of 
such species to be used in a broad range of applications such as synthetic ribonucleases11, 
11 19 T i i 
luminescent sensors , contrast agents , radiopharmaceuticals ' and models for 
biomolecules.14 
The increase in thermodynamic stability has been attributed, in part, to the 
macrocyclic effect. ' ' In order for an acyclic compound to coordinate a metal, its 
donor atoms must adopt a specific geometry around the ion in order to fill its inner 
coordination sphere. Macrocycles, on the other hand, have a pre-arranged set of donor 
atoms, thus lowering the entropic barrier of formation and providing a more stable 
complex in comparison to their acyclic analogues. 
A large portion of recent literature has focused on the design, synthesis and 
coordination chemistry of tetraazamacrocyclic systems, particularly derivatives of cyclen 
and cyclam17 (Figure 1). Extensive work on these ligands alone has shown that they 
1 
adopt a range of configurations when complexed to a metal cation. In 1964, Bosnich and 
1 X 
coworkers developed a nomenclature for the various configurational geometries of 
cyclam when complexed to a small metal cation (Figure 2). Due to the flexible nature of 
the macrocyclic ring, complexes of cyclam tend to adopt a range of configurational 
geometries in both the solid state and in solution. Most cyclam complexes exist in the 
trans-I, trans-III or cis-V coordination configurations in the solid state,19"21 while in 
solution, a number of configurational diastereomers can exist in equilibrium.22'23 This 








Figure 1: Cyclen (1) and Cyclam (2). 
V 
< / ^ \ > «' 1 ^ \ ^ / |N< ^ 
Figure 2: Bosnich-Tobe nomenclature of coordination geometries of six cyclam 
complexes. 
2 
In order to fully envelope an octahedral metal, a cyclic polyamine bearing only 
four donor atoms must possess further functionality. Typically, this functionality is added 
to the amine nitrogens, however, ligands that are "C-functionalized" have been studied as 
well. ' The term "pendant arm" refers to additional donor groups attached to the 
periphery of a macrocyclic chelator. They serve several purposes: to fill the first 
coordination sphere of a metal complexed by the ligand, to balance the positive charge of 
the metal cation and to act as a site for further chemistry.17 Syntheses and coordination 
chemistries of pendant-armed polyamines have been extensively studied and reviewed;14' 
1 *7 OA 0f\ "Xfi 
' ' ' a small sample of these ligands bearing four pendant arms is shown in Figure 3. 
Specifically, 1,4,7,10-tetraazacyclododecane-l,4,7,10-tetraacetate (DOTA) (3) and 
1,4,8,1 l-tetraazacyclotetradecane-l,4,8,ll-tetraacetate (TETA) (4) have received a great 
"1*7 TQ 
deal of interest with respect to their use as chelators for radiopharmaceuticals, " in both 
imaging and therapy applications. 
f J R = CH2CH2CONH2 f J f J 
r^N N^r, o-rurunu e o O c J ^ N N ^ X O O Q Q O O C ^ N N . . C O O 0 
R I J R K-OH2OH2UH ^ ^ ^ J ^^ I J 
* 'm 
m=n=0,1 ^ 4 
Figure 3: Some known tetra-substituted azamacrocyclic systems; common pendant-
armed ligands DOTA (3) and TETA (4). 
The use of radioisotopes of Cu, Ga, In, and Tc in imaging applications has created 
a need for strong bifunctional chelators for complexing these metals to biological 
molecules.40'41 Both DOTA and TETA act as bifunctional chelators (BFCs) in 
radiopharmaceuticals; they simultaneously bind to a radioactive metal and can be 
covalently linked to a biomolecule. The binding of a BFC to copper must remain intact in 
vivo in order for the radioisotope to reach the desired target, thus the factors that support 
demetallation must be studied in order to optimize performance. While both the 
thermodynamic and kinetic stabilities of BFC complexes determined in vitro are useful 
gauges for assessing the viability of a ligand for use in radiopharmaceuticals, the kinetic 
inertness of copper(II) complexes has been shown to be more predictive of in vivo 
stability.40'42 Complexes of ligands such as TETA demonstrate a higher kinetic inertness 
towards demetallation relative to complexes of acyclic analogues such as EDTA 
(ethylenediamine tetraacetic acid).40'42'43 However, Anderson and coworkers have shown 
with model experiments that Cu(II) dissociates from TETA in vivo and binds strongly to 
proteins such as superoxide dismutase, found in rat livers, limiting its use as an effective 
BFC in imaging agents in humans.44 Thus in order to utilize pendant-armed 
azamacrocycles in radiopharmaceuticals, BFCs that form kinetically inert complexes in 
vitro must also resist transchelation to peptides in vivo. 
In 1980, Wainwright et al. developed a synthetic method to add reinforcement to 
macrocyclic tetraamines without losing the saturated character of the ring (Figure 4) by 
joining two adjacent nitrogens with an ethylene bridge.45'46 By limiting the flexibility of 
,N HN. N HN. 
k h T H h r ^ N HN 
5 6 
Figure 4: Reinforced chelators designed by Wainwright and coworkers with two non-
adjacent nitrogens bound through an ethylene bridge. 
4 
the macrocycle, only the trans configurations of the ligand were observed in various 
Ni(II) complexes.45'46 Bridged cyclen 5, also studied by Hancock and coworkers, has 
shown a dramatic enhancement in the formation constants of certain transition metal 
complexes when compared to cyclen.47'48 Weisman, Wong and coworkers subsequently 
synthesized ligands where two non-adjacent nitrogens are bridged by an ethylene "cross-
bridge"49' 50 (Figure 5). It was anticipated that this type of bridging would allow the 
ligand to adopt several low energy conformations where "all four nitrogen lone pairs 
were convergent upon a cleft"50, suitable for cis-V coordination of small metal cations 
(Figure 6). The Cu(II) complex of 8 showed that the ligand adopted a distorted 
[2323]/[2323] diamond lattice conformation.49 
N HN N HN. 
NH N NH N 
7 8 
Figure 5: Ligands synthesized by Weisman, Wong and coworkers: cross-bridged cyclen 
(CB-cyclen) and cross-bridged cyclam (CB-cyclam) 
AN JH* 
Figure 6: Three-dimensional representation of CB-cyclam (8) with all four nitrogen lone 
pairs convergent upon a molecular cleft. The ligand adopts a cis-\ folded configuration 
when complexed to a small metal cation. 
5 
The parent cross-bridged ligands, 7 and 8, have been converted to a number of 
A^TV'-difunctionalized pendant-arm derivatives, " with the most attention directed 
towards carboxymethyl pendant arms. The free carboxylate in these ligands serves to 
both fill the first coordination sphere of the metal and to neutralize the charge of the 
overall complex. The Cu(II) complexes of both CB-D02A (9) and CB-TE2A (10) 
(Figure 7) have been prepared and characterized.51'55 The solid state structures of both 
Cu-CB-D02A and Cu-CB-TE2A show N4O2 donor sets with both carboxylates bound to 
the metal. However, only in Cu-CB-TE2A does the ligand fully encapsulate the metal, as 
the cleft of CB-D02A is a bit smaller.51 
9 10 
Figure 7: Ligands CB-D02A (9) and CB-TE2A (10). 
In order to assess the potential of cross-bridged ligands as BFCs in 
radiopharmaceuticals, the in vivo behaviors of the corresponding 64Cu(II) complexes 
were determined through biodistribution studies in rats and compared with those of non-
cross-bridged analogues. 64Cu-CB-TE2A was found to have the most efficient rat liver 
and blood clearance when compared to that of 64Cu-CB-D02A, 64Cu-TETA and 64Cu-
D02A.52'55 These data were consistent with metabolism studies that confirmed greater in 
vivo stability correlated with decreased transchelation of 64Cu(II) to proteins.55 Weisman, 
6 
Wong and coworkers developed a convenient, yet qualitative assay to determine in vitro 









< 1 min 
11.8(2) min 
Table 1: Half lives of various Cu(II) complexes at 90 °C in 5 M HC1. 
Cu(II) complexes under pseudo-first order conditions in 5M HO.56 These kinetic data 
(Table 1) coupled with resistance towards Cu(II)/Cu(I) reduction and subsequent Cu(I) 
loss were found to correlate well with the results of the biodistribution study confirming 
that CB-TE2A was a superior BFC for radio-imaging.56 
Both TETA and CB-TE2A were evaluated as BFCs of 64Cu in bioconjugates of 
the somatostatin analogue, tyrosine-3-octreotate (Y3-TATE), for use in positron emission 
tomography (PET) to image neuroendocrine tumors with somatostatin receptors (Figure 
r^ H 
H O O C ^ N i^^N-D-Ple-Cys-Tyr-D-Trp-Lys-Thr-Cys-ThrtOH) 
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Figure 8: Structures of TETA-Y3-TATE and CB-TE2A-Y3-TATE. 
7 
8). The Cu(II) complexes of these bioconjugates showed similar affinity for 
somatostatin receptors in vitro, however a 4.4x greater tumor uptake was detected with 
64Cu-CB-TE2A-Y3-TATE than with 64Cu-TETA-Y3-TATE at 4 hours post injection.57 
These data coupled with the differences in biodistribution of 64Cu-CB-TE2A-Y3-TATE 
and 64Cu-CB-TETA-Y3-TATE confirmed that the cross-bridged type ligands are much 
more suitable BFCs for radiolabeling biomolecules and as such require further study. 
8 
II. Background 
A. Cyclic Polyamines bearing q-Aminophosphonic Acids 
a-Aminophosphonic acids represent an important class of biologically relevant 
compounds due to their resemblance to naturally occurring amino acids and have been 
extensively reviewed (Figure 9).58"77 a-Aminophosphonic acids differ from their a-amino 
© 9 © "ff 




Figure 9: Simple amino acid glycine, 11 and phosphonic acid analogue 12. 
acid analogues in several ways: the phosphorus is tetrahedral while the carbonyl carbon is 
trigonal planar, the phosphonic acid functionality of aminomethylphosphonic acid is 
more acidic (pKai(12) = 0.5, pKa2(12) = 5.38)78 than the acetic acid functionality of 
glycine (pKa(ll) = 2.36) , the phosphorus atom is larger than the carbon and an 
additional hydroxyl group is present in the phosphonic acid.64'77 These compounds 
exhibit very little mammalian toxicity and efficiently mimic amino acids, making them 
important antimetabolites that can compete with their carboxylic counterparts for active 
sites on cell receptors.64 Their unique properties allow them to encompass a broad range 
of applications. Aminophosphonic acids have been used as agrochemicals since 1954. 
AMPA (aminomethylphosphonic acid), 12, acts in similar ways to glycine in suppressing 
the growth of tobacco rootlets.77 Derivatives of aminophosphonic acids have been 
9 
used as antithrombotic agents, which aid in the breakdown of thrombin, a biological 
compound necessary for blood clotting.77'79 Open chain aminopolyphosphonates act as 
multidentate ligands for selective cation complexation in several applications such as 
corrosion inhibitors80and removal of metal overload from organisms.81 Most notably, 
metal complexes of aminophosphonates have attracted interest due to their biomedical 
applications in anti-cancer agents,82'83 NMR imaging agents84 and 
radiopharmaceuticals. 
The coordination chemistry of tetraazamacrocyclic aminophosphonates has been 
studied extensively due to their ability to form both very thermodynamically stable and 
kinetically inert complexes.86 The first such compound, DOTP (13, Figure 10) (H8-
DOTP = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylene phosphonic acid) 
was originally synthesized in 1984 ; a modified synthesis was published later by Sherry 
^ / — \ ^ "-.. ! , 
2
"03P N N P032" ©,N \ y<? ©,N I I / P^ I C-
2
" ° 3 P \ / N N^/P032" H->. / \ H» . / 
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13 
Figure 10: Structure of DOTP (13); Representations of hydrogen bonding in 
aminophosphonate and amino acid derivatives.77 
and coworkers. A comparison of the pKa's of the first protonation of ligand 3 and 
ligand 13 has been reported86 as shown in Scheme 1. The first pKa of 3 (11.74) is lower 
than the first pKa of 13 (13.7) by two orders of magnitude indicating 13 is a stronger 
base. This increased basicity was directly related to the increased thermodynamic 
stability of the corresponding Cu(II) complexes. The explanation proposed by Sherry 
stated that an electrostatic effect of the double negative charge on the neighboring 
10 
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Scheme 1: Protonation of ligands 3 and 13. 
phosphonate group increased the electron density of the amine nitrogen, thus increasing 
its basicity through induction.86'89 An alternative explanation of the increased basicity 
could stem from the increased hydrogen bonding ability of the phosphonate versus the 
acetate90 (Figure 10). Furthermore, the C-P and P-0 bond lengths in the phosphonate 
functionality are longer than the C-C and C-0 bond lengths of the acetate. This could 
allow for a stronger hydrogen bond between the negatively charged oxygen and the 
ammonium proton and potentially decrease the strain in the H-bonded ring (Figure 10). 
Azamacrocycles bearing acetate pendant arms have been known to possess this type of 
intramolecular hydrogen bond. ' Extensive study of DOTP as a chelator for 
lanthanides has been conducted by Sherry93"96 for use as ligands for MRI contrast agents. 
Anderson and coworkers, in collaboration with Sherry, have measured the 
biodistribution of three Cu(II) complexes of cyclen ligands bearing methylene 
phosphonic acid pendant arms in an investigation of their possible use in 
radiopharmaceuticals.52 The 64Cu complexes of DOTP (13), D02P (14) 
11 
I \ / \ , /—\ ^ 
.NH N P032" NH N P032" 
"OsPv^N HN 2 0 3 P J ^ N N^/P032-
14 15 
Figure 11: Ligands D02P (14) and D03P (15). 
(1,4,7,10-tetraazacyclododecane-1,7-di(methylenephosphonic acid)) and D03P (15) 
(l,4,7,10-tetraazacyclododecane-l,4,7-tri(methylenephosphonic acid)) were all found to 
have significant uptake in bone, likely due to the binding of the methylenephosphonate 
groups to hydroxyapatite (Figure ll).97 Of the three, 64Cu-D02P possessed the fastest 
blood and liver clearance; 64Cu-D03P and 64Cu-DOTP showed higher liver uptake, 
possibly due to the large negative charge of the complexes under physiological 
conditions.97 Metabolism studies of 64Cu-D02P suggested that D02P can be used as a 
BFC for radiopharmaceuticals.97 
In 2000, Hermann and coworkers synthesized a cyclam ligand bearing two 
methylenephosphonic acids (Figure 12).90 The solid state structure of 1,8-disubstituted 
2 ^c\ *une 
2
" 0 3 P ^ N HN H O - P ^ N H2N® C J ©6 r j o 
NH Nd.P03 2- ©NH2 N^.P-OH 
16 H4-I6 
Figure 12: Ligands TE2P (16) and H4-TE2P (H4-I6). 
H4-TE2P (H4-I6) indicated the presence of two intramolecular hydrogen bonds, between 
the negatively charged phosphonate oxygen and an ammonium proton on nitrogen 4. The 
hydrogen bond was also present in solution, confirmed by values of protonation 
12 
constants, titration experiments and VT-NMR. The source of the increased basicity 
reported by Sherry and Hermann of cyclic polyamines bearing phosphonic acid pendant 
arms relative to acetate pendant arms can be explained by this intramolecular hydrogen 
bond but not by the dispersion of electron density by the highly charged phosphonate, an 
explanation reported previously.86'89 At 25 °C, the Cu(II) complex of TE2P was found to 
no 
exist with pentacoordinated Cu(II) with the cyclam ring in the trans-l configuration. 
When heated, the complex isomerizes to a hexacoordinate isomer with the cyclam ring in 
QO 
the trans-Ill configuration. The kinetic acid decomplexation data of the trans-Ill 
complex indicated a half-life of approximately seven months in 5M HCIO4 at 25 °C.98 
This impressive kinetic inertness makes TE2P an attractive candidate as a BFC for 
radioimaging. 
B. Synthesis of Phosphonic Acid Pendant Arms on Cyclic Polyamines 
The direct synthesis of a-aminophosphonic acids was first reported by Moedritzer 
in 1965 through a Mannich-like mechanism." Primary and secondary amines were 
allowed to reflux in the presence of aqueous formaldehyde, phosphorous acid and 6M 
HC1 and the isolated aminophosphonic acids were recovered in a wide range of yields 
(35-75%)." Hg-DOTP (Hg-13), the first polyamine bearing phosphonic acid pendant arms 
QQ 
was synthesized using these conditions. Subsequently, Sherry and coworkers were able 
to optimize the synthesis of Hg-DOTP by substituting dry paraformaldehyde for aqueous 
formaldehyde. The isolated ligand required no further purification and was obtained in 
good yield (Scheme 2), however the harsh conditions limit the use of this procedure to 
Q Q 
systems with sensitive functionality. 
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Scheme 2: Synthesis of H8-DOTP (H8-13). 
An alternative approach to the formation of aminophosphonic acids involves the 
formation of phosphonate esters followed by ester cleavage to yield the acid. Formation 
of a-aminophosphonates and their transformation to a-aminophosphonic acids has been 
C o £li~y I-II-I i f\f\ i n c 
extensively reviewed. ' ' ' SN2 displacement of substituted chloro- and 
bromomethanamines has recently been reported (Scheme 3).106'107 The reaction was 
P(OEt)3 ° 
R 2 N ^ C I ^ R2N.^.P-OEt 
OEt 
Scheme 3: Formation of a-aminophosphonic acid ethyl ester. 
reported to be carried out in high yield and purity, however formation of either chloro- or 
bromomethanamines on cyclic polyamines would likely cause polymerization or lead to 
aminals. Parker and coworkers have recently reported a novel synthesis of 
aminophosphonate esters by the addition of diethyl-2-bromoethylphosphonate to cyclen 
O 
/ \ Biv .P-OEt / \ 
NH HN OEt r^NH H N > 
C J ** L J ° 
NH HN LiOH, ^ N H N ^ P - O E t \ / EtOH / H20 \ / ~ O E t 
1 17 
Scheme 4: Formation of ligand 17. 
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(1) with LiOH (Scheme 4). 108 The procedure was selective for the formation of only a 
single pendant arm, but a low yield (43%) makes this approach not very attractive. 
The more common approach towards formation of aminophosphonates involves 
the use of trialkyl109"119 or dialkyl90'106'12<M27 phosphites and aqueous formaldehyde or 
paraformaldehyde. Sherry reported the synthesis of a 1,7-di-protected cyclen derivative 
with triethyl phosphite and paraformaldehyde to form ligand 19 (Scheme 5).115 The crude 
material was purified on a silica gel column in 75% yield. Sherry has also used these 
O 
NH N'C b Z
 P ( 0 E t ) 3 \ ° ; EtO-P^N N' 
I J ** Et0 k J % 
^ N HN 75% yield _ ^N N f .P-OEt Cbz' \ / Cbz \ / ^ ^ 
18 19 
Scheme 5: Formation of di-pendant armed ligand 19. 
conditions for the formation of a trifluoroethyl ester derivative of 19, by substituting 
tris(2,2,2-trifluoroethyl) phosphite for triethyl phosphite, in order to utilize 19F NMR for 
1 TO 
the determination of the solution structure of various lanthanide complexes. Hermann 
and coworkers have reported the synthesis of a series of bis(methylphosphonate) esters 
with the use of diethyl phosphite and paraformaldehyde (Scheme 6).90 The reactions 
N HNL X^ V / ^N NC P-OEt 
> OEt N ' S > i 
I *- O I I OEt 
vlH l < Benzene, reflux
 E t 0 _ j i ^ N N ^ 
20 21 
Scheme 6: Formation of phosphonates ester 21 with diethyl phosphite. 
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were run in benzene at reflux in order to azeotropically remove the water produced, 
forcing the equilibrium towards product formation. 
The hydrolysis of an alkylphosphonate can be carried out under basic or acidic 
conditions. In the case of ethyl phosphonates, basic hydrolysis yields exclusively 
115 177 178 17Q 
partially-hydrolyzed phosphonates. ' ' ' There are several distinct mechanisms 
possible for hydrolysis in base. In one mechanism, the hydroxide displaces an alkoxide 
by SN2 attack at the phosphorus atom ~ ' ~ and as another equivalent of hydroxide 
removes the new acidic proton from the phosphonate, the negative charge built up around 
the phosphorus makes further attack of hydroxide at the phosphorus atom a higher 
energetic process (Figure 13). In a second possible mechanism, hydroxide can perform 
R-P-O O H ' H R-P-Ov R^P-O. 
^ O 0 0 ^ o 
R = Alkyl 
Figure 13: Mechanism of basic hydrolysis of an ethyl phosphonates by SN2 
displacement. 
an E2 elimination, abstracting a methyl proton while the phosphonate acts as a leaving 
group (Figure 14). Ethylene gas is formed as a byproduct of this reaction. Presence of 
ethylene in a reaction flask strongly suggests the phosphonates is formed through an E2 
elimination. A third possibility is an addition/elimination mechanism which would 
require attack of hydroxide at the phosphorus, forming a pentacoordinate intermediate, 
followed by expulsion of alkoxide (Figure 14). Alkaline hydrolysis of ethyl 
1 l O 1 K 
phosphonates has been reported to occur exclusively with P-0 bond cleavage. 
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Figure 14: E2 elimination and addition/elimination mechanisms of base hydrolysis. 
procedures for the base hydrolysis of cyclic amines bearing phosphonates pendant arms 
typically involve highly basic solutions of either potassium hydroxide or sodium 
l i e i ryy i OQ 
hydroxide. ' ' Vizza and coworkers appended ethyl phosphonate pendant arms on 
1,7-dimethylcyclen and were able to isolate the partially-hydrolyzed phosphonate 24 after 
hydrolysis with potassium hydroxide (Scheme 7). The authors noted that methylene 
O 
ii O . / 1 O 
N HN ^ H V / n N N P-OEt KOH ^ N P-OK 
I I *~ O I J OEt *• 0 I J OEt 
NH N EtO-P-J^N N KO-pV^N N 
' ' OEt * ' OEt u — ' 
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Scheme 7: Formation of ligand 24 by Vizza and coworkers. 
protons on each ethyl ester were diastereotopic, as seen in the 'H NMR spectrum. After 
basic hydrolysis, the time-averaged structure makes the remaining ethyl ester methylene 
protons enantiotopic. Coincidentally, the coupling between these protons and the methyl 
"2 1 
protons and the coupling between these protons and the P were very similar, 
simplifying the JH resonance to a pentet. 122 
17 
Acid hydrolysis of alkyl phosphonates yields the fully hydrolyzed phosphonic 
acid.134 Similar to basic hydrolysis, acid hydrolysis can follow through multiple possible 
pathways (Figure 15). In all three mechanisms, the phosphoryl is protonated by the acid 
and water can either remove a methyl proton in an E2 elimination, producing ethylene 
gas, attack the methylene carbon of the ethyl ester by an Sn2 displacement or attack the 
phosphorus to form a pentacoordinated species that expels ethanol after a proton 
transfer.134'136'137 According to Gerrard133 and Blumenthal,138 acid hydrolysis of 
phosphonates occurs with approximately 70% C-0 cleavage and 30% P-O cleavage. 
Cadogan reported that C-O was predominate as well, but didn't report to what extent.139 
Currently, there is little known as to whether an E2 elimination mechanism or an SN2 
mechanism or both are the cause for the C-O bond cleavage. 
'""'^ :OH2 
R-p-0 • R-P=0 + H2C=CH2 + H30 
lf?r A O : O H 2 ? ©
 w ? H 
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l f ? ^ = O H 2 OH, .H + R ^ H O 
R-P-OB - P-OEt - — -
 H o ;P-OEt ^ R-P-OH + H O ^ 
OEt OEt + H ^ O B OEt 
H 
Figure 15: Mechanisms for acid hydrolysis of alkyl phosphonates. 
Acid hydrolysis of aminophosphonate esters on cyclic polyamines has been 
reported.77'90'108'115'116'127'140'141 Sherry reported the acid hydrolysis of ligand 19 with 
6M HC1 (Scheme 8). The acid simultaneously hydrolyzed the ethyl ester and removed 
18 
the protecting group; ligand 25 was isolated in 90% yield after recrystallization as an HC1 
salt.115 The ligand was complexed with lanthanides for use as MRI contrast agents. 
S^ r~\ xbz ° ^ r^ 
EtO-P ^N Nk 6MHCI HO-P ^N HN 
I J ff " 0 H I J 2 
^u ^-N N ^ . P - O E t NH N. .P-OH 
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^ ' OEt > ' OH 
19 25 
Scheme 8: Acid hydrolysis of ligand 19 performed by Sherry.115 
In 2000, Hermann and coworkers described the hydrolysis of ethyl phosphonates 
on a 1,7-dimethyl cyclam. The ester was hydrolyzed with 6M HC1, acids were removed 
on a Dowex 50 ion exchange column and the fractions containing the product were 
transferred onto an Amberlite 50 column (carboxylic ion exchanger) and eluted with 10% 
aqueous ammonia. The product was isolated in a 70% yield from the column (Scheme 9). 
The authors did not report the identity of any byproducts of the reaction and used ion 
exchange chromatography in both subsequent publications involving acid hydrolysis of 
alkyl phosphonates to purify their compounds. ' 
N N ^ - O E t
 H C | " > N ^ P - O H 
i? I J 0Et * ff I J 0H # 8 H 2 ° O E t O - P ^ N N ^ 2) Ion Exchange H O - P ^ N N 
OEt L ^ J Chromatagraphy ^ ^ J 
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Scheme 9: Hydrolysis of ligand 26 performed by Hermann.90 
Formation of methyl phosphonate esters has been reported previously using very 
similar conditions as for the ethyl analogues.58'62'77'10(M02'104'105 Alkaline hydrolysis of 
methyl esters was found to occur with P-O bond cleavage exclusively. ' The 
hydrolysis in acid, however was found to be similar to ethyl phosphonates where both 
19 
P-0 and C-0 cleavage were reported.132'135 Interestingly, there are no reports in the 
literature of direct SN2 displacement of hydroxide at the methyl carbon, a plausible 
pathway for basic hydrolysis. Work done by Gerrard and coworkers indicated that basic 
hydrolysis occurred only through P-0 bond cleavage. Hydrolysis of phosphonates 
formed with optically active sec alcohols revealed a complete retention of configuration 
of the alcohol after the hydrolysis of the phosphonates was complete.133 According to 
Westheimer, this mechanistic requirement can be transferred to methyl esters.132 The 
rates of methyl hydrolysis have been reported to be faster than ethyl hydrolysis in both 
I O C 
acid and base solutions. 
Other reagents have been shown to dealkylate alkyl phosphonates without the 
need for the presence of water during the course of the reaction. Reaction with HBr in 
AcOH has been reported to cleave alkyl phosphonates in high yield and purity.77'90'113 
Alkyl phosphonates react with trimethylsilyl bromide or trimethylsilyl iodide to form 
trimethylsilyl esters, which cleave easily in water.117"119 Boron tribromide has also been 
reported to cleave alkyl phosphonates.142'143 
The attachment of f-butyl phosphonate ester pendant arms to a cyclen has been 
recently reported. Manning and coworkers reacted tri-t-butyl phosphite, 
paraformaldehyde and a 1,7-di-protected cyclen to form ligand 28 (Scheme 10).144 
=
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Scheme 10: Formation of t-butyl phosphonates 28 followed by deprotection with TFA. 
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?-Butyl phosphonate formation has been reported in the literature with the use of either 
tri-f-butyl phosphite or di-?-butyl phosphite as the nucleophile for the Mannich-type 
reaction.145"151 Deprotection off-butyl esters with mild acid trifluoroacetic acid (TFA) 
produced phosphonic acid 29. Manning also reported an improved synthesis of tri-f-butyl 
phosphite, a reagent originally synthesized by Mark and coworkers. The sensitivity of 
tri-f-butyl phosphite towards air, water and heat was reported by Manning. 
C. Phosphonic Acid Pendant Arms on Cross-Bridged Tetraamines. 
The goal of the work herein is to synthesize methylphosphonic acid pendant 
armed derivatives of CB-cyclen (7) and CB-cyclam (8) in order to make model 
compounds for the determination of the corresponding Cu(II) complexes' in vivo and in 
vitro stability. The syntheses of CB-cyclen (7) and CB-cyclam (8) were reported by 
Weisman, Wong and coworkers (Scheme ll).49'51'153 They utilized a condensation 
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Scheme 11: Synthetic sequence to form cross-bridged tetraamines. m=n=0, (CB-cyclen, 
7), m=n=l (CB-cyclam, 8). 
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hydrogens in the cis configuration. Regioselective alkylation on two non-adjacent 
nitrogens with benzyl bromide produced dibenzyl salts 32 in high yield and purity. 
Double reductive ring opening with excess NaBH4 yielded the dibenzyl cross-bridged 
ligands 33 which were debenzylated via hydrogenolysis to obtain the parent cross-
bridged ligands. A key step in this sequence lies in the highly regioselective alkylation51 
of 31. As shown in Figure 16, the three-dimensional structure of 31 is a cis fused, all 
chair conformation possessing a cleft. Two equivalent nitrogen lone pairs are oriented 
exo to the cleft while the other two lone pairs are oriented endo.51 The molecule 
undergoes an enantiomerization where the exo and endo nitrogen lone pairs interconvert 
through a conformational process involving two ring flips and the inversion of all four 
nitrogens.51 The first alkylation takes place at a more sterically accessible exo lone pair, 
conformationally locking that nitrogen from inversion. The regioselective second 
alkylation then occurs on the other exo nitrogen. Double reductive ring opening of 
endo C r y SP 
0 exo 0 
R-X 
R-X 
Figure 16: Alkylation of bisaminal 31 (m=n=l). 
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ligands 32 is described in Figure 17. Dialkylated salt is converted into a tricyclic 
iminium ion via a twist-boat conformation in order to arrange the lp-N-C-N+ torsion 
angle into a stereoelectronically idealized arrangement for cleavage.51 7 and 8 were 
synthesized by this reported procedure.49'51'153 
m , m 
N T N ' R ®N^ N ' R H - B H 
R I, ,1 R W W 
n 
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R ^ y R ^ S e HBH3 R ^ 
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Figure 17: Mechanism of double-reductive ring opening of ligands 32. 
The formation of ligand 35 has been reported in the patent literature (details not 
reported) by Winchell and coworkers (Scheme 12).1 4 The procedure listed involved the 
use of phosphorous acid and aqueous formaldehyde. No further details were listed with 
regards to purification, yield or speciation. 
.NLHNL H-P-OH M N P-OH ( \ J ° H • 9 C I J AH •«!« 
NH N o H O - P ^ N N 
\—J aq. J^ OH ^ 1 
H H 
7 35 
Scheme 12: Formation of ligand 35. 
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III. Results and Discussion 
A. Synthesis of Phosphonate Ester Pendant Arms on CB-Cyclen (7) and CB-
Cvclam (8). 
(1) The synthesis and characterization of 1,4,7,10-
tetraazabicyclor5.5.21tetradecane-4,10-bis(methanephosphonic acid diethyl ester) 
(36) 
The most common synthetic technique for appending polyamines with 
phosphonic acid pendant arms is the use of the Moedritzer conditions that form the 
aminophosphonic acid through a Mannich-type mechanism. These reaction conditions 
are highly acidic (cone HC1) and produce a broad range of yields, making them less 
attractive for use with expensive cross-bridged tetraamines.88'89'" Weisman proposed the 
formation of phosphonate esters as synthetic intermediates due to their ease of synthesis 
(mild formation conditions and typical high yields). This was to be followed by 
phosphonate ester hydrolysis to obtain the ionizable ligands. Compound 7 was allowed to 
react with triethyl phosphite and paraformaldehyde in THF at room temperature for four 
days under N2 (Scheme 13). Ethyl phosphonate 36 was isolated after a basic extraction as 
a yellow oil in 84% yield and characterized by H, C, P NMR and high resolution 
-N^HN
 p ( 0 E t ) 3 | ^ t f r N N P-OEt 
1 ^ ° L I I °E t 
•NH^N^ THF, RT, 4d, N2 EtO-P. > ^N f 1 \ / 84% yield
 0 E t 
7 36 
Scheme 13: Synthesis of 36. 
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FAB mass spectrometry (HRFABMS). As the spin of 31P is Vi, some *H's and 13C's 
couple to the phosphorus allowing better identification of NMR resonances. The 
methylene protons flanked by the nitrogen and phosphorus are enantiotopic by symmetry 
(structure is time-averaged Cj\). However, the resonance in the !H NMR that 
corresponds to these protons is a doublet, due to the coupling with the NMR active 31P 
(2/HP = 7.6 Hz).155 The methylene protons on the ester substituent are diastereotopic 
based on symmetry, and couple to each other, as well as to the methyl protons and the 
-3 1 
" P. The coupling constants are difficult to extract from the complicated resonance in the 
!H NMR spectrum. In the 13C NMR, the carbon flanked by the phosphorus and the 
nitrogen possesses a one bond coupling constant with the phosphorus, which is typically 
11S 116 199 19R 
on the order of 150-160 Hz. ' ' ' This doublet is used as a diagnostic peak for the 
-2 1 
formation of the pendant arm. P coupling with other carbons is seen as well, however, 
those coupling constants are typically on the order of 4-8 Hz. As shown by *H NMR, the 
yellow oil is quite hygroscopic, a characteristic seen with many cross-bridged tetraamines 
prepared thus far. The isolated material contained a small amount of mono-armed 
product, l,4,7,10-tetraazabicyclo[5.5.2]tetradecane-4-(methanephosphonic acid diethyl 
ester) (0.1 molar equivalents relative to 1.0 of product). An increase in reaction time to 6 
days produced a similar result, as did the addition of extra equivalents of reagents. 
Because the reaction is controlled by thermodynamic conditions, Le Chatelier's principle 
suggests the byproduct present should fully convert to product with the addition of 
further equivalents of reagents. No further purification was attempted. 
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(2) The synthesis and characterization of 1.4,8,11-
tetraazabicyclor6.6.21hexadecane-4,l 1-bis(methanephosphonic acid diethyl 
ester) (37) 
CB-cyclam (8) was subjected to the same set of conditions as in the formation of 
36 (Scheme 14). Compound 8 was stirred in THF for 4 days under N2 in the presence of 
N HN
 P(OEt)3, ^ 0 - T r N N P-OEt 
I 1 1 ^ ° I L J 0Et 
k N H k N T THF,RT,4d,N2 E tO-PON ^NT 
Cj 8 4 % V i e l d O^TL^J 
8 37 
Scheme 14: Synthesis of 37 
triethyl phosphite and paraformaldehyde. The product was isolated from a basic 
extraction and solidified under vacuum in good yield (84%). The 'H NMR spectrum of 
ligand 37 indicated no observable impurities. This was in contrast to 36, which contained 
a small percentage of mono-armed material. ]H NMR assignments were made with the 
assistance of 2D homo- and heteronuclear NMR experiments ^H-COSY and gHMQC). 
The time-averaged C2 symmetry of the ligand can be seen in the H NMR spectrum by 
the appearance of an AA'XX' spin system corresponding to the ethylene cross-bridge. As 
in 36, the methylene protons on the ethyl ester are diastereotopic and their resonances 
overlap, thus they have a complicated resonance pattern due to couplings with P and the 
methyl protons. 
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(3) Attempted synthesis and characterization of 1,4,7,10-
tetraazabicyclor5.5.21tetradecane-4,10-bis(methanephosphonic acid methyl ester) 
(38) 
Methyl phosphonates are known to hydrolyze faster than their ethyl analogues in 
both acidic and basic solutions, making them attractive precursors to ionizable methyl 
phosphonic acid pendant arms. ' ' As the conditions used for the preparation of 
36 produced only a slightly impure product, the synthesis of 38 was attempted under the 
same conditions. CB-cyclen 7 was stirred in THF for four days under N2 in the presence 
of trimethyl phosphite and paraformaldehyde (Scheme 15). The initial solution became 
opaque ten minutes after the addition of the trimethyl phosphite and paraformaldehyde, 
f 1 1 - 1 * . O I I J OMe 
S h T N T THF, RT,4d, N2 MeO-PON NT 
^
 /
 OMe ^ ' 
7 38 
Scheme 15: Attempted synthesis of 38. 
then after 1 hour, the solution became transparent and was allowed to stir for 1 day. This 
unusual behavior was never seen in any other phosphonate ester forming reaction with 
cross-bridge ligands. A basic extraction afforded the ligand in poor yield (-10%) and 
purity. It is quite possible that the methyl phosphonate functionality hydrolyzed, either 
partially or fully, in the strongly basic (pH=14) aqueous phase during the course of the 
extraction. The crude *H NMR spectrum also indicated the presence of more than one 
ligand containing a methyl phosphonate. Attempts to extract the product from an ice cold 
aqueous phase (pH = 14) produced similar results. Further synthetic work is required in 
order isolate pure ligand in respectable yield. 
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(4) The synthesis and characterization of 1,4,8,11-
tetraazabicyclor6.6.21hexadecane-4,l l-bisCmethanephosphonic acid dimethyl 
ester} (39) 
CB-cyclam (8) was dissolved in THF and stirred with paraformaldehyde and 
trimethyl phosphite under N2 for four days (Scheme 16). The product was extracted 
N HN P ( 0 M e ) 3 , f ^ 0 f / N ^ Nx, P~°Me 
f I I &*- O I I I OMe 
k N H k N ^ THF,RT,4d,N2 M e O - P ^ N % ^ 
l^J 76% 6i^ KJ 
8 39 
Scheme 16: Synthesis of 39. 
from a strongly basic solution and solidified to a white solid upon the removal of solvent. 
Ligand 39 was formed in 76% yield and high purity. Resonance assignments were aided 
by 2D NMR experiments ('H-COSY and gHMQC). The relative ease of formation of 
both ligands 37 and 39 with respect to ligands 36 and 38 was not expected. 
(5) The synthesis of di-tert-butyl morpholinomethylphosphonate (40) 
Although the synthesis of ligands 36 through 39 utilized trialkyl phosphites, the 
same product could be formed through the use of dialkyl phosphites due to similar 
mechanisms. The acidic proton on the dialkyl phosphite (pKa = 1.3)157 can protonate the 
aminomethanol intermediate, making formation of the iminium ion easier due to the loss 
of H2O instead of hydroxide. Water can also be removed in the presence of molecular 
sieves, forcing the equilibrium towards product. To test this, morpholine was allowed to 
reflux overnight in the presence of paraformaldehyde and commercially available di-t-
butyl phosphite (1.5 molar equivalents relative to 1.0 molar equivalents of morpholine) 
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over 3 A sieves (Scheme 17). Compound 40 was isolated from a basic extraction in 74% 
yield with 0.17 molar equivalents of di-?-butyl phosphite still present. The addition of t-
butyl phosphonates could be attempted on a cross-bridged tetraamaine. 
O 
ii 
H - P - O t - B U / / \ jf 
/ \ ut-bu , n / \ II 
O NH *• O N ^ P - O ' 
MeCN, 1d, N2 ° ' 
Reflux, 74% yield 
40 
Scheme 17: Synthesis of 40. 
(6) Attempted synthesis of 4Jl-bis-(4-carbo-t-butoxymethyl)-l,4JJ0-
tetraazabic yclo F5.5.21 tetradecane(41). 
The synthesis of compound 41 was attempted under the conditions used for the 
synthesis of 40 (Scheme 18). The reaction became a very dark red color after only a few 
O 
H - P - O t - B u , ^ >, i v O 
6t-Bu 
.ISL HNL ot-Bu , ^ ; n ^-N N P-Ot-Bu 
^ N H ^ ""MeCN, Vd,N2** t - B u o X > ^J 
u _ v Reflux r^u ^_, 
7 41 
Scheme 18: Attempted synthesis of 41. 
hours. The H NMR of the crude mixture as well as the material collected after a basic 
extraction indicated a complex mixture of products. It is quite possible that the strong 
base 7 was merely protonated by the acidic di-?-butyl phosphite, inhibiting the Mannich-
like reaction. However, if this was the case, then after a basic extraction, the starting 
material should have been recovered. Since the lH NMR spectrum revealed a mixture of 
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materials, clearly some other reaction occurred. The reaction to form 41 was attempted in 
dry THF due to the success of the formation of 36, 37 and 39 under similar conditions 
(vide supra). Reactions were run at room temperature for both 3 days and 4 days utilizing 
2.5 equivalents of both paraformaldehyde and di-/-butyl phosphite. Reactions were also 
attempted in MeCN, giving similar results. A new synthetic direction was thus necessary. 
The synthesis of tri-f-butyl phosphite has been reported in the literature152 and its 
reaction with paraformaldehyde and cyclen have also been reported.144 The authors 
described the sensitivity of the reagent to heat, air and water, both once it was formed, as 
well as during the course of reaction.144 With this in mind, tri-?-butyl phosphite was 
synthesized according to literature procedures in 63% yield with approx 91% purity 
based on !H NMR (the presence of tri-?-butyl phosphate accounted for the 9% impurity). 
The procedure used to add r-butyl phosphonate arms to cyclen144 was followed with CB-
cyclen (Scheme 19). The reaction was run for 2 days under N2 and the products were 
isolated from a basic extraction. The *H NMR and 13C{ 'HJNMR spectra indicated the 
1 i I 1 I i O 1 v O 
.N . HN. P(Ot-Bu)3, •K^O'T ,N . HN. . N . N^P-Ot-Bu .N. N^P-Ot-Bu 
( X } n ( X 1 + C \ } 0'-Bu + O ( \ 1 6t-Bu 
SH^V THF, 2d, RT, N2 ShTN^ S H S ^ t-BuO-F* > ^hT 
Ot-Bu 
7 7 42 41 
Scheme 19: Attempted synthesis of 41 with tri-t-butyl phosphite. 
presence of 7, 42, and 41, with 42 being the dominant species in solution. The same result 
was obtained when the reaction was allowed to run for 6 days and as well as with an 
excess of reagents. Further work in this area is paramount, as is the preparation of tri-f-
butyl phosphite in higher purity. 
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(7) Attempted synthesis of 1,4,8,1 l-tetraazabicyclo[6.6.21hexadecane-4 ,11-
bis(ethanephosphonic acid dimethyl ester) (46). 
In 2007, Heroux et al. reported their exploration of the role pendant arm length 
played in the kinetic inertness of various cross-bridged tetraamine Cu(II) complexes. 
Their assays involved acid dissociation experiments and resistance to reduction of 
Cu(II).158 Previous experiments on ,/V-carboxyethyl pendant-armed cyclen and cyclam 
derivatives indicated a change in coordination modes, dissociation kinetics and redox 
chemistry relative to their Af-carboxymethyl analogues like DOTA (3) and TETA (4).159" 
163
 The cross-bridged ligands studied are shown in Figure 18. The lengthening of the 
pendant arms (from 9 to 43 and from 10 to 44, respectively) resulted in a small decrease 
on the kinetic inertness (half-life) of their Cu(II) complexes relative to the short armed 
Cu(II) complexes. However, [Cu-44] was less resistant to reduction by 400 mV 
compared with [Cu-10], suggesting that [Cu-44] could be susceptible to physiological 
reductants.158 Biodistribution studies of the 64Cu complexes revealed poorer tissue 
.N N^ COOe N N ^ ^ 
e00C.J^N N ^ / \ / N N 
^ \ / ©OCX) \ / ^ , 
9 43 
N NC' cooe
 N N C ^ ^ 
0OOC. M N ^ / \ ^ N N 
^
 e o o c
 ^ 
10 44 
Figure 18: Ligands of the Cu(II) complexes studied by Heroux et al. to determine 
effects of ./V-carboxyethyl pendant arms versus ,/V-carboxymethyl pendant arms on kinetic 
inertness and resistance to Cu(II)/Cu(I) 
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clearance of the "long-armed" complexes with respect to the "short-armed" complexes, 
which indicated that resistance to reduction is a useful tool to assess, qualitatively, the in 
vivo stability of these complexes. 
The addition of ethanephosphonic acid pendant arms on CB-cyclam (8) would 
serve as an appropriate model to determine if the presence of the phosphonate moiety 
could influence the kinetic inertness and/or resistance to reduction similar to the results 
obtained for carboxylate-armed analogues. The conditions reported for the formation of 
the ^-butyl ester precursor to 44 were implemented with CB-cyclam (8) and ten 
equivalents of commercially-available dimethyl vinylphosphonate (Scheme 20). The *H 
J. ..J. ^ . P - O M e I J , / \ .P-OMe I J , x \ ^P -OMe 
f > ^i OMe r ^ ^ - I - ( ^ ^ 
^ N H ^ MeCN,4d,N2 ^ N H k N MeO-^-? V 
8 45 46 
Scheme 20: Attempted synthesis of 46. 
1-3 1 
and C{ H} NMR spectra of the crude product indicated the presence of predominantly 
mono-armed ligand 45, with less di-armed ligand 46 (approximately 0.3 molar 
equivalents of 46 to 1.0 molar equivalent of 45). It was hypothesized that the large 
amount of reagent present was affecting the polarity of the solvent, which affected the 
rate of the Michael addition of dimethyl vinylphosphonate. Several different reaction 
conditions were attempted as summarized in Table 2. The reaction was run with less 
reagent and more polar solvents, but the crude !H and 13C{ 'H} NMR spectra indicated 
the crude still contained predominantly 45. The same result was seen with microwave 















MeCN, RT, N2, 2d 
DMF, RT, N2, 2d 
Microwave, MeCN, 
30 min, 80 °C 







Table 2: Various reaction conditions used for the attempted synthesis of 46. 
possible explanations involve either the hydrolysis of the methyl esters during the course 
of extraction from a pH 14 aqueous solution, preventing the resulting phosphonic salt 
from being extracted into the organic phase, or the de-arming of the ligand by hydroxide 
(reverse Michael addition). In order to prevent these, the extraction was attempted from 
an ice-cold aqueous phase (pH =14). However, the recovered yields didn't improve and 
the isolated material was similar in composition to those reactions described previously. 
Further work in this area is clearly required. 
B. Formation of Ionizable Phosphonate Pendant Arms on CB-cyclen (7) and CB-
cyclam (8). 
(1) The synthesis and characterization of 1,4,7,10-
tetraazabicyclo[5.5.21tetradecane-4,10-bis(methanephosphonic acid monoethyl 
ester sodium salt) (47) 
Compound 36 was brought to reflux for 1 day in the presence of 4 equivalents of 
NaOH to form sodium salt 47 (Scheme 21). The sensitivity of basic hydrolysis of 36 was 
not expected as only 4 equivalents of sodium hydroxide were needed for hydrolysis in 1 
day. Reported procedures of base hydrolysis of aminophosphonates on macrocycles 
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Scheme 21: Synthesis of partially-hydrolyzed phosphonate 47 
I IS 199 1 
generally involved highly basic solutions. ' Ligand 47 was characterized by H, 
13C{'H} and ^P^H} NMR, HRFABMS and elemental analysis. The once diastereotopic 




Figure 19: Time-averaged structure of a partially-hydrolyzed phosphonate. The 
methylene protons shown are interconverted by a sigma plane in ligand 47. 
structure in solution (Figure 19). Interestingly, the coupling constant between those 
methylene protons and the methyl protons was very similar to the coupling constant 
between the methylene protons and the phosphorus, simplifying the resonance in the1!! 
122 
NMR to a pentet. This feature has been previously reported on an analogous system. 
The P{ H} spectrum indicated the presence of 0.05 molar equivalents of the 
monoarmed ligand relative to 1.0 molar equivalent of 47. No further attempts to purify 
this mixture were attempted. 
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(2) The synthesis and characterization of 1,4,8,11-
tetraazabicyclor6.6.21hexadecane-4,l l-bisCmethanephosphonic acid monoethyl 
ester sodium salt) (48) 
Attempts to partially hydrolyze ligand 37 with 4 equivalents of NaOH, as was 
done with 36, failed. The starting phosphonate 37 was dissolved in a 0.4 M NaOH (12 
equivalents of NaOH to 1 equivalent of 37) solution and refluxed for 24 hours (Scheme 
22). The solvent was removed and ice cold methanol was added to the crude isolated 
solids to dissolve the ligand and remove it from the bulk NaOH. However, some NaOH 
dissolved as well, which made analysis difficult. The crude mixture was dissolved in a 
minimal amount of -78 °C MeOH in order to dissolve the ligand and not the excess 
NaOH. The ligand was characterized by *H, " C ^ H } , 31P{'H} NMR, and HRFABMS. 
Elemental analysis revealed 24 molar equivalents of NaOH, 7 molar equivalents of 
MeOH and 20 molar equivalents of water present in the sample relative to 1 molar 
equivalent of 48. Titration of the sample with 0.1 N HC1, performed by Prof. Ed Wong, 
indicated the presence of 19 ± 5 molar equivalents of NaOH relative to 1 molar 
equivalent of 48. Unlike ligand 47, the diastereotopic methylene protons on the ethyl 
ester stay diastereotopic upon base hydrolysis of compound 37, due to the time-averaged 
C2 symmetry of the solution structure. However, the resonance for these protons 
simplified into a pentet as well, which indicated that the coupling constant between the 
accidentally isochronous methylene ester protons and the methyl protons was very 
N N P-OEt
 0 . 4 M N a O H r % N N r ° N a 
0 1 J OEt
 : *~ O f 1 J OEt 
EtO-P^ N N Reflux, 1d,N2 NaO-P-^N N 
O^l^J 71%yield OEt k j 
37 48 
Scheme 22: Synthesis of ligand 48. 
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similar to the coupling with the 31P. Ligand 48 was used without further purification for 
Cu(II) complexation. 
(3) The synthesis and characterization of 1,4,7,10-
tetraazabicyclor5.5.21tetradecane-4,10-bis(methanephosphonic acid) 
(372HC1-3H90)(H4-CB-D02P) 
The hydrolysis of ligand 36 was carried out under a series of different conditions 
in order to attempt to produce 50 and prevent any reverse Mannich from taking place 
(Scheme 23). Those reaction trials are summarized in Table 3 with a listing of the 
( J ) H 6M HCI 
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-50% 49, -50% 50 




-20% 49, -80% 50 
-20% 49 and incompletely hydrolyzed 
ligand 
mixture of 36, 49 and incompletely 
hydrolyzed ligand 
-66% 49, -33% 50 
Table 3: Summery of reaction trials for the acid-assisted hydrolysis of 36. 
percentage of products of each reaction. In all trials, either a significant amount of reverse 
Mannich occurred or very little hydrolysis occurred. In the two trials in 6 M HCI run at 
50 °C and room temperature, the H NMR of the crude indicated the presence of a small 
36 
amount of phosphorous acid which suggested that increases in reaction time should still 
produce some 49. The hydrolysis of 36 was attempted at lower acid concentrations in 
order to form less 49, however the presence of phosphorous acid in the crude ]H NMR 
spectra suggested reverse Mannich had taken place, only to a lesser extent. The attempted 
purification of a select few reaction trials with ion-exchange chromatography (Amberlite 
50, carboxylic acid exchanger, eluted with water) failed to separate the mixtures. 
Alkyl phosphonates have been converted to their corresponding phosphonic acids 
by means other than HC1 hydrolysis. Reactions with HBr in AcOH and with 
trimethylsilyl bromide (TMS-Br) have successfully cleaved alkyl phosphonates to form 
phosphonic acids in high yield and purity. ' The conversion of 36 to 50 was 
attempted with an HBr/AcOH solution using a published procedure for the cleavage of 
1 1 ^ 
another aminophosphonate. The reaction was run for both 1 day and for 6 days, 
however these reactions were incomplete and the crude *H NMR spectrum again 
indicated the presence of 49. Cleavage of 36 was also attempted with TMS-Br following 
a published procedure.119 The room temperature reaction cleanly cleaved the ethyl 
phosphonate with little formation of 49 (-5%). The 31P{1H} NMR spectrum, however, 
indicated the presence of five distinct peaks, four of them integrated for approximately 
the same amount while the fifth peak was much smaller than the other four (peak at 14.3 
ppm was ligand 50). These impurities were not identified. 
The synthesis of ligand 50 has been reported in the patent literature (details not 
reported) utilizing the Moedritzer conditions.1 The procedure reported for the synthesis 
of 13 was followed for the formation of 50-2HC1 (Scheme 24). The crude material 
contained 0.08 molar equivalents of ligand 49-2HC1 and 0.04 molar equivalents of H3PO3 
37 
1 O l 
relative to 1.0 molar equivalent of 50 as shown in the H and P NMR spectra. Attempts 
to separate the impurities with ion-exchange chromatography (Amberlite 50, carboxylic 
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Scheme 24: Synthesis of 50-2HC1. 
2HCI 
(4) The synthesis and characterization of 1,4,8,11-
tetraazabicyclor6.6.21hexadecane-4,11 -bis(methanephosphonic acid) 
f510.6HCH.lH2O) (H4-CB-TE2P) 
The hydrolysis of ligand 37 was carried out under reflux in 6 M HC1 for 24 hours 
(Scheme 25). The JH NMR spectrum of crude product indicated the presence of 0.08 
molar equivalents of monoarmed material relative to 1.0 equivalent of 51, however the 
i i ^ \ n i i ^ \ n 
. N . NL P-OEt e . . ^ , / N . N. P-OH 
O f \ 1 OEt 6 M H Q > O ^ \ 1 OH • 0.6HCI 
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OEt L ^ J 64% yield £ H k ^ 
37 51 
Scheme 25: Synthesis of ligand 51. 
impurities were separated on an ion-exchange column (Amberlite 50, carboxylic ion 
exchanger) by elution with water. Microwave-assisted hydrolysis afforded product with 
-12% de-arming according to ]H NMR analysis. The purified ligand was characterized 
by 'H, 1 3 C { J H } and "Pf1!!} NMR. ^-COSY and gHMQC experiments were used to 
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identify every resonance in the !H NMR spectrum. This *H NMR spectrum is consistent 
with a solution state [2323/2323] diamond lattice conformation or a [2233/2233] 
conformation, both di-inside-protonated. As shown in Figure 20, the two upfield patterns 
correspond to the pseudo-equatorial and pseudo-axial protons on the central methylene of 
the three carbon bridge. In either conformation, the pseudo-equatorial proton exhibits one 
H neq 
Figure 20: Upfield region of the !H NMR spectrum of 51. 
large coupling, with the pseudo-axial proton, and four smaller gauche couplings with the 
rest of the protons in the spin system (Figure 20) giving a resonance that is a doublet of 
multiplets. The pseudo-axial proton, on the other hand, experiences three large couplings 
and two smaller gauche couplings giving a resonance that appears like a quartet of 
multiplets (Figure 20). An x-ray quality crystal was grown by slow diffusion of acetone 
into water; the structure is shown in Figure 21. The close proximity of the two 
phosphonic acid pendants suggested a hydrogen bond between a phosphonic acid proton 
and an oxygen on the other phosphonic acid moiety. The distance between the placed 
proton and the oxygen was measured at 1.6 A, the distance between the two oxygen 
atoms was found to be 2.4 A, and the angle between the oxygen/hydrogen/oxygen atoms 
was measured to be 166°. Interestingly, the ligand backbone was found to be in the 
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Cll 
Figure 21: X-ray structure of H4-CB-TE2P (51). Side view revealed a hydrogen bond 
between a phosphonic acid proton on one pendant arm and an oxygen atom on the other 
arm. Back view showed a [2233/2233] ligand conformation. Hydrogens were removed 
for clarity. 
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[2233/2233] conformation (Figure 21). A possible explanation for this conformational 
preference could be due to the hydrogen bond between the pendant arms in the solid state 
forcing the ligand into this geometry. 
C. Copper (II) Complexation of Cross-Bridged Ligands Containing Ionizable 
Phosphonate Pendant Arms. 
(1) Cu(II) Complexation of CB-DQ2P-Et (47). 
Ligand 47 was refluxed in MeOH in the presence of Cu(C104)2-6H20 for 1 day 
(Scheme 26). The purified blue solids were isolated from slow diffusion of Et20 into 
95% EtOH and were characterized by UV-vis spectroscopy (A,max = 672 nm, s = 44 M"1 
O 
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0 - P ^ ^ . N N 
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Scheme 26: Complexation of ligand 34. 
cm'1), HRFABMS and elemental analysis. The pH of the solution was lowered to 8 using 
0.1 M NaOH. pH was monitored with a pH electrode calibrated with aqueous solutions of 
buffer at pH = 7 and 10 using the so called "practical method".164'165 The presence of 
0.05 molar equivalents of the mono-armed Cu(II) complex was inferred by elemental 
analysis. The formation of mono-armed complex occurred from the presence of 0.05 
molar equivalents relative to 1.0 molar equivalent of 52 of the single pendant armed 
version of 47 present in the reaction mixture. A low-quality X-ray crystal was obtained 
from slow diffusion of Et20 into 95% EtOH. The X-ray structure (Figure 22) indicated 
the coordination of the ligand nitrogens around the Cu(II) with both pendant arms 
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coordinating to the Cu(II) as well. However, the unit cell also indicated the presence of 
mono-armed complex, present in a 1:3 ratio with the di-armed complex. Unfortunately, 
the structure refinement was not well behaved. The R factor was found to be very high so 
bond lengths and bond angles are not accurate from this highly disordered structure. 
m feJ-L£» 
CD V* f ~ ly 'Y 
Ci;p (1.0 
Figure 22: X-ray crystal structure of complex 52. The left-hand structure is a di-armed 
complex, The right hand structure is a monoarmed complex. 
(2) Cu(TD Complexation of CB-TE2P-Et (48) 
Ligand 48 was refluxed in MeOH in the presence of Cu(C104)2-6H20 for 1 day 
(Scheme 27). The complex was characterized by UV-vis spectroscopy (Xmax = 646 nm, s 
= 18 M"1 cm"1), HRFABMS and elemental analysis. 1,1,1,3,3,3-hexafluoroisopropanol 
f ^ ^ i Cu(CI04)2 6H20 
O I I J OEt ^ 
NaO~P\ N N Reflux, MeOH 
OB I J N* PH = 8 
^ ^ 82% yield 
N N P - 0 
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Scheme 27: Complexation of ligand 48. 
was present as indicated by the elemental analysis of the complex. It had been used to 
separate the complex from the NaCl byproduct. Several attempts were made to isolate an 
X-ray quality crystal. Et20 diffusion into MeOH, MeCN, 95% EtOH and abs EtOH 
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produced blue oils. Et20 diffusion into 95% EtOH at 0 °C produced a blue oil as well. 
Further work to obtain an X-ray quality crystal is required. 
(3) Cu(II) Complexation of CB-TE2P (51) 
Ligand 51 was complexed with CUCI22H2O in MeOH following the procedures 
described for the formation of 52 and 53 at pH = 8 (Scheme 28). The resultant blue solid 
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Scheme 28: Complexation of 51. 
was characterized by UV-vis spectroscopy (A,max(MeOH) = 639 nm; 8 = 35 M"1 cm"1) 
and HRFABMS. The blue color did not appear to change over the course of the reaction. 
Typically, most cross-bridged pendant armed ligands are complexed in basic solution 
because the complexation kinetics in acidic solution tend to be very slow due to the 
protonation of the highly basic cross-bridged macrocycle.51'54 Even at pH = 8, the cross-
bridged ligands are still protonated which requires that the complexation reaction take 
place at reflux for 1 day. Hermann and coworkers have shown that azamacrocycles 
bearing phosphonic acid pendant arms tend to have faster complexation kinetics than 
analogous systems with acetate pendant arms.166 The deprotonated phosphonates rapidly 
coordinate the divalent metal in solution, followed by a rate-limiting step involving the 
removal of the proton on the nitrogen and insertion of the metal into the macrocycle.166' 
167
 Since the phosphonate-containing ligand can form this reaction intermediate faster 
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(due in part to the higher negative charge present in the phosphonate moiety with respect 
to the acetate moiety), and the increased hydrogen bonding ability of the phosphonate 
relative to the acetate makes removal of the ammonium proton faster, the overall 
complexation kinetics tend to be faster than for those ligands containing acetate pendant 
arms. 
In order to determine if H4-CB-TE2P (51) can exhibit faster complexation 
kinetics than CB-TE2A (10), a series of complexations were performed under various 
conditions, summarized in Table 4. The reactions were analyzed by UV-vis 
spectroscopy, specifically the presence of the complex absorption band and the lack of an 
aqueous Cu(II) absorption band. First, H4-CB-TE2P (51) was allowed to complex with 
CuCl2-2H20 in MeOH at pH 8. The pH electrode used to measure the acidity was 
calibrated with aqueous buffers at pH = 7 and 10. The electrode was placed into the 
methanolic solution of 51 and the pH was raised with 0.1 M NaOH solution. No 
correction for methanol was used. The UV-vis spectrum taken 5 minutes after the 
addition was identical to that of the fully complexed ligand. When the pH was lowered to 
5, the same result was observed. This was unexpected, as complexation of CB-TE2A (10) 












Time to completion 
< 5 min 
< 5 min 
~ 60 min 
Table 4: Time required for full complexation of H4-CB-TE2P (51) under various 
conditions. 
in acidic solution typically required very long reaction times and high temperatures. 
When the solvent was switched to EtOH, full complexation took 60 min at room 
temperature. The full characterization of the complex was completed for a sample of the 
complex formed in MeOH at pH = 5 (Scheme 29). Cyclic voltammetry conducted in 0.1 
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N sodium acetate revealed a quasi-reversible reduction with an Ep = -0.96 V (vs. 
Ag/AgCl), indicating a good resistance to Cu(II)/Cu(I) reduction. Numerous attempts 
O 
? CO OH " 0.6 HCI CuCI2 2H20 
1^1 ^ f f e 
N N P-0 
o L I J 0H •cu2+ e 
OH 
H O - P ^ N - N ' . 1 1 H , 0 RS f l ux 'MeOH 
I ^ ^ I i i. i n2vj pH = 5,5 mm 
OH K ^ 86% yield 
51 54 
Scheme 29: Complexation of ligand 51 in MeOH at pH = 5. 
were made to grow an X-ray crystal. Et20 diffusion into solutions of 54 in MeOH, 
MeCN, 95% EtOH and abs EtOH at both room temperature and 0 °C produced oils. 
Evaporation from a 0.1 M HCIO4 solution produced oils as well. Ba(OH)2 and Ca(OH)2 
solutions were added to methanolic solutions of 54 in order to form barium and calcium 
salts. Slow evaporation produced non-X-ray quality solids. Solids were produced upon 
very slow diffusion (performed in NMR and EPR tubes) of Et20 into a 1,1,1,3,3,3-
hexfluoroisopropanol solution of the complex, however, neither case produced crystals 
that diffracted X-rays. Et20 diffusion into a 1,1,1,3,3,3-hexfluoroisopropanol solution of 
complex in an EPR tube at 0 °C produced solids that were still not X-ray quality. Further 
work to obtain an X-ray quality crystal is required. 
D. Kinetic Dissociation of Cu-CB-TE2P (54) 
As discussed previously, the acid dissociation kinetics of cross-bridged Cu(II) 
complexes in vitro have been a useful gauge for the prediction of in vivo stability.56 The 
half-life of decomplexation of 54 was conducted under pseudo-first order conditions (5M 
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Figure 23: Isosbestic plot and pseudo-first order fit of the kinetic data for the half-life of 
decomplexation of Cu-CB-TE2P (54) in 5M HC1 at 90 °C. 
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Figure 24: Half-lives of Cu(II) complexes of various tetraamine ligands in 
5M HCI at 90 °C. 
HCI) at 90 °C. The UV-vis trace was monitored over the course of several hours by Prof. 
Ed Wong of the University of New Hampshire and the isosbestic plot and the pseudo-first 
order plot are shown above (Figure 23, black arrows indicate the loss complex and the 
increase of free Cu(II)). The half life was found to be 3.8 hours in 5 M HCI at 90 °C. 
Figure 24 shows the half-life of decomplexation of several related cross-bridged Cu(II) 
complexes. It is interesting to note that clearly Cu-CB-TE2A (Cu*10) remains the most 
kinetically-inert complex of the series (ti/2 =154 h), the half-life of Cu-CB-TE2P (54) 
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was only 3.8 hours. This result was not expected as the presence of the phosphonate has 
been shown to result in a more kinetically inert complex as described previously. A 
possibility for the short half life could stem from the close proximity of the phosphonate 
arms when bound to the Cu(II). As the phosphonate moiety is larger than the acetate 
moiety, there may not be enough room to accommodate both phosphonates as they are 
bound to the Cu(II) which could make the first mechanistic step (removal of one pendant 
arm from the Cu(II)) faster with coordinating phosphonates relative to coordinating 
carboxymethyl pendant arms. Complexation of CB-TE2P with Zn(II) would allow NMR 
to be used as a means to probe the kinetics of decomplexation. However, the 3.8 hour 
half-life under such acidic conditions suggests that CB-TE2P (54) is still a viable ligand 
for use in radiopharmaceutical applications. 
E. Biodistribution of 64Cu-CB-TE2P (54) 
Since CB-TE2P (51) serves as a model for a BFC in a radiopharmaceutical, the in 
vivo behavior of the 64Cu complex was investigated. The biodistribution of 64Cu-CB-
TE2P was performed by Riccardo Ferdani under the guidance of Prof. Carolyn Anderson 
at the Washington University School of Medicine, St. Louis, MO. The tissue clearance of 
64Cu-CB-TE2P was compared against that of the 64Cu complexes of CB-TE2A (10), 
diamsar and NOTA (Figure 25). Male Lewis rats were injected with a solution of the 
64Cu complexes made from the ligands above and the amounts of 64Cu remaining in 
selected tissues were determined at 1 hour, 4 hours and 24 hours post-injection. The data 
(Figure 26) are listed as %ID (percent injected dose) versus time. Significantly, the blood 
clearance of 64Cu-CB-TE2P indicated a slightly improved clearance with respect to 64Cu-
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Figure 25: Ligands used in the biodistribution study of 64Cu-CB-TE2P. 
CB-TE2A, a requirement of a radiopharmaceutical in order to create a background 
contrast for a PET scan, while the kidney clearances of these two complexes were 
similar. The liver and marrow clearances of 64Cu-CB-TE2P proved to be the most 
interesting. The significant enhancement in the liver clearance of 64Cu-CB-TE2P versus 
those of Cu-CB-TE2A indicated that a phosphonate-containing BFC in a bioconjugate 
should have improved liver clearance behavior. The slight decrease in bone-marrow 
clearance of 64Cu-CB-TE2P versus that of 64Cu-CB-TE2A indicated the possibility of the 
phosphonate containing ligand to be a candidate for bone imaging. The uptake of 
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Phosphonate ester pendant arms were appended onto CB-cyclen (7) and CB-
cyclam (8). Attempts were made at synthesizing ?-butyl phosphonates, and long-arm 
phosphonates. The base hydrolysis of ligands 36 and 37 afforded the partially-hydrolyzed 
ligands 47 and 48 which were complexed with Cu(II). Acid hydrolysis of ligand 36 
caused significant de-arming of the ligand while the acid hydrolysis of ligand 37 caused a 
small amount of de-arming, however, the impurity can be separated on an ion-exchange 
column. Ligand 51 was complexed with Cu(II) and experiments under various conditions 
revealed that complexation of ligand 51 can occur quickly under conditions in which 
other cross-bridge ligands complex slowly. The acid-assisted decomplexation kinetics of 
Cu-CB-TE2P in 5 M HC1 at 90 °C indicated a half-life of 3.8 hours, less kinetically inert 
than Cu-CB-TE2A, however inert enough to indicate promise for a phosphonate-armed 
cross-bridged cyclam as a BFC for radiopharmaceuticals. The biodistribution of Cu-
CB-TE2P indicated an improved liver clearance, when compared to Cu-CB-TE2A, as 
well as a potential to be used as a BFC for bone imaging. 
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CHAPTER II 
SYNTHESIS OF BIFUNCTIONAL CHELATORS BEARING 
UNSYMMETRICAL PENDANT ARMS ON CROSS-BRIDGE CYCLAM 
I. Introduction 
In order to use azamacrocycles as bifunctional chelators (BFCs) for the purpose of 
radioimaging and targeted therapy, they must be covalently bound to either a peptide or 
monoclonal antibody. " Typically, this addition is done by coupling the biomolecule 
to the BFC via a reaction with the pendant arm resulting in a new functionality present on 
the BFC. There are examples of C-functionalized BFCs that conjugate via an extra 
pendant arm attached to the macrocyclic backbone; however this arm will typically not 
94 9S 179 
be involved in coordination of the radiometal. ' ' As shown in Figure 8 (Chapter I), 
the bioconjugate of both TETA (4) and CB-TE2A (10) possess an amide as the linking 
functionality between the BFC and the somatostatin derivative Y3-TATE. The amide is 
formed during the coupling of the N-terminus of the peptide to a free carboxylate on the 
BFC. In both cases, the overall charge of the bioconjugate is now different than the 
overall charge of the ligand-metal complex itself, due to the conversion of an ionizable 
pendant arm to a neutral amide. A further complication exists from a synthetic 
standpoint. Both TETA and CB-TE2A have more than one free carboxylate present for 
coupling with the N-terminus of Y3-TATE, resulting in poor yields of the desired 
bioconjugate (~ 10% yield).57 In order to sidestep this problem, macrocyclic chelators 
need be synthesized with only one free carboxylate in order to prevent the over-coupling 
with biomolecules. 
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Formation of mono-pendant-armed azamacrocyclic systems has been known in 
17^ 177 
the literature for some time. " From a synthetic standpoint, it is clearly easier to fully 
substitute polyamines with excess alkylating agent; however, preparation of single 
pendant armed polyamines requires a more selective synthetic approach. Weisman and 
coworkers developed novel mono iV-formyl protected cyclic polyamines from the 
hydrolytic cleavage of the corresponding orthoamides of 1,4,7-triazacyclononane and 
1,5,9-triazacyclododecane.178 Parker synthesized tritosyl cyclam, which was 
functionalized at the remaining secondary amine, and then detosylated to yield a mono-
pendant-armed derivative of cyclam. Kaden and coworkers synthesized a polyamine 
with one pendant arm by attaching it to a ring nitrogen before cyclization of the 
macrocycle. Unfortunately, the synthetic sequence was time consuming and required 
the cyclization procedure to be carried out every time a new derivative was made. Studer 
was able to prepare several tetraazamacrocycles with one pendant arm by utilizing a five-
1 CI 
fold excess of the macrocycle with an alkylating agent. The procedure relied on the 
ability to separate the mono-armed material from the starting polyamine which limits its 
use in more complex systems, as well as increasing the cost of expensive reagents. 
Handel and coworkers were able to form mono N-substituted derivatives of several 
tetraazamacrocycles through the coordination of a boron atom by three of the nitrogens in 
the ring, leaving the fourth nitrogen to react with the appropriate electrophile (Scheme 
30).182 The use of n-butyllithium as well as the sensitivity of the boron complex to H2O 
H r^i
 H 1 ^ „ A „ 
;» s B(NMe2)3> . A / S a s ? , rN N:] 
H-'HJ'-H ^(ji 3 ) H 2° H'^-R 
Scheme 30: General synthetic sequence developed by Handel to mono-alkylate cyclam. 
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made this procedure only applicable to systems with robust functionality. Handel also 
reported a procedure similar to the one described previously in which a tetraamine was 
used to coordinate to Mo(CO)3 or Cr(CO)3 instead of boron to occupy thee nitrogens of 
cyclam while the fourth could be alkylated.183 Although the reaction could be performed 
in "one-pot", over-alkylated material was found to be present in the crude product.183 
Hermann and coworkers were able to produce a cyclam derivative with one 
methylphosphonate pendant arm (Scheme 31).116 They utilized a procedure developed by 
Yang and coworkers which involved the tri-protection of cyclam with ethyl 
H f ^ l H O A I ^ X H 1^1 H 
rN N'N XS
 F A ^ F S C r V C F 3 D Paraformaldehyde, s" N ' N 
I J F3° ° ^ I J Triethyl phosphite I J O 
H'NL ,% Et3N,MeOH F»CTT > ^ ^ " H'V " M " 0 H 
^ ^ 92% yield O ^ - ^ 82% yield ^ - " ^ 
Scheme 31: Synthetic sequence to produce a methylphosphonate on cyclam. The first 
step was developed by Yang et al., the second step developed by Hermann et al.n 
trifluoroacetate.184 The reaction was run in neat ethyl trifluoroacetate yet interestingly, 
showed no presence of the tetraamide. This is in contrast to most reactions with cyclam in 
the presence of excess electrophile where the tetrasubstituted molecule is produced in 
significant quantities.184 The goal of this work will be to attain a synthesis of a single 
pendant arm derivative of CB-cyclam (8) and use that as a springboard for the synthesis 
of a range of unsymmetrical pendant-armed cross-bridged macrocycles. 
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II. Background 
The synthesis of mono-pendant-armed derivatives of CB-cyclen (7) and CB-
cyclam (8) and their conversion to unsymmetrical pendant-armed ligands has been 
reported and are based on two different synthetic strategies. The first is based on the 
benzylation/ reductive ring opening/ debenzylation procedure described previously 
(Scheme 11, Chapter 1)." The synthetic sequence, developed by Weisman, Wong and 
coworkers, relies on the regioselective dibenzylation of 31 (Figure 16, Chapter 1) in 
MeCN to yield dibenzyl salt 32 with benzyl protecting groups on non-adjacent nitrogens. 
A double reductive ring opening with NaBELt yields the dibenzyl cross-bridged ligand 
(33) which when subjected to hydrogenolysis forms the parent ligand 34. As described by 
Weisman, Wong and coworkers, the monobenzylation of bisaminal 31 (m=n=l) can be 
performed under kinetic control with benzyl bromide in toluene; dibenzylation was 
m 
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Scheme 32: Synthetic sequence to form monobenzyl salt 55; 3-D representation of 55. 
prevented by precipitation of 55.51 As seen in Scheme 32, the three-dimensional 
representation of 55 revealed the presence of a single exo lone pair which can be used for 
further chemistry, as confirmed by an X-ray crystal structure.51 Methylation of 55 was 
carried out with excess Mel in MeCN to yield mixed benzyl/methyl salt 56 which was 
55 
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reduced with NaBtLj to yield 57, as reported by Hill, in a two-step overall yield of 64-
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Scheme 33: Synthetic sequence to form single pendant-armed ligand 58 185 
single pendant-armed ligand 58. This synthetic sequence was the first reported to form 
a single pendant-armed cross-bridged ligand, however the methyl substituent can not 
coordinate a metal in the cleft of the ligand and is difficult to remove or functionalize. 
A variation of this procedure was developed by Bist that involved the addition of 
excess allyl bromide instead of methyl iodide to form monoallyl / monobenzyl salt 59 
Scheme 34).186 This salt was reduced in the presence of NaBtLj in good yield to afford 
unsymmetrical monoallyl/monobenzyl ligand 60. Unfortunately, attempts to remove the 
allyl protecting group were unsuccessful. Bist was also able to produce a variant of 55 
with a 4-nitrobenzyl protecting group instead of benzyl. The nitrobenzyl group could be 
reduced to an aniline pendant arm, providing a site to be used for further chemistry. 
56 
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Scheme 34: Attempted preparation of monobenzyl CB-cyclam (61).186 
A second strategy to form single pendant-armed derivatives of CB-cyclam (8) 
involved statistical alkylation of the parent ligand. Sprague et al. reported the synthesis 
(carried out by coauthor Yijie Peng) of r-butyl ester 62 from the statistical alkylation of 8 
NH N Na2C03, CH3CN ^NH N )l^ A ^ N N 
l ^ J RT, 14 h, 39% yield L J ° I I 
8 62 63 
Scheme 35: Preparation of mono-f-butyl ester 62. 
in a 0.1 M solution of MeCN with f-butyl bromoacetate (Scheme 35).54 The analysis of 
the crude mixture indicated the presence of 45-50% 62, dialkylated byproduct 63, and 
starting material 8. The desired product was isolated in a modest 39% yield after flash 
chromatography. Compound 62 was used to prepare a range of unsymmetrical pendant-
armed species and the in vivo stabilities of the corresponding 64Cu(II) complexes were 
analyzed.54 While the synthesis of 62 afforded a single pendant-armed ligand which 
57 
could be used as a starting point for a host of different unsymmetrical pendant-armed 
ligands, the yield of the reaction, as well as the method of purification, argues for the 
development of a new strategy for the formation of new single pendant-armed 
macrocycles. Herein, an unusually selective monoalkylation of CB-cyclam (8) with 
bromoacetamide will be discussed. The origin of the selectivity of the reaction has been 
probed and this new ligand has been used as a springboard for the synthesis of a range of 
new unsymmetrical pendant-armed species. 
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III. Results and Discussion 
A. Synthesis and Cu(II) Complexation of 4-(carbamoyImethyl)-lA8,ll-
tetraazabicyclor6.6.21hexadecane(64). 
CB-cyclam (8) was dissolved in MeCN and a solution of one equivalent of 2-
bromoacetamide in MeCN was added dropwise to 8 (final concentration of 8 in MeCN 
was 55 mM) in order to form ligand 64 (Scheme 36). The reaction was stirred at room 
temperature for 24 h under N2. The crude product was extracted from a strongly basic 
(pH =14) solution with CHCI3. Recrystallization of monoamide 64 from hot MeCN 
afforded the pure ligand in 84% yield. The 'H NMR of the crude solid (before extraction) 
S H S ^ MeCN,24h,N2 k N H k N ^ 
f \ 84% yield f j 
8 64 
Scheme 36: Synthesis of monoamide 64. 
indicated the presence of dialkylated ligand 66 in a 20:1 ratio of 65 to 66 (Scheme 37) as 
determined by the relative integrations of the AB resonances for the pendant-armed 
methylenes of 65 and 66. For every mole of 66 formed, one mole of protonated starting 
ligand 8H+ should be present. Although the presence of 8 was difficult to see in the'H 
NMR spectrum, the 13C NMR spectrum indicated the presence of another species in 
addition to 65 or 66. Although the reaction was expected to give a statistical alkylation, 
the reaction was clearly selective towards formation of 65. 
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Scheme 37: Ratios of products in the alkylation of CB-cyclam with 2-bromoacetamide as 
indicated by the crude *H NMR spectrum. 
The Cu(II) complex of ligand 64 was readily prepared from Cu(N03)2 in 


















Scheme 38: Complexation of ligand 64. 
crude product yielded the X-ray quality crystals which were used to determine the solid 
state structure (Figure 27), which confirmed an expected cis-V configuration of the 
ligand around the metal. Important bond angles and bond lengths are listed in Table 5. 
The Jahn-Teller elongation of the six-coordinate Cu(II) is shown in the Cu(l) - 0(6) 
(nitrate oxygen) bond at 2.662(2) A and the Cu(I) - N(l) bond at 2.177(0) A, which are 
longer than the Cu(l) - 0(1) (amide oxygen) distance of 1.983(4) A. The slightly 
distorted octahedral geometry of Cu(II) in the cleft of ligand 64 is confirmed by the near-
linear bond angles for N(l) - Cu(l') - 0(6) of 174.17(83)°, N(6) - Cu(l) - 0(1) of 
170.16(49)°, and N(3) - Cu(l) - N(2) of 177.45(31)°. Both nitrate counter ions are present 
in the structure which neutralize the charge from the Cu(II) and hydrogen bond with the 
60 
ligand. The nitrate bound to the Cu(II) is hydrogen-bonded with the amine hydrogen 
(H(42) - 0(5)) with a bond distance of 2.105 A. The second nitrate counter ion is 
hydrogen-bonded with the cis amide proton (H(40) - 0(3)) with a bond distance of 
2.008 A. 
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Table 5: Selected bond distances (A) and bond angles (°) for 67. 
61 
B. Experiments to Probe the Selectivity of the Formation of 64. 
(1) Computational analysis of T64H1+. 
The following experiments were carried out in an attempt to determine why the 
rate of the second alkylation of 8 with 2-bromoacetamide is so much slower than the rate 
of the first alkylation of 8 with bromoacetamide. As stated above, the alkylation of 8 with 
one equivalent of 2-bromoacetamide was expected to be a statistical one, but instead was 
selective for monoalkylation. To gain further insight as to why the second alkylation is 
significantly slower than the first, a molecular model of the reaction intermediate was 
studied using density functional theory (DFT). The XYZ coordinates of the X-ray crystal 
structure were used as a starting geometry. The Cu(II) and the two nitrate counter ions 
were subsequently removed from the input and a proton was added to the tertiary 
nitrogen bearing the pendant arm. This cationic species represents the reaction 
intermediate resultant from SN2 displacement. A Merck Molecular Force Field (MMFF) 
minimization produced a structure possessing a hydrogen bond between the lone pair of 
the secondary nitrogen and an amide proton with the amine proton exo to the cleft of the 
molecule (Figure 28 A). The secondary nitrogen was inverted, then reoptimized using 
MMFF to produce a second conformation; one with the amine proton endo to the cleft 
and a hydrogen bond between an amide proton and the exo lone pair of the secondary 
nitrogen (Figure 28 B). Both isomers (A and B) are in the [2323/2323] ligand 
conformation, B was found to be lower in energy by 3 kcal/mol. The distance between 
the amide NH and the secondary amine was 2.01 A in B and the angle from the amide 
nitrogen to the secondary amine nitrogen through the amide proton was 167°. Both of 
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these values are within the acceptable range for hydrogen bonding. Both geometries 
were reoptimized at the B3LYP/6-31+G* level. The DFT energies suggest that geometry 
B is lower in energy than geometry A by 1 kcal/mol in the gas phase. 
A B 
Figure 28: B3LYP/6-31+G* minimized geometries of [64-H]+, A and B. Geometry B is 
lower in energy by 1 kcal/mol, computed using Spartan '02. 
Figure 29: Representation of an intramolecular hydrogen bond between an amide NH 
and the lone pair of the secondary amine. 
63 
If an intramolecular hydrogen bond was present that tied up the lone pair of the 
secondary amine (Figure 29), the difference in rate of the second alkylation could be 
explained. 
(2) Synthesis of 4-(A^-methylcarbamoylmethyl)-1,4,8,11-
tetraazabicyclor6.6.21hexadecane (68) and 4-(N,N-diethylcarbamoylmethvl)-
1,4,8,1 l-tetraazabicyclor6.6.21hexadecane (69). 
In order to obtain additional experimental evidence for or against the involvement 
of an intramolecular hydrogen bond, the same reaction conditions for the formation of 64 
were used with chloro-Af-methylacetamide and chloro-./V,./V-diethylacetamide instead of 2-
( \ ) 1* !U C \ ) " 
NH N MeCN,24h, N2 V N H N 
l^  J 72% yield f I 
8 68 
CO 1!q-^ Ctf* + xCtf* " CO 
NH N , , _K1 NH N ^ \ . . ^ ^ ^ N N NH N 
k^ MeCN k^  ;" U kJ 
8 69 70 8 
Relative ratios 3 I 1 I 1 
Scheme 39: Synthesis of 68 and attempted synthesis of 69. 
bromoacetamide (Scheme 39). If the intramolecular hydrogen bond with an amide proton 
is the source of the selectivity, then the reaction with a secondary amide should show 
selectivity towards monoalkylation while the tertiary amide should not. The crude 
reaction mixture of the synthesis of 68 indicated a ratio of 8:1 of 68 relative to the 
64 
dialkylated species as determined by integrations of the AB resonances of the pendant-
arm methylene protons. Although the selectivity for monoalkylation was not as high as 
was the case for 64, the reaction was still reasonably selective. The product was isolated 
by recrystallization from MeCN which contained a ratio of 33:1 of 68 relative to the 
dialkylated species. The reaction of CB-cyclam (8) with one equivalent of chloro-./V,./V-
diethylacetamide revealed a 3:1:1 ratio of 69:70:8 based on the 'H NMR spectrum of the 
crude reaction mixture, indicating a much decreased selectivity. 
(3) Synthesis (as part of a mixture) of 4-carbo-r-butoxymethyl-l,4,8,11-
tetraazabicvclor6.6.21-hexadecane (62). 
The alkylation of 8 with r-butyl bromoacetate was carried out under the exact 
conditions (concentrations, temperature, etc.) used for the formation of 64 (55 mM 
MeCN) in order to determine the selectivity of the reaction. CB-cyclam (8) was stirred in 
^ ,,Bfqoxcyji°x orvJxXm 
N m ^ r MeCN (55 mM), ^ N H N T . © X A > ^ N f © k N S r © 
M N2,24 h, rt 1 * 1 * Br ^^CT^ I I • Br H tHT * Br 
8 62 H+ 69 H+ 8 H+ 
Relative ratios 2.7 '. 1 I 1 
Scheme 40: Attempted formation of mono-?-butyl ester 62 under the conditions for the 
formation of monoamide 64. 
MeCN with the alkylating agent for 1 day under N2 (Scheme 40). An analysis of the 
crude mixture by ]H NMR indicated the presence of a 2.7:1:1 ratio of 62:63:8, clearly 
indicating an approximately statistical alkylation of 8. The fact that the reactions of 8 
with 2-bromoacetamide and chloro-A^-methylacetamide show selectivity for 
monoalkylation while those with chloro-A^jV-diethylacetamide and £-butyl bromoacetate 
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are much less so, indicates that the amide NH appears to play a major role in the decrease 
in rate of the second alkylation of 64 and 68. 
(4) Analysis of H NMR chemical shifts of T64-H1+ under various 
concentrations. 
*H NMR has been used for the determination of the existence of intramolecular 
hydrogen bonds in solution.188"191 In order to differentiate between intra- and 
intermolecular hydrogen bonds, the chemical shift of any proton involved in a hydrogen 
bond can be plotted against various concentrations of the hydrogen-bonded species. A 
change in chemical shift upon a change in concentration suggests that an intermolecular 
hydrogen bond exists.190'191 Conversely, if the chemical shift of the hydrogen-bonded 
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Scheme 41: Synthesis of reaction intermediate model [64H+]TsO~. 
could be involved in an intramolecular hydrogen bond or no hydrogen bond at all. In 
order to determine if [64H]+ possessed an intramolecular hydrogen bond, a model of the 
reaction intermediate was studied in a range of concentrations in d3-MeCN and the amide 
chemical shifts were recorded. Monoamide 64 was dissolved in d3-MeCN to make a 55 
mM sample with one equivalent of anhydrous tosic acid producing [64H+]TsO~ 
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(Scheme 41). The 'H NMR chemical shifts were recorded for the downfield NH protons 
in a 55 mM (A), 5.5mM (B) and 0.55 mM (C) solution in d3-MeCN (Figure 30). The 
chemical shift data are summarized in Table 6. The "inside proton" corresponds to the 
ammonium hydrogen and its chemical shift is in the downfield region due to the 
hydrogen bonding character of the molecular cleft as well as the positive charge from the 
nitrogen (Figure 30). The change in chemical shift of the +NH proton over the course of 
two ten-fold dilutions is quite small (AS = 0.14), suggesting its involvement in an 
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Figure 30: Downfield region of H NMR of [64H+]TsO\ Compound concentration in A 
is 55 mM; concentration in B is 5.5 mM, concentration in C is 0.55 mM (The black 
arrows indicate the amide peak that shifts upfield upon dilution); a representation of the 
hypothesized reaction intermediate is shown on top. 
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Table 6: Chemical shift data (ppm) from Figure 17. 
intramolecular hydrogen bond. The secondary amine proton at 8 7.93 ppm changes very 
little upon dilution (A8 = 0.01), again suggesting participation in an intramolecular 
hydrogen bond. This is supported by the computationally-derived structure (Figure 28 
B). The downfield amide NH resonance (black arrow in Figure 30) shifts upfield 
considerably over the course of the two ten-fold dilutions (A8 = 0.42 ppm) with respect to 
the upfield amide NH (A8 = 0.13). The change in chemical shift for the upfield amide NH 
is comparable in magnitude to the change in chemical shift of the secondary amine 
proton, leading to the conclusion that the upfield amide proton could also be involved in 
an intramolecular hydrogen bond, while the downfield amide peak could be involved in 
1Q7 
an intermolecular hydrogen bond, most likely in the form of a dimer. However, Pernn 
has suggested that the HE proton tends to be downfield of the Hz proton in acetamide, a 




Figure 31: Nomenclature of amide hydrogens in acetamide; Hz is cis to carbonyl, HE is 
trans. 
assignments made by this !H NMR dilution study. The chemical shifts of the amide 
protons of acetamide are reported to be HE = 8 6.7 ppm and Hz = 8 6.4 ppm as a 3M 
solution in MeCN.195 However, there is evidence that as the concentration of amides 
decreases, the relative position of the chemical shifts of their amide protons switch (i.e. 
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the chemical shift of HE will decrease upon dilution eventually becoming upfield from 
the Hz proton).1 Further experimentation is required to solve this discrepancy. 
(5) Influence of dfi-DMSO on the chemical shifts of r64H+l TsO'. 
The addition of incremental amounts of a strong hydrogen bond accepter has 
helped in the differentiation between hydrogens that are involved in intra- and 
intermolecular hydrogen bonds. According to Anslyn and Dougherty, DMSO has one 
of the largest hydrogen bond accepting abilities (/?) of common solvents, thus its 
influence on chemical shift can be seen with the addition of small quantities of it.197 All 
NH protons in [64-H+]TsO" should hydrogen bond with DMSO to force a downfield shift 
in their !H NMR resonances, however, those involved in an intramolecular hydrogen 
bond should show less change upon the addition of DMSO, due to the competition 
between hydrogen bond acceptors. Ligand 64 was dissolved in d3-MeCN with one 
equivalent of anhydrous tosic acid to make a 55 mM solution, the concentration at which 
the alkylation of 8 and bromoacetamide was run. d6-DMSO was added to create 5% and 
10% (vol:vol) solutions in d3-MeCN and the chemical shifts of the NH protons were 
measured (Figure 32, Table 7). 
The overall change in chemical shift (A5) of the +NH inside proton was negligible 
upon the addition of d6-DMSO. This was expected as the inside proton is encapsulated in 
the molecular cleft of [64H+]TsO~, minimizing the exposure to solvent. The overall 
downfield shift of the sec NH resonance indicated a slight equilibrium exposure to the 
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Figure 32: Downfield region of !H NMR of [64H+]TsO", A: 55mM in d3-MeCN, B: 5% 
d6-DMSO, C: 10% d6-DMSO. 
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Table 7: Chemical shifts of NH protons in 'H NMR of [64-H+]TsO 
intramolecularly hydrogen-bonded, however, this DMSO study suggested that this NH 
was also partially exposed to solvent. Both the upfield amide NH resonance and 
downfield amide NH resonance shift downfield upon the addition of d6-DMSO, however, 
the upfield resonance shifts downfield 1.6 times further than the downfield resonance. 
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The difference in the change of chemical shift (A8) indicated that one of these amide 
NH's was involved in an intramolecular hydrogen bond, most likely the downfield amide 
resonance due to the smaller change of chemical shift over the additions of d6-DMSO. 
However, the *H dilution experiment suggested that the upfield resonance was involved 
in an intramolecular hydrogen bond. Alternative experiments were required to solve the 
discrepancy in the data. 
(6) Attempted determination of the rate of H/D exchange of NH protons in 
r68-Hl+. 
Proton exchange rates have been utilized for the determination of protein folding 
for several years. " Professor Brian Linton (Bowdoin College) has used H/D 
exchange rates to quantify hydrogen bonding in small amides.202 Based on personal 
correspondence with Prof. Linton, the H/D exchange rate of [68-H]+ could provide 
insight into the presence or absence of an intramolecular hydrogen bond when compared 
to that of a model amide. Due to the nature of a hydrogen bond, the rate of exchange of a 
proton involved in a hydrogen bond should be slower than that of one that does not 
hydrogen bond under the same set of conditions. The measurement of the H/D exchange 
rate of jV-methylacetamide, (which is an appropriate model for the secondary amide in 
68) was attempted (Figure 33). The experiment was carried out in a 55 mM solution of 
./V-methylacetamide in MeCN with 100 molar equivalents of d4-MeOD relative to 1 molar 
equivalent of ./V-methylacetamide in order to maintain pseudo-first order kinetics. Under 
these conditions, the equilibrium was reached in less than 2 min, preventing the kinetic 
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Figure 33: Proposed H/D exchange of 7V-methylacetamide and 68 with d4-MeOD to 
determine the presence of an intramolecular hydrogen bond. 
MeOD relative to 1 molar equivalent of N-methylacetamide. According to Anslyn and 
Dougherty, in order to maintain pseudo-first order conditions, there must be at least a 
i nn 
10:1 molar ratio of reagents. Comparison of the H/D exchange rates of N-
methylacetamide and that of [68H]+ required that the conditions be identical, thus with 
three exchangeable protons on the protonated ligand [68H]+, 30 equivalents of d4-MeOD 
provided enough deuterium to maintain pseudo-first order conditions over the course of 
this reaction. However, the reaction with jV-methylacetamide reached equilibrium in less 
than 2 min, making measurement of the reaction rate by NMR too difficult. An attempt 
was made to measure the H/D rate of exchange on ./V-methylacetamide in CDCI3, a less 
polar solvent also preferred by Prof Linton. However, equilibrium was still reached in 
less than 2 min in a 55 raM solution of ./V-methylacetamide in CDC13. Due to the inability 
to measure an H/D exchange rate of a model molecule, further experiments in this respect 
were abandoned. 
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(7) Antiperiplanar coupling of pendant arm methylene carbon and amide 
hydrogen in a gHMBC. 
In order to fully understand the results obtained from the 'H NMR dilution 
experiment described above (vide supra), the identification of amide resonances must be 
made via an independent experiment, ^-coupled 13C NMR spectroscopy has been useful 
for the determination of dihedral dependence in coupling though an amide 
functionality. In the case of acetamide, coupling was seen between the methyl carbon 
and an amide NH (Figure 34), however, no coupling was seen between the acetyl methyl 
carbon and the amide proton in N-methylacetamide (Figure 34).203 Because N-methyl 
acetamide is known to exist in predominantly the trans conformation, the coupling in 
acetamide must be seen only between the so-called cis amide proton and the acetyl 
Coupling seen 
O > O 
H 3 C r V H CIS H3C^N 
V H VH 
^ - ^ trans ^ 
No coupling seen No coupling seen 
Figure 34: ^C/'H coupling in acetamide and N-methyl acetamide. 
carbon. The observation of coupling between the acetyl methyl carbon and an 
antiperiplanar amide NH would allow for the identification of both amide resonances in 
the ]H NMR spectrum of [64H+]TsO. A gHMQC spectrum was used to identify the 
methylene carbon of the pendant arm of [64H+]TsO\ The gHMBC (Figure 35) 
spectrum revealed no coupling between either amide resonance and the pendant arm 
methylene (methylene carbon and amide resonances identified by black arrows). The 
exchange of the two amide resonances could have averaged out the appearance of any 
coupling in the 2D experiment. Attempts to increase the amplitude of the cross peaks 
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only made the contour plot noisier. As such, the gHMBC failed to help assign the amide 
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Figure 35: The gHMBC spectrum of [64H+]TsO\ 
(8) Through-space coupling of NH protons of r64H+lTsO' in a 2D NOESY. 
Nuclear Overhauser Enhancement Spectroscopy (NOESY) is a useful technique 
to aid in the determination of the three-dimensional solution structure of hydrogen-
bonded systems.191 Presumably, if an amide NH of [64H+]TsO is hydrogen-bonded to 
the lone pair of the secondary amine, then there should be a difference in enhancement 
between one amide NH and the amino proton and the other amide NH and the amino 
proton. The 2D NOESY plot is shown in Figure 36. The spectrum indicated that both 
amide resonances contained an NOE with the amino proton. Attempts to quantify the size 
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of the enhancements were unsuccessful. Independent verification of the amide resonance 







Figure36: 2D NOESYof [64H+]TsO 
C. Synthetic Derivatives of Monoamide 64. 
(1) The synthesis of 4-acetoamido-ll-carbo-?-butoxymethyl-l,4.8.11-
tetraazabicvclor6.6.21hexadecane (71). 
Monoamide 64 can be used as a springboard for the synthesis of a range of 
unsymmetrical pendant-armed cross-bridged ligands, taking advantage of the high yield 
single alkylation reaction. The preparation of monoamide / mono-r-butyl ester ligand 71 
75 
was previously reported and isolated in a 17% overall yield from CB-cyclam (8) 
(Scheme 42).54 The low yield of the first reaction was due to the statistical alkylation 
NH N Na2C03, MeCN, ^NH N Na2C03, MeCN, X N N 
C j 14h,RT L J 14h,RT H j N ' ^ l j 
^ ^ 39% yield ^ 43% yield \ ^ 
8 62 71 
Scheme 42: Preparation of ligand 71 as previously reported. 71 was isolated in a 17% 
overall yield from ligand 8. 
of ligand 8 and necessary column chromatography to isolate pure ligand 62. However, 
when the synthetic approach towards ligand 71 utilized monoamide 64 as the synthetic 
intermediate, ligand 71 was isolated in an overall yield of 68%, making this a viable and 
much improved approach to cross-bridged derivatives (Scheme 43). 
NH N MeCN, 24 h, N2 k N H N Microwave 70 °C, X ^ A ^ N N 
l ^ J 84% yield | ^ | 30 min, 80% yield ° k j 
8 64 71 
Scheme 43: Alternative synthetic route towards the formation of mixed pendant armed 
ligand 71. 
(2) The synthesis and characterization of 4-carboxvmethyl-1,4,8,11-
tetraazabicyclor6.6.21hexadecane dihvdrochloride trihydrate 
(72-2.3HC12.8H20). 
The monoarmed ligand, CB-TE1A (72), has been prepared from the 
trifluoroacetic acid mediated deprotection of ligand 62 and was isolated as a 
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trifluoroacetate salt. Acid hydrolysis of ligand 64 with 6M HC1 produced ligand 72 as an 
HC1 salt in a 98% yield (Scheme 44). CB-TE1A was characterized by 'H, "Cl 'H} NMR 
^
N C r 6MHCI> r % N ^ X - 2 3 H C I 
NH N Microwave ^ N H N • 2.8 H20 
f J 150 °C, 30min f J 
^ ^ 98% yield ^ ^ * NH4CI 
64 72 
Scheme 44: Acid mediated hydrolysis of monoamide ligand 64. 
and Laser Desorption Ionization Mass Spectrometry. One molar equivalent of ammonium 
chloride was present in the sample as well. The free amine potassium carboxylate salt of 
ligand 72 was isolated by acid hydrolysis of ligand 64, followed by a CHCI3 extraction 
from a strongly basic aqueous KOH solution (Scheme 45). Ligand 73 was characterized 
by *H, "Cf'H} NMR and HRFABMS. 
I l / \ /NH2 i I / ^ r>K 
N N C ^ Y 1)6MHCI ^ N N ^ Y C -v. " \ II i) " iv n v i s"v. " v . || . . n k J Microwave ^ M U ^ M ^ 
N H N
 -ten or- on
 m in N H N 
1 1 150 G, 30 min I i 
\ / 63% yield \ ^ 
64 2 > K O H 73 
Scheme 45: Synthesis of ligand 73. 
(3) The synthesis and characterization of 4-benzyl-l 1- carboxvmethvl -1,4,8,11-
tetraazabicyclo[6.6.21hexadecane dihydrochloride monohydrate 
(752.5HCM.5H7Q). 
Weisman, Wong and coworkers have shown that Cu-CB-TEl A has comparable 
acid dissociation kinetics and resistance to Cu(II)/Cu(I) reduction relative to Cu-CB-
TE2A indicating that only one carboxylate is required in order to retain the kinetic 
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inertness of the complex.204 Recent reports have suggested that increasing the lipophilic 
character of a BFC can impart improved biodistribution properties of the complex. ' 
Ligand 75, an appropriate model ligand for such work, was synthesized from a two-step 
sequence starting from monoamide 64 (Scheme 46). Unsymmetrical pendant-armed 
r V i T ^ , ^ C \ ] o 6MHCI, ^ r \ l l - 2 5 H C I 
NH N MeCN 70 °C k ^ V ^ N N Microwave ' ^ A ^ N N •1.5H20 
k j 24h,N2 ' k j 150°C,30min ^ J 
98% yield 9 4 % y ie ld N H 4 C I 
64 74 75 
Scheme 46: Two step synthesis for ligand 75 from monoamide 64. 
ligand 74 was prepared by alkylation with a small excess of benzyl bromide in MeCN at 
reflux for 1 day. The ligand was isolated by extraction from a strongly basic aqueous 
solution in excellent yield. The white solid was characterized by 'H, " C ^ H } NMR and 
HRFABMS and required no further purification. The acid-catalyzed hydrolysis of ligand 
74 was completed under microwave conditions (150 °C, 30 min) in a closed vessel 
microwave reactor. The residue was dissolved in H2O and the solvent was removed under 
reduced pressure in order to remove excess HC1 from the sample. Ligand 75 was isolated 
as a white solid in excellent yield and characterized by 1H, 13C{ XH} NMR and 
electrospray ionization mass spectrometry. The elemental analysis of ligand 75 indicated 
the presence of 2.5 molar equivalents of HC1, 1.5 molar equivalents of water and 1 molar 
equivalent of ammonium chloride relative to 1.0 molar equivalent of 75. 
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(4) The synthesis and characterization of 4-(2-carbamoylethyD-l 1-
(carbamoylmethyl)-1,4,8, ll-tetraazabicyclor6.6.21hexadecane(76-0.5H?O) 
As described previously (Chapter 1), Heroux and coworkers compared the 
kinetic inertness of Cu(II) complexes of ligands containing Af-carboxyethyl pendant arms 
and Af-carboxymethyl pendant arms. The results of the experiments indicated that the N-
carboxyethyl pendant arms caused a decrease in both the half-life of decomplexation of 
the complex in 5M HC1 and the resistance to Cu(II)/Cu(I) reduction. The Cu(II) complex 
of a ligand containing one ,/V-carboxymethyl pendant arm and one ./V-carboxyethyl 
pendant arm could provide more insight into the relationship between pendant arm length 
and kinetic inertness. Monoamide ligand 64 and acrylamide were allowed to stir in 
MeCN for 5 days (Scheme 47). The crude solid was washed with hot EtOAc to remove 
o ^^^ 
c\y> -J - r \ } I ..H.ci-/.H-20^ C \ ] ° 
NH N MeCN, RT, H ^ N ^ - Z ^ N N H C X / \ ^ N N U 5d,N2 T U T U 
^ ^ 99% yield O ^ ^ O ^ ^ 
64 76 77 
Scheme 47: Synthesis of ligand 76 and proposed synthesis of ligand 77. 
excess acrylamide. White solid, 76, required no further purification and was characterized 
by 'H, 13C{]H} NMR and HRFABMS. Elemental analysis indicated the presence of 0.5 
molar equivalents of water relative to 1.0 molar equivalent of 76. Acid hydrolysis of 
ligand 76 to ionizable ligand 77 was never attempted and should be followed up in the 
Weisman-Wong group in the future. 
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IV. Conclusion 
An unusually selective mono-alkylation of parent ligand CB-cyclam (8) with 2-
bromoacetamide in MeCN allows preparation of monoamide ligand 64 in high yield. An 
X-ray structure of 67 was obtained and indicated a six-coordinate geometry about the 
Cu(II) with a Jahn-Teller elongation along the Cu(l) - 0(6) (nitrate counterion) bond. 
The selectivity*of the monoalkylation was hypothesized to stem from an intramolecular 
hydrogen bond that could exist from the amide proton to the secondary amino nitrogen 
lone pair (Figure 29). B3LYP/6-31+G* minimized geometries of [64H+] indicated the 
presence of a hydrogen bond in a low energy conformation. Alkylations of CB-cyclam 
with chloro-A^-methylacetamide, chloro-A^TV-diethylacetamide and f-butyl bromoacetate 
indicated the requirement of one amide proton in order to observe high selectivity for 
monoalkylation. The chemical shifts of the N/f protons of [64H+]TsO~ were measured 
as a function of concentration to determine which protons were involved in intra- and 
intermolecular hydrogen bonds. Only one amide NH was found to significantly change 
chemical shift upon dilution, which suggested that the other amide NH was involved in 
an intramolecular hydrogen bond. The NH resonances in the 'H NMR spectrum of 
[64H+]Ts0~ were measured upon the addition of d6-DMS0. Both amide resonances 
shifted downfield upon this addition, however, the chemical shift of the resonance 
identified as that involved in an intramolecular hydrogen bond shifted further downfield 
than the other amide NH peak. This result is in conflict with the conclusions based upon 
lH NMR dilution study. The measurement of the H/D rate of exchange of N-
methylacetamide was attempted for comparison with the H/D rate of exchange with 
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[68H] to indicate the presence of a hydrogen bond. However, conditions could not be 
found to measure the H/D exchange rate of the model compound. gHMBC and NOES Y 
were utilized to attempt to independently identify both amide resonances and find 
coupling through the proposed hydrogen bond, respectively. Unfortunately both 
experiments failed to provide information to either validate or invalidate the hypothesis. 
The origin of the selectivity of the monoalkylation is still not fully understood. Several 
other ligands were shown to be obtainable utilizing monoamide 64 as a synthetic starting 
point. The synthesis of ligand 71 was improved utilizing monoamide 64 as a synthetic 
intermediate. Acid-catalyzed hydrolysis of 64 afford CB-TE1A (72) and, following an 
extraction from a strongly basic KOH solution, potassium carboxylate salt 73. Ligand 75 
was formed in a two step synthesis from monoamide 64. The corresponding Cu(II) 
complex can be used as a model for bioconjugates possessing one carboxylate pendant 
arm and one lipophilic pendant arm. Michael addition of acrylamide with 64 afforded 
ligand 76, however the hydrolysis was not attempted. 
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Chapter III 
ADVANCES IN THE SYNTHESIS OF CROSS-BRIDGED CYCLAMS BEARING 
PHOSPHONIC ACID PENDANT ARMS FOR USE IN 
RADIOPHARMACEUTICALS 
I. Introduction 
Radiopharmaceutical agents have the ability to be used both as imaging agents 
and in targeted therapy applications.41'207 Those that act through receptor binding are 
classified as receptor-based target-specific radiopharmaceuticals. " These types of 
systems have the general structure shown in Figure 37. The radionuclide is coordinated 
Linker / PKM AAAAA/VAAAAAfl 
Figure 37: General structure of a receptor-based target-specific radiopharmaceutical. 
to a bifunctional chelator (BFC), an organic molecule that both coordinates with the 
metal as well as provides a covalent linkage to the rest of the system. The targeting 
molecule can be large biological molecules such as a peptide, protein or antibody, or a 
smaller organic molecule such as dopamine or folic acid.205'208 These two major 
components are covalently linked by a pharmacokinetic modifier (PKM). The choice of 
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this linking functionality is dependent on the desired properties of the overall 
radiopharmaceutical.205 The linker can be a simple hydrocarbon chain to tune 
lipophilicity or a peptide to increase the overall hydrophilicity. The biodistribution 
properties of several n i In and 99mTc complexes have been reported to change through 
alteration of the PKM.209'210 The 8 -amino acid peptide, "Octreotide", has been labeled 
with11'in using diethylene triamine pentaacetic acid (DTPA) as a BFC and is available 
for human use as a diagnostic imaging agent for neuroendocrine tumors (Figure 38) 205 
Unfortunately, DTPA was found to be a poor ligand for 64Cu(II) complexation as a 
H 0 2 C ^ /—\ / — \ /—C0 2 H 
N N N 










Figure 38: BFC DTPA and [1HIn]DTPA-octreotide (OctreoScan). 
large amount of the 64Cu(II) complex was found to dissociate in human serum.42'211 It has 
been demonstrated that cyclic BFCs form kinetically more inert complexes than their 
acyclic analogues, a necessary trait for 64Cu(H)-containing radiopharmaceuticals used in 
PET (Positron Emission Tomography) imaging. 42 
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Positron Emission Tomography is a nuclear medicine imaging technique that can 
image structures and physiological processes in a living organism.208 Generally, it relies 
on the ability of a biologically-significant molecule to deliver a positron-emitting 
radiometal to a target organ. As the metal decays (Figure 39), it ejects a positron from 
the nucleus which will annihilate upon contact with an electron, releasing two 511 keV 
511 keV y-ray 
positron emission n - ^ 
«Cu • P+ P annihilation 
(t1/2 = 12.8 h) . . . . 
v
 "^ ' 511 keV y-ray 
Figure 39: Radioactive decay of 64Cu; emitted positron (P+) is annihilated with an 
electron (P") releasing two gamma rays in opposite directions. 
90R 
gamma rays 180° apart. The gamma rays are detected by a circular array of 
photomultiplier tubes and the location of the radionuclide is determined through 
tomographic image reconstruction, a process that creates 2D cross-section data. The 
selection of a radiometal is critical in the design of a radiopharmaceutical used as a PET 
imager because the half-life should be long enough to allow for significant organ uptake 
9flR 91 "\ 
and radioactive decay to yield considerable contrast. ' The benefit of utilizing 
radioisotopes of copper lies in the well-established coordination chemistry of the metal, 
9f\R 911 
the range of half-lives and the range of energies of emitted particles. ' Table 8 lists 
the decay characteristics of various copper isotopes, however, only Cu is used in PET 
imaging. 60Cu, 61Cu and 62Cu are all positron emitters and can emit photons by electron 
capture, making them useful in imaging applications. Cu can emit an electron from its 
nucleus while 64Cu emits positrons, electrons and photons by electron capture, making 
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them useful for therapeutic applications. 60Cu, 61Cu 62Cu and 64Cu can all be used for 
SPECT (Single-Photon Emission Computed Tomography) imaging as they all emit X-ray 

































Table 8: Decay characteristics of copper radionuclides. 
As described previously (Chapter 1), 64Cu-TETA-Y3-TATE and 64Cu-CB-
TE2A-Y3-TATE were evaluated as radiopharmaceuticals for the detection of 
neuroendocrine tumors (Figure 40).57 The data reported suggested that cross-bridged 
H 
OOOC . N „ N N-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(OH) 
S S 
6 4Cu-TETA-Y3-TATE 
r ^ H 
I l/\.N-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(OH) 
64Cu-CB-TE2 A-Y3 -TATE 
A-Y3-TATE and 64Cu-CB 
charges are -1 and +1 respectively. 
Figure 40: Bioconjugates 64Cu-TET - -   64 u- -TE2A-Y3-TATE. Overall 
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ligands are superior BFC's for use in radiopharmaceuticals due to their kinetic inertness 
and favorable biodistribution properties.57 However, a larger retention of 64Cu was found 
in the liver after administration of 64Cu-CB-TE2A-Y3-TATE compared to 64Cu-TETA-
Y3-TATE. The authors suggest that the difference in the overall charge of the 
bioconjugate was related to the difference in renal retention.57 Studies have reported a 
correlation between charge and renal uptake of 4Cu and n In compounds. ' ' Renal 
uptake of n l In was largest for positively charged peptide conjugates and lowest for 
negatively charged peptide conjugates,215 and a similar result was seen with 
azamacrocyclic complexes of 64Cu.40 Tuning the lipophilicity of bioconjugates as well as 
maintaining charge neutrality are interesting modifications that could be made to the 
complexed bioconjugates of cross-bridged BFC. 
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II. Background 
Weisman, Wong and coworkers proposed the formation of a second generation of 
cross-bridged azamacrocyclic systems bearing only one ionizable pendant arm.204 Their 
idea was based on the retention of solution inertness and reduction stability in vivo of the 
BFC of 64Cu-CB-TE2A-Y3-TATE, as described previously.216 This was unexpected as 
the bioconjugates' overall charge was +1 (Figure 40) while the acid-assisted dissociation 
kinetics and resistance to Cu(II)/Cu(I) reduction were determined on charge neutral Cu-
CB-TE2A. The model compound, CB-TE1A (72), was complexed with Cu(II) and 
exhibited a reduction potential (Em) of only 120 mV higher than Cu-CB-TE2A (-0.95 
versus -1.07 V respectively) while maintaining quasi-reversibility. This suggests that 
single-pendant arm carboxylate ligands should form stable Cu(II) complexes for in vivo 
applications. 
Phosphonic acid pendant arms on CB-cyclam (8) have been studied for their role 
in Cu(II) coordination chemistry (vide supra). Cu-CB-TE2P (51) was evaluated as a 
model complex for radiopharmaceutical applications by acid-assisted decomplexation 
(ti/2(5 M HC1, 90 °C) = 3.8 h), resistance to Cu(II)/Cu(I) reduction (quasi-reversible, Ep = 
-0.96 V) and biodistribution in male rats (Chapter 1). These data confirm that 
phosphonic acid pendant arms are a suitable alternative to carboxylate pendant arms on 
cross-bridged ligands. Replacement of the carboxylate arm on CB-TE2A-Y3-TATE with 
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a phosphonic acid arm allows for the formation of a charge neutral bioconjugate (Figure 
41) which has the potential to show improved biodistribution properties compared with 
charged analogues.40'57'215 
Figure 41: BFC complex of proposed bioconjugate with a single phosphonic acid 
pendant arm. 
The formation of 64Cu-CB-TE2A-Y3-TATE from a diprotected CB-TE2A has 
been reported and is shown in Scheme 48.57 The f-butyl protected CB-TE2A is 
OH 
Q f ^ i 1) Deprotection f ^ 
/ \ s r r l ^ 2) Bioconiuqation r (C\ 
U " ° 3) 6<Cu labeling U K l ^ S " " M K 
H O ^ ° H ^ O H 
Scheme 48: Formation of 64Cu-CB-TE2A-Y3-TATE. 
deprotected in the presence of weak acid trifluoroacetic acid (TFA), isolated as a TFA 
salt and then conjugated to Y3-TATE using solid-phase peptide synthesis methods.216 
Complexation with 4Cu was done with a large excess of CB-TE2A-Y3-TATE and 
radiochemical purity was determined by radio-TLC. Unfortunately, the hydrolysis of an 
ethyl phosphonate on CB-cyclam {vide supra), which required strong acid and high 
temperatures, was isolated as an HC1 salt. The presence of HC1 could denature a peptide 
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during the course of bioconjugation. As such, preparation of a f-butyl phosphonate was 
proposed. Scheme 49 shows the proposed retrosynthetic analysis for the formation of 
potential BFC 78, a mixed-pendant arm ligand with a f-butyl protected phosphonic acid 
3^ ° ^ k^ <J 
78 79 64 
Scheme 49: Retrosynthetic analysis of the formation of potential BFC 78. 
pendant arm for coordinating a metal and a methyl carboxylate pendant arm for coupling 
with the N-terminus of Y3-TATE. The proposed synthesis is based upon the formation of 
monoamide 64, described previously (Chapter 2). Hydrolysis of 64 yields ligand CB-
TE1A (74, Chapter 2). Esterification of carboxylic acid 72 with benzyl alcohol would 
form ligand 79. Formation of a ?-butyl protected phosphonate pendant arm on ligand 79 
followed by hydrogenolysis to remove the benzyl protecting group would yield ligand 78, 
which can be further coupled with Y3-TATE then deprotected in order to prepare a 
bioconjugate for study. 
Recent literature reports have indicated that an increase in lipophilicity of a BFC 
can impart improvements, such as faster liver clearance, in the biodistribution of either 
the BFC or related bioconjugates. ' In order to determine the effect of linker 
character on cross-bridged ligands with phosphonic acid pendant arms, the formation of 
compound 86 was proposed (Scheme 50). This synthesis was based on previous work by 
1 86 
Shanta Bist, as well as current research being developed in the Weisman research 
group.217 The proposed synthetic sequence involves the isolation of mono-p-nitrobenzyl 
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salt 80, a compound originally synthesized by Bist, but has also been reported by 
Hermann. The addition of an allyl protecting group on ligand 80 could afford mixed 
pendant-armed salt 81. Double reductive ring opening of ligand 81 can yield 
unsymmetrical cross-bridged ligand 82 which can be deallylated in the presence of 
potassium r-butoxide and DMSO to yield mono p-nitrobenzyl CB-cyclam 83. 
Deallylation can occur through the formation of a dimsyl anion in situ which can 
isomerize the allyl functionality to an enamine followed by cleavage with H2O. These 
conditions have been reported previously,219"223 but have been carried out by current 
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members of the Weisman research group. Mannich-like conditions can be used for the 
formation of ?-butyl protected phosphonates followed by reduction of the p-nitro 
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Scheme 50: Proposed formation of ligand 86. 
substituent to ap-amino functionality forming ligand 85. Addition of succinic anhydride 
yields ligand 85 which can be coupled to a biological molecule via the N-terminus. 
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Herein are reported the attempted synthetic formations of two single phosphonate 
pendant-armed cross-bridged ligands 78 and 86 as potential BFCs for use in 
radiopharmaceuticals. 
91 
III. Results and Discussion 
A. Attempted Preparation of Ligand 79. 
(1) Fischer esterification of CB-TE1A (72). 
The synthesis of a benzyl ester of ligand CB-TE1A (Scheme 51) is critical 
because a free carboxylate can attack tri-f-butyl phosphite, the reagent used to form t-
77 
butyl protected phosphonates in the following step, allowing multiple products to form. 
Unfortunately, ligand 72 is soluble in only MeOH, EtOH and water. The presence of 
either alcohol will compete with benzyl alcohol (BnOH) for Fischer esterification and the 
presence of water will force the equilibrium towards ligand 72. Several different reaction 
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Scheme 51: Proposed formation of ligand 79 by Fischer esterification. 
trials were attempted and are summarized in Table 9. Ligand 72 was isolated as a 
hydrochloride salt (2.3 molar equivalents) and attempts at Fischer esterification were 
carried out without the presence of another acid. Removal of water produced by the 
Fischer esterification has been accomplished by azeotropic distillation with toluene or 
benzene in a Dean-Stark trap.224 After 6 days at reflux with a Dean-Stark trap, only 
starting material could be seen in the !H NMR spectrum of the crude product. The lH 
NMR spectrum of the reaction with BnOH in d6-DMS0 at room temperature was 
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analyzed daily. The reaction afforded no product after 7 days. Microwave heating 
conditions were implemented, and Et20 was used to wash away excess BnOH. *H NMR 
spectrum of the crude reaction material indicated the presence of starting material and 
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Table 9: Reaction trials with ligand 72 and BnOH to form 79. 
Fischer esterification was then attempted in the presence of catalytic amounts of 
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Table 10: Reaction trials with ligand 72, BnOH and TsOH to form 79. 
out in neat BnOH at 70 °C with conventional heating and 30 min at 125 °C with 
microwave heating. The !H NMR spectrum in both cases, after removal of BnOH with 
Et20, indicated no reaction had taken place. The polarity of the solvent in these cases 
could not have been high enough to stabilize the transition state of the reaction (the 
dielectric constant of BnOH is 4.5 at 30 °C)225 thus increasing the time required to reach 
equilibrium. As such, reactions were attempted in more polar solvents MeCN (dielectric 
93 
constant = 37.50 at 20 °C) and DMF (dielectric constant = 36.70 at 20 °C). Starting 
material 72 does not appear to be soluble in either solvent, but may have some slight 
solubility at high temperatures. However, both trials indicated only the presence of 
starting material and benzyl alcohol. The only reaction trial that indicated the presence of 
some product was conducted under microwave heating in neat BnOH with 0.1 molar 
equivalents of TsOH relative to 1.0 molar equivalents of 72. LDI (Laser Desorption 
Ionization) mass spectrometry of the crude product indicated the presence of benzyl ester. 
However, after a basic extraction from an ice cold aqueous phase, only starting material 
was isolated. 
(2) Coupling of CB-TE1A (72) with benzyl alcohol in the presence of DCC and 
DMAP. 
Coupling reactions are a common technique for the formation of esters utilizing 
dicyclohexylcarbodiimide (DCC) and dimethylamino pyridine (DMAP). The carboxylate 
adds to DCC allowing the newly formed ester to be easily cleaved by any alcohol present. 
Ligand 72 was partially dissolved in DMF in the presence of DCC and DMAP following 
a procedure for the formation of benzyl esters of amino acids (Scheme 52). The crude 
reaction mixture indicated no product had formed after 2 days. The same result was seen 
after 7 days. 
c y>Y .2,HC, U rNv5T 
V Y # 2 8 H 2 ° DCC, DMAP Y Y 
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Scheme 52: Proposed formation of ligand 79 by a coupling reaction. 
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(3) Alkvlation of CB-TE1A-K+ (73) with benzyl bromide 
Alkylation of amino acids with benzyl bromide is well known and several 
reported procedures have been recently published.227"232 Unfortunately, CB-TE1A (72) 
possesses two nucleophilic sites: a free carboxylate and a secondary amine. In order to 
impart some enhanced nucleophilic character to the carboxylate, alkylation with one 
equivalent of benzyl bromide was carried out with the potassium salt of CB-TE1A (73) 
cftr .02": eft*" 
NH N Morw NH N 
I I MeCN I | 
73 79 
Scheme 53: Alkylation of ligand 73 with benzyl bromide. 
(Scheme 53). The crude lH NMR spectrum indicated the presence of three AB 
resonances and no free benzyl bromide. This indicated that the rates of alkylation of the 
secondary amine and the free carboxylate are similar under these conditions. 
In order to attempt to slow down the rate of alkylation at the secondary amine 
relative to the rate of alkylation of the free carboxylate, another alkylation was carried out 
with ligand 73, but as a tosic acid salt (Scheme 54). The highly basic nature of the cross-
bridged ligand should ensure that once protonated, the lone pair of the secondary nitrogen 
would be involved in a hydrogen bond, slowing down its rate of alkylation relative to the 
free amine. Ligand 73 was protonated with one equivalent of anhydrous tosic acid in 
MeCN and stirred for 10 minutes. One equivalent of benzyl bromide was added and the 
reaction was stirred for 24 hours. 'H NMR of the crude product indicated the same result 
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as previously described. Further attempts at formation of ligand 79 via alkylation were 
abandoned. 




 2)BnBr,MeCN ^ J 
73 79 
Scheme 54: Attempted synthesis of ligand 79. 
(4) Fischer Esterification of ligand 72 with MeOH 
An alternative approach towards the formation of ligand 79 involves the 
esterification of 72 with MeOH in order to form methyl ester 87 followed by 
transesterification with benzyl alcohol (Scheme 55). Although this synthetic 
^NH^N^ •2.8H20 H+ NwNr S H S ^ 
^ -NH.C, ^ <J 
74 87 79 
Scheme 55: Proposed formation of ligand 79 by Fischer esterification with MeOH 
followed by transesterification. 
pathway adds a step to the synthesis of 78, it avoids the use of large amounts of high 
boiling benzyl alcohol, a difficult solvent to remove. Also, the solubility of ligand 87 may 
be greater in a larger range of solvents compared to that of 72 which has limited 
solubility. Reaction trials for the formation of ligand 87 are summarized in Table 11. 
Since 72 is isolated with 2.8 molar equivalents of HC1 relative to 1.0 molar equivalents of 
the ligand, the HC1 already present could act as the necessary catalyst. Compound 72 was 
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dissolved in MeOH and heated at reflux for 1 day over 3 A sieves. The crude lH NMR 
spectrum indicated no reaction had taken place. Fischer esterification of ligand 72 was 
attempted with both an ion exchange resin and a drop of 0.1 M HC1 as the acid catalyst, 
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Table 11: Reaction trials for the formation of methyl ester 87. 
B. Attempted Formation of Mono p-nitrobenzyl Ligand 83. 
In order to determine the kinetic inertness and biodistribution properties of a 
single phosphonic acid pendant-armed cross-bridged cyclam, model ligand 90 was 
prepared from monobenzyl ligand 61, prepared by Matthew Young.217 The conditions 
used for the preparation of ligand 37 (Chapter 1) were used to prepare ligand 88 
(Scheme 56), which was isolated in 85% yield. Ligand 88 was characterized by !H, 13C 
and 31P NMR and HRFABMS. The hydrolysis of ligand 88 was carried out under 
conditions identical to those used for the formation of ligand 51, refluxing 6 M HC1 for 
one day. Ligand 89 was characterized by !H, 13C{1H}, and 31P{'H} NMR, HRFABMS 
and elemental analysis. Elemental analysis indicated the isolated sample had 2 molar 
equivalents of HC1 relative to 1.0 molar equivalent of ligand 89. Both the *H and 31P{!H} 
NMR spectra and elemental analysis indicated the presence of 0.08 molar equivalents of 
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89-3HC1 relative to 1.0 molar equivalent of 89. Purification of ligand 89 with ion 
exchange chromatography was not attempted, nor was Cu(II) complexation. 
^
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Scheme 56: Formation of ligand 89, Cu(II) complexation was not attempted. 
As described previously, ligand 80 can be converted into ligand 83. The synthetic 
sequence carried out is shown in Scheme 57. Ligand 80 was synthesized using previously 
reported conditions. Mono p-nitro salt 80 was stirred in MeCN with 60 molar 
equivalents of allyl bromide relative to 1.0 molar equivalent of 80 for 11 days in a sealed 
flask which was wrapped in foil. Ligand 81 slowly precipitated from solution over the 11 
day reaction period and was isolated by vacuum filtration. Characterization was 
completed with *H and ^C^H} NMR, HRFABMS and elemental analysis. Interestingly, 
ligand 81 was found to be unstable in water. The lH NMR spectrum of 81 in D2O 
indicated the presence of approximately 0.05 ± 0.01 molar equivalents of starting ligand 
80 and 0.05 ± 0.01 molar equivalents of allyl alcohol relative to 1.0 molar equivalents of 
81. However, the }H NMR spectrum of the exact same sample in d4-MeOD revealed no 
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Scheme 57: Attempted synthesis of ligand 83. 
NO, 
Double reductive ring openings of unsymmetrical di-armed salts (analogues of 
81) have been reported with the use of NaBH4.186'234 As described by Martin and Young, 
the reaction of NaBfLt in 95% EtOH formed small amounts of hydroxide and ethoxide 
which caused deallylation of allyl analogues of 81.217 '233 Reductive ring opening with the 
less basic reducing agent sodium cyanoborohydride in MeCN was found to be effective. 
Double reductive ring opening of ligand 81 was carried out in MeCN for 2 days in the 
presence of excess sodium cyanoborohydride (care must be taken when working with 
reagents that can produce HCN). Once the reaction solvent was removed, neutralization 
of the excess cyanoborohydride was done with dropwise addition of a 25% HBr solution. 
HBr was used because HC1 resulted in the mono HC1 salt of ligand 82, which was 
insoluble in H2O. Water solubility is a necessity in order to isolate free amine 82. 
Removal of allyl protecting groups from amines has been recently reviewed. 
Potassium f-butoxide and DMSO have been reported to deprotect allyl amines with the 
aid of a dimsyl anion in situ. This highly basic species causes isomerization of the allyl 
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amine to an enamine which is hydrolyzed upon subsequent reaction with water. 
Conditions for the removal of allyl protecting groups on cross-bridged ligands have been 
reported.217 Utilizing these same conditions, ligand 81 and potassium f-butoxide were 
heated in DMSO under microwave conditions (25 min, 100 °C, open vessel) (care must 
be taken when heating DMSO in a microwave as it can be explosive)235. The *H NMR 
spectrum of the crude product indicated no aromatic signals suggesting that the ligand 
had de-p-nitrobenzylated instead of deallylated. Since, para-nitro benzyl substituents are 
good SN2 substrates it is possible that dimsyl anion could have attacked the benzyl carbon 
displacing the rest of the ligand. Since this deallylation reaction was crucial to the 
formation of ligand 82, a new synthetic strategy was adopted in order to form potential 
BFC ligand 85. 
C. Alternative Syntheses Towards the Formation of Potential BFC 86. 
(1) The use of ap-methoxyl benzyl (PMB) protecting group on ligand 80. 
TFA (trifluoroacetic acid) has been shown to remove p-methoxy benzyl (PMB) 
protecting groups from cyclic heterocycles through the formation of a PMB cation.236"238 
Addition of anisole to the reaction mixture to trap the PMB cation in situ has been shown 
to improve the reaction.239 Recently, a PMB protecting group of an amine in a cross-
bridged tetraamine has been shown to be cleaved by TFA.217 Since the attempted 
deallylation of ligand 82 removed the p-nitro benzyl group instead, PMB was chosen as a 
substitute for the allyl protecting group. The synthesis of compound 91 was attempted 
with 10 molar equivalents of PMB-Br relative to 1 molar equivalent of compound 80 
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Scheme 58: Attempted synthesis of ligand 91. 
was removed after 11 days and revealed the presence of only starting material. The 
reaction was attempted with 20 molar equivalents of PMB-Br relative to 1.0 molar 
equivalent of 80 in MeCN. However, no precipitate was seen after 14 days and the lH 
NMR spectrum of a small aliquot showed the presence of p-nitrobenzyl bromide, 
indicating the substituent had been removed in solution. Another synthetic pathway 
towards the formation of dibromide salt 91 involves the formation of mono-/?-methoxy 
m 
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salt ligand 92 followed by alkylation with /?-nitrobenzyl bromide (Scheme 59). 
Compound 92 was prepared in 62% yield by the mono-alkylation of ligand 31 (m=n=l) 
in toluene, precipitated from solution, isolated by vacuum filtration and characterized by 
*H and 13C NMR, HRFABMS and elemental analysis. Both the JH NMR spectrum and 
the analysis indicated the presence of 0.16 molar equivalents of toluene relative to 1.0 
molar equivalent of ligand 92. Six molar equivalents of /?-nitrobenzyl bromide were 
added to a stirred solution of ligand 92 in MeCN at room temperature. An aliquot was 
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removed after 6 days and revealed a complex mixture of products. Only compound 92 
was identified in the mixture. The reaction was stirred for an additional 6 days and the H 
NMR of an aliquot indicated that the mixture had become more complex. Further 
attempts to prepare compound 91 were abandoned. 
(2) Attempted synthesis of ligand 86 via ligand 93. 
A second alternative synthetic sequence towards the formation of ligand 86 
involves the intermediacy of mono-anilino/ mono-allyl cross-bridged tetraamine 93 
(Scheme 60). Tin-mediated reduction of compound 82 forms compound 93. 
Unfortunately, deallylation of ligand 93 with potassium f-butoxide and DMSO would 
produce a single-pendant-arm ligand with both anilino and amine functionalities. Recent 
reports have indicated that the nucleophilicities of both tend to be quite similar in water 
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making regioselective reactions difficult.240 Even though these reactions would not be run 
in water, any competition between these two nucleophiles will cause a mixture of 
products to form. Similar to the approach in Scheme 50, succinic anhydride could be 
reacted with 93 to form compound 94. However, unlike the synthesis described in 
Scheme 50, the carboxylate moiety in ligand 94 must be protected in order to prevent a 
reaction with the free carboxylate and tri-r-butyl phosphite two steps later. De-allylation 
of ligand 95 followed by phosphonate formation and acid-free hydrogenolysis of ligand 
96 should yield potential BFC 86. 
Compound 82 was dissolved in 6 M HC1 and stirred in the presence of mossy tin 
over a steam bath for 3 hours (Scheme 61). The free amine was isolated by extraction 
from a strongly basic solution (pH =14) and characterized by H and C{ H} NMR and 
HRFABMS. The *H NMR spectrum of the product was found to be almost identical 
Nk N. > r r ^ Sn,6MHCI - N ^ N [ 1 1 bn, 6MHCI r 1 
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Scheme 61: Tin-mediated reduction of ligand 82. 
to the starting material with the exception of the chemical shifts of the aromatic AA'XX' 
of each species. The electron withdrawing nature of the p-nitro substituent forces the 
resonances of AA'XX' downfield relative to the resonances of the AA'XX' of the 
electron donating anilino substituent. 
The attempted synthesis of ligand 94 was carried out in freshly distilled THF 
(Scheme 62). After the reaction was complete, an extraction was attempted from a 
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Scheme 62: Attempted synthesis of ligand 94. 
strongly basic solution (pH =14) with chloroform and toluene. Neither solvent extracted 
any material from the aqueous solution. The solvent was removed from the aqueous 
solution and a sample of the white solids remaining was analyzed by H NMR. The 
product was present with approximately 0.1 molar equivalents of starting material 93 
relative to 1.0 molar equivalent of 94. Further purification was not attempted. 
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IV. Conclusions 
The syntheses of two different mono-phosphonic acid pendant arm ligands were 
attempted through various synthetic routes in order to produce ligands for use in 
radiopharmaceuticals. The attempted esterification of CB-TE1A (72) with BnOH or 
MeOH failed under various conditions. The attempted alkylation of CB-TE1A-K (73) 
with BnBr produced multiple products indicating that both the secondary amine and the 
free carboxylate were alkylated. The attempted synthesis of ligand 86 via ligand 83 failed 
due to the unexpected de-/?-nitrobenzylation of ligand 82 under the conditions for 
deallylation. Two alternative synthetic routes towards the formation of ligand 86 were 
proposed. First, substitution of an allyl protecting group with a p-methoxy benzyl 
protecting group was attempted and failed to produce ligand 91 via two different 
sequences. Second, the synthesis of ligand 86 was attempted via the formation of ligand 




I. General Methods 
Melting points (mp) were obtained on a Thomas Hoover capillary melting point 
apparatus and were uncorrected. 
Infrared Spectra (IR) were run on a Nicolet MX-1 FT-IR spectrometer and absorptions 
are reported in wavenumber (cm1). 
*H NMR Spectra ('H NMR) were acquired on a Varian Mercury-400BB NMR 
spectrometer or a Varian INOVA-500 NMR spectrometer. Chemical shifts are reported in 
parts per million (ppm) relative to internal Me4Si (TMS) unless otherwise noted and 
coupling constants (J values) are in Hertz (Hz). 
13C{'HI NMR Spectra (13C{!H} NMR) were acquired on a Varian Mercury-400BB 
NMR spectrometer or a Varian INOVA-500 NMR spectrometer. Chemical shifts are 
reported in parts per million (ppm) relative to internal Me4Si (TMS) unless otherwise 
noted and coupling constants (J values) are in Hertz (Hz). 
31P|'H1 NMR Spectra (31P{ 'H} NMR) were acquired on a Varian Mercury-400BB NMR 
spectrometer. Chemical shifts are reported in parts per million (ppm) relative to an 
external 85% phosphoric acid standard 
Low-Resolution Mass Spectra (LRMS) were performed by the University of New 
Hampshire Instrumentation Center on a Hitachi-Perkin-Elmer RMU-60 mass 
spectrometer. 
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Electrosprav Ionization Mass Spectra (ESIMS) was obtained on a Thermoquest LCQ 
mass spectrometer at the University of New Hampshire. 
High-Resolution Mass Spectra (HRMS) were obtained from the Mass Spectroscopy 
Facility at the University of Notre Dame using a JEOL AX505HA high resolution mass 
spectrometer. 
Elemental Analysis (CH&N) was performed by Atlantic Labs Inc., Georgia, USA. 
X-ray Crystallography (X-ray) was performed by Jonathan M. White at the University of 
Melbourne, Parkville, Australia, for compound 67, and Arnold L. Rheingold at the 
University of California, San Diego, La Jolla, California, USA, for compounds 51 and 
52. 
Electrochemical Analysis was collected on a BAS100B electrochemical analyzer. A 
glassy carbon working electrode was used in combination with a Pt auxiliary electrode. 
Ultraviolet-visible spectra (UV-Vis) were acquired on a Varian Cary 50 spectrometer and 
absorptions are reported in nanometers (nM). 
Microwave Reactions were carried out on a CEM® Discover research scale manual 
microwave synthesizer. 
II. Solvents 
Absolute Ethanol (EtOH, ACS/USP grade) was obtained from Pharmco Products Inc. and 
was used without further purification. 
Acetonitrile (CH3CN) was obtained from EMD Chemicals Inc. and stored in an 
Innovative Technology Inc. Pure-Solv Solvent Purification System. Prior to use, the 
solvent was passed through the system's alumina column under low pressure to remove 
trace impurities. 
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Benzene (C^^, ACS grade) was obtained from EMD Chemicals Inc. and was used 
without further purification. 
Chloroform (CHC13, HPLC grade) was obtained from EMD Chemicals Inc. and was used 
without further purification. 
Diethyl Ether (Et20) was obtained from EMD Chemicals Inc. and stored in an Innovative 
Technology Inc. Pure-Solv Solvent Purification System. Prior to use, the solvent was 
passed through the system's alumina column under low pressure to remove trace 
impurities. 
Dimethyl Sulfoxide: (DMSO, ACS grade) was obtained from EMD Chemicals Inc. and 
was stored over 3A molecular sieves. 
Deuterated NMR Solvents were obtained from Cambridge Isotope Laboratories and 
stored over 3A molecular sieves. 
Ethanol (95% EtOH, ACS grade) was obtained from EMD Chemicals Inc. and was used 
without further purification. 
Methanol (MeOH, Reagent/ACS/USP/NF grade) was obtained from Pharmco Products 
Inc. and stored in an Innovative Technology Inc. Pure-Solv Solvent Purification System. 
Prior to use, the solvent was passed through the system's alumina column under low 
pressure to remove trace impurities. 
Tetrahydrofuran (THF) was obtained from EMD Chemicals Inc. and stored in an 
Innovative Technology Inc. Pure-Solv Solvent Purification System. Prior to use, the 
solvent was passed through the system's alumina column under low pressure to remove 
trace impurities. 
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Toluene (PhCH3, ACS grade) was obtained from EMD Chemicals Inc. and stored in an 
Innovative Technology Inc. Pure-Solv Solvent Purification System. Prior to use, the 
solvent was passed through the system's alumina column under low pressure to remove 
trace impurities 
HI. Reagents 
Acrylamide was obtained from Aldrich Chemical Company. 
Allyl bromide was obtained from Aldrich Chemical Company. 
Benzyl Bromide was obtained from Alfa Aesar. 
2-Bromoacetamide was obtained from Aldrich Chemical Company. 
Bromotrimethylsilane was obtained from Alfa Aesar. 
tot-Butyl bromoacetate was obtained from Aldrich Chemical Company. 
2-Chloro-iV-methvlacetamide was obtained from Pfaltz and Bauer, Inc. 
Cupric Chloride Dihydrate was obtained from Aldrich Chemical Company. 
Dimethyl vinylphosphonate was obtained from Alfa Aesar. 
Di-t-butyl phosphite was obtained from Alfa Aesar. 
1,1,1,3,3,3-hexafluoroisopropanol was obtained from Alfa Aesar. 
Hydrobromic Acid was obtained from Alfa Aesar. 
Hydrochloric Acid was obtained from Fischer Scientific. 
4-Methoxybenzyl bromide was obtained from Aldrich Chemical Company. 
iv"-Methylacetamide was obtained from Aldrich Chemical Company. 
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Morpholine was obtained from Fisher Scientific. 
4-Nitrobenzyl bromide was obtained from Aldrich Chemical Company. 
Paraformaldehyde was obtained from Acros Organics. 
Phosphorus trichloride was obtained from Alfa Aesar. 
Potassium Hydroxide was obtained from EM Science Company. 
Sodium Cyanoborohydride (NaBH3CN) was obtained from Aldrich Chemical Company. 
Sodium Hydroxide was obtained from EM Science Company. 
Succinic Anhydride was obtained from Aldrich Chemical Company. 
Trace Metal™ Grade Hydrochloric Acid was obtained from Fischer Scientific. 
Triethyl phosphite was obtained from Acros Organics. 
Trimethyl phosphite was obtained from Aldrich Chemical Company. 
IV. Column Chromatography Solid Supports 
Amberlite CG50 was obtained from Sigma. 
V. Experimental Procedures 
l,4,7,10-Tetraazabicyclo[5.5.2]tetradecane-4,10-bis(methanephosphonic acid 
diethyl ester) (36). Triethyl phosphite (0.25 mL, 1.4 mmol) and paraformaldehyde (43.4 
mg, 2.50 molar equivalents of CH2O) were added to a solution of 7 (0.0955 g, 0.482 
mmol) in 1.5 mL of dry THF and the mixture was stirred under N2 for 4 days. The 
solvent was removed under aspirator pressure and volatile phosphites were removed 
under vacuum. The residue was dissolved in H2O (10 mL), and the solution was made 
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strongly basic (pH=14, slow addition of KOH pellets). The resulting solution was 
extracted with toluene (5x10 rnL), the combined organic phases were dried over anhyd 
Na2S04, the solvent was removed under aspirator pressure, and the residual solvent was 
removed under vacuum to yield 0.2015 g (81%) of clear oil 36: 'H NMR (CDC13, 500 
MHz) 8 1.26 (tapp, 12H, J = 7.1 Hz, P(0)OCH2CH3), 2.71-2.92 (m, 16H), 2.88 (s, 4H, 
NCH2CH2N, cross-bridge), 2.96 (d, 4H, 2Jm = 7.6 Hz, NC//2P), 3.99-4.10 (m, 8H, 
P(0)OC/f2CH3); "C^H} NMR (CDC13, 125.68 MHz) 5 15.59 (d, 3/PC = 5.8 Hz, 
P(0)OCH2CH3), 50.59 (d, lJK = 155.5 Hz, NCH2P), 55.13, 55.73, 58.29 (d, 3/PC = 4.8 
Hz, C3), 60.43 (d, 2JPC = 6.7 Hz, P(0)OCH2CH3); 31P{!H} NMR (CDC13, 161.83 MHz) 5 
22.13; (The 31P{'H} and uC{lK} spectra revealed the presence of 0.03 ± 0.01 molar 
equivalents triethyl phosphate, formed from the oxidation of residual triethyl phosphite 
and 0.1 ± 0.01 molar equivalents of l,4,7,10-tetraazabicyclo[5.5.2]tetradecane-4-
methanephosphonic acid diethyl ester relative to 1.0 molar equivalents of 36); IR (thin 
film) 3448, 2981, 2916, 2820, 1653, 1445, 1374, 1223, 1027, 963; HRFABMS, m/z 
(M+H)+ exact mass calcd for C2oH45N406P2: 499.2814; Found: 499.2803 (error -1.2 
mmu/-2.3 ppm). 
l,4,8,H-Tetraazabicyclo[6.6.2]hexadecane-4,ll-bis(methanephosphonicacid 
diethyl ester) (37). Triethyl phosphite (0.18 mL, 1.0 mmol) and paraformaldehyde (32.5 
mg, 2.5 molar equivalents of CH20) were added to a solution of 8 (0.0982 g, 0.4338 
mmol) in 1.5 mL of dry THF and stirred under N2 for 4 d. The solvent was removed, the 
residue was dissolved in H20 (20 mL), and the solution was made strongly basic (pH=14, 
slow addition of KOH pellets). The resulting solution was extracted with toluene (5x11 
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mL), the combined organic phases were dried over anhyd Na2S04, the solvent was 
removed under aspirator pressure, and the residual solvent was removed under vacuum to 
yield 0.2156 g (94%) of waxy white solid 37: mp 42-44 °C; 'H NMR (CDC13, 500 MHz) 
8 1.22-1.32 (m, 14H), 1.32-1.41 (m, 2H), 2.20-2.28 (m, 4H), 2.27-2.35 (XX' of AA'XX', 
2H, NCH7/CH7/N, cross-bridge), 2.38 (dt, 2H, 7 = 12.0, 3.2 Hz), 2.50-2.75 (m, 6H), 2.60 
(dd, 2H, 27HH = -15.6 Hz, 27HP = -2.2 Hz, NC/7HP) 2.77-2.87 (m, 2H), 2.82 (tapp, 2H, 27HH 
= -16.0 Hz, 27HP = -16.0 Hz, NCHHP), 3.04-3.13 (AA' of AA'XX', 2H, NCHtfCH/fN, 
cross-bridge), 3.70 (tt, 2H, 7= 11.7, 4.2 Hz), 3.99-4.10 (m, 8H, P(0)OCH2CH3); 13C{'H} 
NMR (CDCI3, 125.68 MHz) 5 15.54 (37PC = 4.8 Hz, OCH2CH3), 15.59 (37PC = 5.8 Hz, 
OCH2CH3), 27.10 (C6,i3), 49.24 (lJPC - 160.3 Hz, NCH2P), 49.88 (coincident with 
downfield line of doublet at 49.24), 54.94 (37PC = 15.4 Hz, C5,n), 55.55, 55.79 (Ci5,i6), 
59.41, 60.24 (27PC = 6.7 Hz, OCH2CH3), 60.47 (27PC = 7.7 Hz, OCH2CH3); [Note: ]H-
COSY and gHMQC experiments aided resonance assignments (see figure below for 
compound numbering)]; 31P {'H} NMR (CDCI3, 161.83 MHz) 5 26.98; IR (CH2C12) 
3476, 2980, 2905, 2799, 1669, 1446, 1390, 1366, 1343, 1323, 1292, 1245, 1161, 1126, 
1098, 1028; HRFABMS, m/z (M+H)+ exact mass for C22H49N406P2: 527.3127; Found: 
527.3127 (error -0.8 mmu/-1.6 ppm). 
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Numbering for 37. 
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l,4,8,ll-Tetraazabicyclo[6.6.2]hexadecane-4,ll-bis(methanephosphonicacid 
dimethyl ester) (39). Trimethyl phosphite (0.1053 g, 0.8487 mmol) and 
paraformaldehyde (0.0255 g, 2.5 molar equivalents of CH2O) were added to a solution of 
8 (0.0768 g, 0.3393 mmol) in 1.5 mL of dry THF and stirred under N2 for 4 d. The 
solvent was then removed under reduced pressure, the residue was dissolved in H2O (7 
mL), and the solution was made strongly basic (pH=14, slow addition of KOH pellets). 
The resulting solution was extracted with toluene (5x5 mL), the combined organic 
phases were dried over anhyd Na2S04, the solvent was removed under aspirator pressure, 
and the residual solvent was removed under vacuum to yield 0.1218 g (76%) of waxy 
white solid 39: mp = 105-108 °C; *H NMR (CDCI3, 500 MHz) 5 1.31-1.48 (m, 4H), 2.28-
2.37 (m, 4H), 2.35-2.43 (XX' of AA'XX', 2H, NCUHCHHN, cross-bridge), 2.47 (dt, 2H, 
J= 12.1, 3.5 Hz), 2.59-2.66 (m, 2H), 2.68-2.78 (m, 4H), 2.71 (dd, 2H, 27HH = -15.8 Hz, 
VHP = -2.3 Hz, NCtfHP), 2.86 (ddd, 2H, J = 14.6, 11.0, 3.9 Hz), 2.91 (tapp, 2H, 27HH = -
15.8 Hz, 27Hp = -15.8 Hz, NCHtfP), 3.06-3.13 (AA' of AA'XX', 2H, NCHHCUHN, 
cross-bridge), 3.74-3.83 (m, 1H), 3.74 (d, 6H, VHp = 14.9 Hz, P(0)OC//5), 3.76 (d, 6H, 
37HP = 14.9 Hz, P(0)OCH3); l3C{lR} NMR (CDC13, 125.68 MHz) 5 28.00 (C6,i3), 49.38 
(PCH2N, lJPC = 160.3 Hz), 50.90, 52.02 (OCH3, %c = 6.7 Hz), 52.36 (OCH3,2Jpc = 6.7 
Hz), 55.70 (C5,i2, 3JPC= 15.4 Hz), 56.58, 56.66 (NCH2CH2N, cross-bridge), 60.25; [Note: 
'H-COSY and gHMQC experiments aided resonance assignments (see figure below for 
compound numbering)]; 31P{'H} NMR (CDC13, 161.83 MHz) 5 27.30; IR (KBr) 3421, 
2954, 2899, 2841, 2815, 2772, 1466, 1447, 1367, 1296, 1230, 1126, 1032, 832, 693; 
HRFABMS, m/z (M+H)+ exact mass for C i s H ^ C ^ : 471.2501; Found: 471.2503 
(error -1.2 mmu/-2.6 ppm). 
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13 
Numbering for 39. 
T>i-tert-butyl morpholinomethylphosphonate (40). Di-tert-butyl phosphite (0.47 
mL, 2.2 mmol) and paraformaldehyde (0.0656 g, 2.50 molar equivalents of CH2O) were 
added to a stirred solution of morpholine (0.1270 g, 1.458 mmol) in 4.8 mL of dry MeCN 
o 
and heated to reflux for 1 day under N2 over 3A molecular sieves. The solution was 
filtered, the solvent was removed from the filtrate under aspirator pressure, the residue 
was dissolved in H2O (20 mL), and the solution was made strongly basic (pH=14, slow 
addition of KOH pellets). The resulting solution was extracted with CHCI3 (5 x 20 mL), 
the combined organic phases were dried over anhyd Na2SC>4, the solvent was removed 
under aspirator pressure, and the residual solvent was removed under vacuum to yield 
0.3542 g (74%) of yellow oil 40: !H NMR (CDC13, 400 MHz) 5 1.52 (s, 18H, OC(CH3)3), 
2.64 (d, 2H, 27PH = 11.9 Hz, NGf/2P), 2.61-2.66 (m, 4H, C#2N), 3.69 (AA' of AA'XX', 
4H, CH2OCH2); 13CCH} NMR (CDCI3, 125.68 MHz) 5 29.52 (d, 3/PC = 3.8 Hz, 
POC(CH3)3); 54.02 (d, 37PC = 10.6 Hz, CH2NCH2P); 56.53 (d, Vrc = 167.9 Hz, NCH2P); 
66.04 (CH20); 81.14 (d, 27pC = 8.6 Hz, POC); (The 'H and 13C{'H} spectra indicated the 
presence of 0.17 ± 0.01 molar equivalents of residual di-tert-butyl phosphite relative to 
40); IR(CC14) 3448, 2979, 2934, 2854, 2803, 1664, 1453, 1417, 1370, 1259, 1172, 1119, 
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984; HRFABMS, m/z (M+H)+ exact mass calcd for Q3H29O4NP: 294.1834; Found: 
294.1815 (error -1.9 mmu/-6.6 ppm). 
l,4,7,10-Tetraazabicyclo[5.5.2]tetradecane-4,10-bis(methanephosphonicacid 
monoethyl ester sodium salt) (471.5H2ONaOH). 1,4,7,10-
Tetraazabicyclo[5.5.2]tetradecane-4,10-bis(methanephosphonic acid diethyl ester) 
(0.0908 g, 0.1821 mmol; contained 0.1 ± 0.01 molar equivalents of 1,4,7,10-
tetraazabicyclo[5.5.2]tetradecane-4-methanephosphonic acid diethyl ester and 0.03 ± 
0.01 molar equivalents of triethyl phosphate relative to 47) and sodium hydroxide 
(0.0291 g, 0.728 mmol) were dissolved in H20 (2 mL) and heated to reflux for 24 h. The 
solvent was removed under reduced pressure, the crude was dissolved in cold methanol 
(1 mL) and removed from insoluble solids (sodium hydroxide). The methanol was 
removed under reduced pressure and residual solvent was removed under vacuum to 
yield white solid 471.5H2ONaOH (0.0835 g, 80% yield): *H NMR (D20, 500 MHz, 
internal ref C//3CN set to 5 2.06) 8 1.41 (t, 6H, J = 1.1 Hz, P(0)OCH2C#3), 3.08-3.20 
(m, 7H), 3.17 (d, 4H, 2/PH = 7.1 Hz, NCH2P), 3.22-3.41 (m, 7H), 3.23 (s, 4H, 
NCH2C/f2N, cross-bridge), 4.08 (p, 4H, J = 7.1 Hz, P(0)CO/2CH3); l3C{lH} NMR 
(D20, 125.68 MHz, internal ref CH3CN set to 5 1.47) 5 16.80 (d, 37PC = 5.8 Hz, 
P(0)OCH2CH3), 48.02, 48.72 (d, '/Pc = 140.1 Hz, NCH2P), 51.28, 54.85 61.05 (d, 2JPC = 
5.8 Hz, P(0)OCH2CH3); ^?{lH} NMR (D20, 161.83 MHz) 23.60; (The 31P{'H} 
spectrum indicated the presence of 0.07 ± 0.02 molar equivalents of 1,4,7,10-
tetraazabicyclo[5.5.2]tetradecane-4-methanephosphonic acid monoethyl ester sodium salt 
relative to desired product of 1.0 molar equivalents); IR (KBr) 3423, 2974, 2927, 2894, 
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2863, 1482, 1389, 1171, 1065, 1050, 943; HRFABMS, m/z (M+H)+ exact mass for 
C16H35N406P2Na2: 487.1827; Found: 487.1826 (error -0.2 mmu/-0.3 ppm); Anal. Calcd 
for C,6H35N406P2Na2-(Ci3H28N403PNa)o.o5-(H20)i.5-(NaOH): C, 35.05; H, 6.96; N 10.31. 
Found: C, 34.98; H, 7.24; N, 10.16. 
l,4,8,ll-Tetraazabicyclo[6.6.2]hexadecane-4,ll-bis(methanephosphonicacid 
monoethyl ester sodium salt) (48). 1,4,8,1 l-Tetraazabicyclo[6.6.2]hexadecane-4,l 1-
bis(methanephosphonic acid diethyl ester) (0.0511 g, 0.0970 mmol, 37) was dissolved in 
a 0.4 M NaOH solution (3 mL) and the mixture was brought to reflux for 1 day. The 
solvent was removed under reduced pressure and the residue was washed with 0 °C 
methanol (1 mL), the solvent was removed under reduced pressure and residual solvent 
was removed under vacuum. The crude product was dissolved in 3 mL MeOH and the pH 
was lowered to 7 with 1 mL of 1M HC1 solution. White solids were separated by 
centrifugation, and the pH of the supernatant was raised to 14 with crushed NaOH. The 
solvent was removed under reduced pressure and residual solvent was removed under 
vacuum to yield white solid 2 (0.1433 g, 71%): *H NMR (D20, 500 MHz, internal ref 
C#3CN set to 8 2.06) 8 1.23 (t-like, 6H, J = 7.0 Hz, P(0)OCH2C#3), 1.60-1.76 (m, 4H), 
2.79-3.17 (m, 22H), 3.38-3.49 (m, 2H), 3.90 (p, 4H, / = 7.1, P(0)OC//2CH3); ^ Q ' H } 
NMR (D20, 100.53 MHz, internal ref CH3CN set to 8 1.47) 8 17.09 (d, VPC = 5.4 Hz, 
P(0)OCH2CH3), 24.69, 49.69 (d, lJPC = 140.0 Hz, NCH2P), 52.17, 52.84 (d, 37PC = 5.4 
Hz), 53.12, 56.56, 56.97, 61.20 (d, 2JPC = 6.1 Hz, P(0)OCH2CH3); 31P{1H} NMR (D20, 
161.83) 8 21.98; IR (KBr) 3448, 1645, 1450, 1392, 1318, 1175, 1086; HRFABMS, m/z 
(M+Na)+ exact mass for Ci8H38N406P2Na3: 537.1960; Found: 537.1970 (error +1.0 
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mmu/+1.8 ppm); Anal Calcd for 
Ci8H38N406P2Na2-(NaOH)24-(H20)2o-(NaCl)o.3(CH3OH)7: C, 14.46; H, 6.31; N, 2.70; CI, 
0.51. Found: C, 14.60; H, 6.02; N, 2.30; CI, 0.64. (Titration of 48 with 0.101 N HC1 
revealed 19 ± 5 molar equivalents of NaOH relative to 1 molar equivalents of 48) 
l,4,7,10-Tetraazabicyclo[5.5.2]tetradecane-4,10-bis(methanephosphonicacid) 
(50-2HCl-3H2O). This compound was prepared previously (U.S. patent 5874573, 1999) 
and listed with an incomplete procedure. The procedure reported here is similar to a 
procedure reported by Sherry et al. (Inorg. Chem. 1992, 31(21) 4422-4). 1,4,7,10-
tetraazacyclo[5.5.2]tetradecane (0.0828 g, 0.418 mmol) and H3PO3 (0.1370 g, 1.671 
mmol) were dissolved in 4 M HC1 (0.8 mL) and brought to reflux. Paraformaldehyde 
(0.0376 g, 2.50 molar equivalents of CH2O) was added in small portions over the course 
of 1 hour. The reaction was allowed to stay at reflux for an additional 30 min, the heat 
was removed, the reaction mixture was cooled to room temperature, acetone (7 mL) was 
added in one portion and the cloudy white mixture was allowed to stand for 24 h. The 
white crystalline solids were isolated by suction filtration, washed with hot acetone (2x6 
mL), and dried under vacuum to yield 0.1493 g (68%) of 50-2HCl-3H2O: !H NMR (D20, 
500 MHz, internal ref C//3CN set to 5 2.06) 8 3.17-3.28 (m, 4H), 3.20 (s, 4H, 
NCH2CH2K cross-bridge), 3.37-3.52 (m, 8H), 3.40 (d, 4H, 2Jm = 10.8 Hz, NC#2P), 
3.57-3.63 (m, 4H); 13C{'H} NMR (D20, 125.68 MHz, internal ref CH3CN set to 5 1.47) 
5 46.63 54.66 (d, ^PC = 146.8 Hz, NCH2P), 54.78, 56.06 (d, 37PC = 4.8 Hz, C3); ^P^H} 
NMR (D20, 161.83 MHz) 8 14.30; (The !H and 31P{1H} NMR spectra indicated the 
presence of 0.04 ± 0.02 molar equivalents of H3PO3 and 0.08 ± 0.01 molar equivalents of 
117 
l,4,7,10-tetraazabicyclo[5.5.2]tetradecane-4-(methanephosphonic acid) dihydrochloride 
relative to 50. Attempted purification by ion-exchange chromatography failed to separate 
these impurities.); IR (KBr) 3410, 3008, 2968, 2926, 2754, 2627, 1499, 1488, 1415, 
1325, 1144, 1096, 945; HRFABMS, m/z (M+H)+ exact mass calcd for Ci2H29N406P2: 
387.1562; Found: 387.1538 (error -2.5 mmu/-6.4 ppm); Anal. Calcd for 
C12H28N4O6P2-(HCl)2-(H2O)3-[C1iH25N4O6P-(HCl)2]0.04-(H3PO3)0.02: C, 28.22; H, 7.07; N 
11.00; CI, 13.93. Found: C, 28.36; H, 6.84; N, 10.88; CI, 14.02. 
l,4,8,ll-Tetraazabicyclo[6.6.2]hexadecane-4,ll-bis(methanephosphonicacid) 
(H45i-O.6HCM.lH2Q). 0.3440 g (0.6533 mmol) of 37 was dissolved in 32 mL of a 6M 
HC1 solution prepared from TraceMetal™ grade hydrochloric acid (Fisher Scientific), 
and refluxed under N2 for 1 d. The solvent was removed under reduced pressure and the 
crude product was dissolved in 4 mL of H20 and chromatographed using a weakly acidic 
cation exchange column (Amberlite CG50, H+ form, 7.7 g, column size = 27 cm x 2 cm). 
The product was eluted with H20 (first 30 mL of elutant was discarded), fractions 
containing the product were combined (35 fractions, 3 mL each), the solvent was 
removed under reduced pressure, and residual solvent was removed under vacuum to 
yield 0.1919 g (64%) of white solid H4510.6HCM.lH2O: mp 182-185 °C; 'H NMR 
(D20, 500 MHz, internal ref C#3CN set to 6 2.06) 8 1.74-1.83 (dm, 2H, J = 16.6 Hz, 
Hfeq), 2.29-2.42 (qm-like, 2H, /f6ax), 2.49-2.58 (dm, 2H, J= 13.9 Hz, H2eq), 2.80-2.93 (m, 
4H, Hls BB' of AA-BB' , #7), 2.95-3.18 (m, 8H, HIS AA' of AA'BB', H7, H3eq, NCtfHP), 3.29-3.37 
(dm, 2H, J = 13.2 Hz, H5sq), 3.45 (td, 2H, J = 13.7, 3.7 Hz, tf2ax), 3.76 (ttapp, 2H, J = 14.6, 
3.7 Hz, tf3ax), 3-96 (td, 2H, J = 13.0, 3.4 Hz, ff5ax), 4.17 (tapp, 2H, 27HH = -14.6 Hz, 2JPC = 
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-14.6 Hz, NCH/fP); 13C {!H} NMR (D20, 125.68 MHz, internal ref CH3CN set to 8 
1.47) 8 20.23 (C6), 48.75 (C15), 52.01 ('/PC = 137.2 Hz, NCH2P), 52.34 (37Pc = 9.6 Hz, 
C3), 52.64 (C2), 58.17 (br, C5), 58.47 (C7) [Note: 'H-COSY and gHMQC experiments 
aided resonance assignments (see figure below for compound numbering)]; P { H} 
NMR (D20, 161.83 MHz) 8 9.48; IR (KBr) 3397 (br), 2983, 2851, 1655, 1491, 1470, 
1241, 1183, 1097, 1073, 1047, 903; HRFABMS, m/z (M+H)+ exact mass for 
Q4H33N4O6P2: 415.1875; Found: 415.1877 (error -1.2 mmu/-2.9 ppm); Anal. Calcd for 
Ci4H32N406P2-(HCl)o.6-(H20)u: C, 36.87; H, 7.69; N 12.28; CI, 4.66. Found: C, 36.56; 
H, 7.84; N, 12.06; CI, 4.81. Diffusion of acetone into an aqueous solution of 
H45i-O.6HCM.IH2O produced crystals suitable for X-ray diffraction. 
13 
Numbering for H4-CB-TE2P 
52. A solution of Cu(C104)26H20 in 3.5 mL MeOH (0.2341 g, 0.6318 mmol) was 
added to a 7.7 mL MeOH solution of 47 (0.3235 g, 0.5670 mmol; contained 0.07 ± 0.02 
molar equivalents of l,4,7,10-tetraazabicyclo[5.5.2]tetradecane-4-methanephosphonic 
acid monoethyl ester sodium salt relative to 1.0 molar equivalents of 47). Aq NaOH (0.3 
mL of a 0.4 M NaOH solution) was added to raise the pH of the solution to 8 and the 
solution was brought to reflux for 24 h. The solution was allowed to cool to room 
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temperature and insoluble solids were removed by centrifugation. Diethyl ether (30 mL) 
was added to the supernatant and blue solids formed after the solution was stirred for 20 
min. X-ray quality crystals were obtained from Et20 diffusion into a 95% EtOH solution 
of the product. 52 was collected and dried under vacuum (0.3165 g, 84% yield). X-ray 
quality crystals were obtained from Et20 diffusion into a 95% EtOH solution of the 
product: Anal Calcd for 
Ci6H34N4O6P2Cu-(NaClO4)i.i-(H2O)i.3-[Ci3H28N4O3PCu-(ClO4)]0.05: C, 29.14; H, 5.58; N, 
8.57; CI, 5.94. Found: C, 29.18; H, 5.54; N, 8.42; CI, 6.17 (Elemental analysis indicated 
the presence of 0.05 molar equivalents of l,4,7,10-tetraazabicyclo[5.5.2]tetradecane-4-
methanephosphonic acid monoethyl ester copper (II) complex); HRFABMS, m/z (M+H)+ 
exact mass C16H35N406P2-Cu: 504.1339; Found: 504.1338 (error +1.0 mmu/+1.9 ppm); 
IR (KBr) 3397, 2976, 2899, 1653, 1483, 1199, 1086, 1035, 948, 857, 787, 624, 577; 
Electronic data: (MeOH) A,max, 672 nm (e = 44 M"1 cm"1). 
53. A solution of Cu(C104)2-6H20 in 2.0 mL MeOH (0.0685 g, 0.185 mmol) was 
added to a 6 mL MeOH solution of 48 (0.1001 g, 0.0482 mmol, contained 24 molar 
equivalents of NaOH, 20 molar equivalents of water, 0.3 molar equivalents of NaCl and 7 
molar equivalents of methanol all relative to 1 molar equivalent of 48). Aq HC1 (0.3 mL 
of a 1.0 M HC1 solution) was added to lower the pH of the solution to 8 and the solution 
was brought to reflux for 24 h. The solution was allowed to cool to room temperature and 
insoluble solids were removed by centrifugation. The resultant blue solution was 
evaporated to dryness, 1,1,1,3,3,3-hexafluoro-2-propanol was added, and solid NaCl was 
removed by centrifugation. The solvent was removed under reduced pressure and residual 
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solvent was removed under vacuum to yield 0.0300 g (82% yield) of 53: Anal Calcd for 
Ci8H38N406P2Cu-(C3H2F60)r(H20)2: C, 34.27; H, 6.02; N, 7.61. Found: C, 34.26; H, 
5.75; N, 7.29. HRFABMS, m/z (M+H)+ exact mass C18H39N406P2-Cu: 532.1652; Found: 
532.1664 (error +2.4 mmu/+4.4 ppm); IR (KBr) 3569, 3411, 2981, 2904, 1483, 1210, 
1097, 1071, 1041, 949, 787, 625; Electronic data: (MeOH) lmax, 646 nm (s = 18 M"1 
cm"1). 
54. A solution of CuCl2-2H20 in 2 mL MeOH (13.2 mg, 0.077 mmol) was added 
to a 2 mL MeOH solution of 51 (35.0 mg, 0.077 mmol). Aq NaOH (0.3 mL of a 0.4 M 
NaOH solution) was added to raise the pH of the solution to 5. The resultant blue solution 
was evaporated to dryness, 1 mL of l,l,l,3,3,3-hexafluoro-2-propanol was added, and 
solid NaCl was removed by centrifugation. The supernatant was placed in an Et20 
diffusion chamber, resulting in formation of blue crystals which were collected and dried 
(47.0 mg, 86% yield). Anal Calcd for Ci4H3oN406P2Cu-(NaCl)o.3-(H2OHC3H2F60)i.2: C, 
29.64; H, 4.86; N, 7.86; CI, 1.49; P, 8.69. Found: C, 29.48; H, 4.96; N, 7.91; CI, 1.78; P, 
8.66. HRFABMS, m/z (M+H)+ exact mass Ci4H3iN406P2-Cu: 476.1015; Found: 
476.1009 (error -0.6 mmu/-1.2 ppm); IR (KBr) 3421 (br), 2867, 1654, 1482, 1150, 1095, 
1055, 972. Electronic data: (MeOH) Xmax, 639 nm (s = 35 M"1 cm"1); Cyclic voltammetry 
conducted in 0.1 N sodium acetate, reduction was quasi-reversible with Ep = -0.96 V 
(Ag/AgCl). 
4-(Carbamoylmethyl)-l,4,8,ll-tetraazabicyclo[6.6.2]hexadecane (64). A 
solution of 2-bromoacetamide (0.6365 g, 4.613 mmol) in dry MeCN (20 mL) was added 
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dropwise to a solution of 8 (1.0432 g, 4.6085 mmol) in dry MeCN (60 mL) under N2, 
over the course of 20 min. The resulting solution was stirred at room temperature for 1 
day. The solvent was removed, the residue was dissolved in H20 (60 mL), and the 
solution was made strongly basic (pH=14, slow addition of KOH pellets with cooling). 
The resulting solution was extracted with CHC13 (5 x 25 mL), the combined organic 
phases were dried over anhyd Na2S04, the solvent was removed via aspirator pressure, 
and residual solvent was removed from the crude viscous oil under vacuum for 2 days. 
The resulting white solid was recrystallized from MeCN affording 1.0980 g (84%) of 
white solid 64: mp 137-139 °C; *H NMR (CDC13, 400 MHz) 5 1.33-1.43 (m, 1H), 1.49-
1.59 (m, 1H), 1.63-1.82 (m, 2H), 2.45-2.80 (m, 19H), 2.86-2.94 (m, 1H), 2.92 and 3.18 
(AB, 2H, / = 16.0 Hz, NC#2CONH2), 3.03-3.13 (m, 1H), 4.93 (br s, 1H, amide N#), 
5.60 (br s, 1H, amide NH), 8.51 (br s, 1H, sec Nfl); "Cf'H} NMR (CDC13, 100 MHz) 8 
24.39, 25.58, 45.88, 49.91, 50.33, 52.28, 53.84, 53.90, 54.14, 54.42, 56.05, 58.59, 59.93, 
174.17; IR (KBr) 3446 (br), 2948, 2919, 2855, 2824, 1677 (C=0, amide I), 1545 (NH2 
bend, amide II) cm"1; MS (ESI) m/z 284.4 (M+H+); Anal. Calcd for C14H29N50-(H20)o.i: 
C, 58.96; H, 10.32; N, 24.55. Found: C, 58.62; H, 10.28; N, 24.62. 
67. A solution of 64 (0.0531 g, 0.1874 mmol) and Cu(N03)2-3H20 (0.0453 g, 
0.1875 mmol) was refluxed in 6 mL of MeOH for 1 d. The resulting blue solution was 
cooled to room temperature, centrifuged, and the supernatant was put in an Et20 
diffusion chamber. The resulting blue solids were suitable for X-ray analysis (0.0700 g, 
79% yield): Anal Calcd for Ci4H29N7OrCu: C, 35.70; H, 6.21; N, 20.82. Found: C, 
35.76; H, 6.02; N, 20.86; HRFABMS, m/z [Cu(N03)-64]+ exact mass C H H ^ C V C U : 
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408.1546; Found: 408.1526 (error -2.1 mmu/-5.1 ppm); IR (KBr) 3244, 3063, 2969, 
2879, 2771, 1664, 1602, 1463, 1383, 1175, 1103, 1014, 825, 703. Electronic data: 
(MeOH) Xmax, 600 nm (e = 88.5 M"1 cm"1), 974 nm (8 = 55.8 M"1 cm"1); Cyclic 
voltammetry conducted in 0.1 N sodium acetate, reduction was quasi-reversible with Ep = 
-0.76 V (Ag/AgCl). 
4-(Ar-methylcarbamoylmethyl)-l,4,8,ll-tetraazabicyclo[6.6.2]hexadecane 
(68). A solution of Chloro-yV-methylacetamide (0.0770 g, 0.7160 mmol) in dry MeCN (2 
mL) was added dropwise to a stirred solution of 8 (0.1621 g, 0.7161 mmol) in dry MeCN 
(10 mL) under N2 over the course of 20 min. The resulting solution was stirred at room 
temperature for 1 day. The solvent was removed, the residue was dissolved in H2O (20 
mL), and the solution was made strongly basic (pH=14, slow addition of KOH pellets 
with cooling). The resulting solution was extracted with CHCI3 (5 x 20 mL), the 
combined organic phases were dried over anhyd Na2SC>4, the solvent was removed under 
aspirator pressure, and residual solvent was removed from the crude viscous oil under 
vacuum for 2 days (the crude *H spectrum indicated the presence of 0.09 ± 0.01 molar 
equivalents of 4,11 -bis(Af-methylcarbamoylmethyl)-1,4,8,11 -
tetraazabycyclo[6.6.2]hexadecane. The resulting yellow solid was recrystallized from 
MeCN affording 0.1620 g (72% yield) of white solid 68: lU NMR (CDC13, 500 MHz) 5 
1.36-1.45 (m, 1H), 1.49-1.64 (m, 2H), 1.67-1.76 (m, 1H), 2.47-2.96 (m, 19H), 2.83 (s, 
3H, C(0)NHC#3), 2.96 and 3.15 (AX, 2H, J= 15.9 Hz, NC//2C(0)NHCH3), 3.07-3.15 
(m, 1H), 5.11 (br s, 1H, amide NH), 8.36 (br s, 1H, Nfl); "C^H} NMR (CDC13, 125.68 
MHz) 8 24.82, 25.78, 46.36, 50.02, 50.69, 51.58, 53.66, 54.02 (2C), 54.47, 54.74, 55.98, 
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58.34, 60.44, 171.56 (The lH spectrum indicated the presence of 0.03 ± 0.01 of 4,11-
bis(A^methylcarbamoylmethyl)-1,4,8,1 l-tetraazabycyclo[6.6.2]hexadecane); IR (KBr) 
3274, 3075, 2916, 2807, 1654, 1560, 1460, 1411, 1114; HRFABMS, m/z (M+H+) exact 
mass for C15H32N5O: 298.2607; Found : 298.2594 (error -1.3 mmu/ -4.2 ppm). 
4-Acetoamido-11 -carbo-f-butoxymethyl-1,4,8,11 -
tetraazabicyclo[6.6.2]hexadecane (71). /-Butyl bromoacetate (0.0685 g, 0.3512 mmol) 
was added to a solution of 4-(carbamoylmethyl)-1,4,8,11-
tetraazabicyclo[6.6.2]hexadecane (0.0663 g, 0.2339 mmol) in 2 mL of dry MeCN and 
heated to 70 °C in a closed vessel (10 mL tube) microwave reactor for 30 min. After this 
reaction period, the mixture was cooled to room temperature and the solvent was 
removed under reduced pressure. The residue was dissolved in H2O (3 mL), washed with 
Et20 (3x3 mL) and the solution was made strongly basic (pH=14, slow addition of KOH 
pellets with cooling). The resulting solution was extracted with cold CHCI3 (5x5 mL), 
the combined organic phases were dried over anhyd Na2S04, the solvent was removed 
under aspirator pressure, and the residual solvent was removed under vacuum to yield 71 
(0.0746 g, 80% yield); (]H spectrum indicated the presence of 5% (+/- 1%) of 4-
(carbamoylmethyl)-l,4,8,l l-tetraazabicyclo[6.6.2]hexadecane); Spectra previously 
reported: Sprague, J.E.; Peng, Y.; Fiamengo,A.L.; Woodin, K.S.; Southwick, E.A.; 
Weisman, G.R.; Wong, E.H.; Golen, J.A.; Rheingold, A.L.; Anderson, C.J.; J. Med. 
Chem. 2007, 50, 2527-2535. 
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4-Carboxymethyl-l,4,8,ll-tetraazabicyclo[6.6.2]hexadecaneDihydrochloride 
Trihydrate (72-2.3HCl-2.8H2ONH4Cl). Compound 64 (0.0495 g, 0.1747 mmol) was 
dissolved in 6 N HC1 (9.5 mL) and raised to 150 °C in a closed vessel microwave reactor 
for 30 min. The solvent was removed under reduced pressure. The crude was dissolved in 
15 mL of H2O and the solvent was removed via reduced pressure. This was carried out 
three times. Residual solvent was removed from the white solid under vacuum (0.0810 g, 
98% yield); *H NMR (D20, 500 MHz, internal ref C//3CN set to 8 2.06) 8 1.69-1.78 (m, 
2H, NCH2Cfle,HCH2N), 2.29-2.48 (m, 2H, NCH2C//axHCH2N), 2.57-2.70 (ddm, 1H, J = 
14.2, 3.2 Hz), 2.66 (ddd, 1H, / = 13.0, 9.0, 3.7 Hz), 2.87-3.04 (m, 5H), 3.08-3.37 (m, 
8H), 3.40-3.51 (m, 2H), 3.53-3.62 (m, 3H), 3.67 and 4.22 (AX, 2H, / = 17.6 Hz, 
NCtf2COOH); 13C{ *H} NMR (D20, 100 MHz, internal ref CH3CN set to 8 1.47) 8 18.63, 
19.31, 41.50, 47.99, 48.64, 48.79, 49.04, 54.77, 54.99, 55.50, 57.73, 58.35, 59.03, 
172.25; IR (KBr) 3406, 3186, 3093, 2988, 2956, 2840, 2753, 2636, 2363, 1728, 1491, 
1480, 1403, 1354, 1241, 1044 cm"1; MS (LDI) m/z 285.1 (M+H+); Anal. Calcd for 
Ci4H28N402-(HCl)2.3-NH4Cl-(H20)2.8: C, 35.61; H, 8.52; N, 14.83; CI, 24.78. Found: C, 
35.90; H, 8.20; N, 14.80; CI, 24.92. 
4-Acetoxymethyl-l,4,8,ll-tetraazabicyclo[6.6.2]hexadecane potassium salt 
(73). 4-(Carbamoylmethyl)-l,4,8,ll-tetraazabicyclo[6.6.2]hexadecane (0.0920 g, 0.3246 
mmol) was dissolved in 6 N HC1 (6.8 mL) and raised to 150 °C in a closed vessel 
microwave reactor for 30 min. The solvent was removed under reduced pressure. The 
crude product was dissolved in 10 mL H20 and made strongly basic (pH=14, slow 
addition of a large excess of KOH pellets). The resulting solution was extracted with 
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chloroform (5 x 10 mL), the combined organic fractions were dried over anhyd Na2S04, 
the solvent was removed under aspirator pressure and the residue was repeatedly 
triturated with Et20 followed by removal of Et20 under reduced pressure (6 x 10 mL). 
Residual solvent was removed under vacuum to yield 0.0656 g (63% yield) of white solid 
73: mp = 156-160 °C; JH NMR (500 MHz, CDC13) 8 1.47-1.57 (m, 1H), 1.62-1.70 (m, 
1H), 1.71-1.89 (m, 2H), 2.36 (ddd, 1H, J= 11.1, 6.3, 4.8 Hz), 2.45 (ddd, 1H, J= 13.2, 
6.2, 2.1 Hz), 2.57-2.65 (m, 2H), 2.65-2.87 (m, 12H), 2.92 (ddd, 1H, / = 13.8, 8.8, 6.5 
Hz), 2.97-3.05 (m, 1H), 3.00 and 3.20 (AX, 2H, J= 13.7 Hz, benzylic CH2), 3.13-3.23 
(m, 1H), 3.27-3.38 (m, 1H), 12.02 (br s, 1H, NH); l3C{lH} NMR (CDC13, 125.68 MHz) 5 
23.70, 26.73, 44.79, 46.90, 49.60, 52.39, 52.61, 53.18, 54.62, 55.60, 55.75, 58.53, 64.48, 
175.92; IR (KBr) 3415, 2958, 2850, 1646, 1570, 1484, 1400, 1319, 1063; HRFABMS, 
m/z (M+H)+ exact mass for C14H28N4O2K: 323.1849; Found: 323.1833 (error -1.6 mmu/-
5.0 ppm). 
4-(Carbamoylmethyl)-ll-benzyl-l,4,8,ll-tetraazabicyclo[6.6.2]hexadecane 
(74). A solution of benzyl bromide (0.0279 g, 0.1631 mmol) in dry MeCN (0.5 mL) was 
added to a stirred solution of 64 (0.0309 g, 0.1090 mmol) in dry MeCN (1.0 mL) at 70 
°C. The solution was brought to reflux and stirred under N2 for 24 h. The solvent was 
removed under aspirator pressure and the crude residue was dissolved in MeOH (4 mL) 
and made strongly basic (pH=14, slow addition of KOH pellets). The solvent was 
removed, the crude white solid was dissolved in H2O (4 mL) and extracted with CHCI3 (6 
x 5 mL), and the combined organic phases were dried over anhyd Na2SC>4. The solvent 
was removed under aspirator pressure and residual solvent was removed under vacuum to 
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yield white solid 74 (0.0400 g, 98%): mp 94-97 °C; lH NMR (CDC13, 500 MHz) 8 1.36-
1.66 (m, 4H), 2.30-2.50 (m, 10H), 2.54-2.68 (m, 4H), 2.70-2.77 (m, 1H), 2.82-2.95 (m, 
2H), 2.90 and 3.15 (AX, 2H, J= 16.9 Hz), 3.21-3.28 (m, 1H), 3.74 and 3.25 (AX, 2H, J = 
13.3 Hz), 3.69-3.78 (m, 1H), 4.17 (ddd, 1H, J= 13.8, 9.7, 4.4 Hz), 6.06 (br s, 1H, amide 
NH), 7.18-7.25 (m, 2H), 7.27-7.34 (m, 4H); 13C{'H} NMR (CDC13, 125.68 MHz) 5 
27.74 (2C), 52.79, 53.21, 53.71, 53.84, 56.15, 56.44, 56.63, 57.46, 57.87, 58.22, 60.09, 
60.62, 126.61, 128.04 (2Q, 128.99 (2Q, 140.62, 175.56; IR (KBr) 3442, 3326, 3252, 
3176, 3059, 3025, 2917, 2802. 2784, 1702, 1677, 1452, 1360, 1260, 1117; HRFABMS, 
m/z (M+H+) exact mass for C2iH36N50: 374.2920; Found : 374.2919 (error -1.4 mmu/ -
3.7 ppm). 
4-Benzyl-ll- carboxymethyl -l,4,8,H-tetraazabicyclo[6.6.2]hexadecane 
Dihydrochloride Monohydrate (75-2.5HCM.5H2ONH4Cl). Compound 74 (0.0241 g, 
0.0645 mmol) was dissolved in 6 N HC1 (2 mL) and heated to 150 °C in a closed vessel 
(10 mL tube) microwave reactor for 30 min. After this reaction period, the mixture was 
cooled to room temperature and the solvent was removed under reduced pressure. The 
residue was dissolved in 15 mL of H2O and the solvent was removed under reduced 
pressure. This process was carried out two additional times. Residual solvent was 
removed under vacuum to yield white solid product (0.0333 g, 94% yield): H NMR 
(D20, 500 MHz, internal ref C//3CN set to 8 2.06) 8 1.76-1.85 (dm, 2H, / = 16.6 Hz, 
NCH2C^HCH2N), 2.27-2.39 (qm-like, 1H, NCH2CHaxHCH2N), 2.39-2.51 (qm-like, 
1H, NCH2Ci/axHCH2N) 2.61-2.70 (dm, 1H, / = 14.4 Hz), 2.75 (ddd, 1H, J= 14.7, 9.2, 
4.6 Hz), 2.88-3.50 (m, 15H), 3.59-3.82 (m, 4H), 3.78 and 4.27 (AX, 2H, J= 17.6 Hz), 
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4.56 and 4.58 (AB, 2H, / = 14.2 Hz), 7.40-7.46 (m, 2H), 7.51-7.58 (m, 3H); " c ^ H } 
NMR (D20, 125 MHz, internal ref CH3CN set to 5 1.47) 6 19.81, 19.91, 46.06, 48.71, 
49.05, 49.49, 54.01, 54.94, 55.97, 56.33, 56.81, 58.10, 58.30, 58.85, 127.81, 129.91 (2C), 
130.85, 132.06 (2Q, 172.10; IR (KBr) 3386, 3155, 3043, 2918, 2850, 2618, 1725, 1494, 
1457, 1406, 1051, 707; MS (ESI) m/z 375.5 (M+H+); Anal. Calcd. for 
C2iH34N402-(HCl)2.5-(NH4Cl)-(H20)i.5: C, 46.18; H, 8.03; N, 12.82; CI, 22.72. Found: C, 
46.00; H, 8.12; N, 12.57; CI, 23.03. 
4-(2-carbamoylethyl)-ll-(carbamoyhnethyl)-l,4,8,ll-
tetraazabicyclo[6.6.2]hexadecane (76) Compound 64 (0.0470 g, 0.1658 mmol) was 
added to a stirred solution of acrylamide (0.0140 g, 0.1969 mmol) in MeCN (3.5 mL) 
under N2. After 5 days, white precipitate had formed. Solvent was removed under 
aspirator pressure and the crude product was washed with hot EtOAc to remove excess 
acrylamide. Product was isolated as a white solid (0.0584 g, 99%): mp 154-156 °C; !H 
NMR (CDC13, 400 MHz) 8 1.40-1.70 (m, 4H), 2.26-2.74 (m, 18H), 2.75-3.01 (m, 3H), 
2.94 and 3.13 (AB, 2H, J = 16.8 Hz), 3.99 (dt, 1H J = 13.1, 6.6 Hz), 4.07 (ddd, 1H, J = 
12.7, 8.4, 5.1 Hz), 5.91 (br s, 1H, amide NH), 6.23 (br s, 1H, amide NH), 7.17 (br s, 1H, 
amide NH), 7-42 (br s, 1H, amide NH); l3cCR} NMR (CHC13, 100 MHz) 5 25.53, 26.19, 
32.64, 51.06, 51.28, 52.31 (2C), 52.59, 53.99, 54.54, 54.64, 55.34, 57.37, 57.60, 59.60, 
174.47, 174.52; IR (KBr) 3452, 3395, 3322, 3261, 3178, 2962, 2902, 2794, 1689, 1667, 
1460, 1405, 1359, 1253, 1119; HRFABMS, m/z (M+H+) exact mass for C17H35N602: 
355.2821; Found: 355.2836 (error +1.5 mmu/ +4.1 ppm); Anal. Calcd for 
Ci7H34N602-(H20)o.5: C, 56.17; H, 9.70; N, 23.12. Found: C, 56.07; H, 9.46; N, 22.88. 
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(10ba,10ca)-Decahydro-3a-allyl-8a-[(4-nitrophenyl)methyl]-lH,6H-
3a,5a,8a,10a-tetraazapyrenium dibromide (81). Allyl bromide (12.4 mL, 0.1433 mol) 
was added via syringe to a stirred solution of 80 (1.0470 g, 2.388 mmol) in 35 mL of 
MeCN. The flask was stoppered, wrapped in aluminum foil and the reaction mixture was 
stirred for l i d . The resultant white precipitate was collected by vacuum filtration, 
washed with 40 mL of MeCN, and allowed to air dry on the funnel to yield 1.14 g (85% 
yield) of 81: mp = 188-194 °C (dec); !H NMR (CD3OD, 500 MHz) 5 1.81-1.89 (dm, 1H, 
J= 15.1 Hz, NCH2CH#eqCH2N), 1.91-1.98 (dm, 1H, J= 15.0 Hz, NCH2CH#eqCH2N), 
2.20-2.32 (m, 1H, NCH2CH/faxCH2N), 2.36-2.49 (1H, m, NCH2CH#axCH2N), 2.99 (td, 
1H, / = 12.3, 3.4 Hz), 3.05 (td, 1H, / = 12.3, 3.2 Hz), 3.07-3.26 (m, 4H), 3.41 (dd, 1H, J 
= 14.2, 3.7 Hz), 3.61 (td, 1H, J= 13.6, 3.5 Hz), 3.73-3.83 (m, 2H), 3.94 (td, 1H, 7= 13.1, 
3.8 Hz), 4.40 (dd, 1H, 7= 13.4, 7.6 Hz, C#HCH=CHH), 4.51-4.62 (m, 2H), 4.65 (dd, 
1H, J= 13.4, 7.1 Hz, CH#CH=CHH), 4.93 and 5.55 (AX, 2H, J= 12.9 Hz, benzylic 
CH2), 5.24 and 5.37 (AX, 2H, J= 1.6 Hz, N2CHCHN2), 5.85 (dd, 1H, / = 10.1, 0.8 Hz, 
CH2CH=CHtfE), 5.99 (dd, 1H, J= 16.9, 1.0 Hz, CH2CH=CH#Z), 6.13-6.22 (m, 1H, 
CH2C//=CHH), 6.17 (ddt, 1H, / = 17.2, 10.0, 7.3 Hz, CH2CH=CHH), 7.91-7.95 (AA' of 
AA'XX', 2H), 8.35-8.39 (XX' of AA'XX', 2H); 13C{'H} NMR (CD3OD, 125.68 MHz) 
5 19.78 (2Q, 47.27, 47.64, 47.90, 48.09, 52.22, 52.36, 61.32, 61.97, 62.02, 62.53, 77.05 
(CH), 78.84 (CH), 124.12, 125.31 (2C), 131.15, 133.77, 136.06 (2Q, 150.99; IR (KBr) 
3404, 3106, 3056, 2981, 2946, 2914, 2852, 1606, 1518, 1346, 1123, 854, 708; 
HRFABMS, m/z (M+) exact mass for C22H33N502Br: 478.1818; Found: 478.1810 (error -
1.5 mmu/-0.7 ppm); Anal. Calcd for C22H33N502Br2: C, 47.24; H, 5.95; N, 12.52; Br, 
28.57. Found: C, 47.33; H, 5.95; N, 12.64; Br, 28.43. 
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4-(Allyl)-ll-[(4-nitrophenyl)methyl]-l,4,8,ll-
tetraazabicyclo[6.6.2]hexadecane (82). (10ba, 10ca)-Decahydro-3a-allyl-8a-[(4-
nitrophenyl)methyl]-lH,6H-3a,5a,8a,10a-tetraazapyrenium dibromide (0.0504 g, 0.0901 
mmol) (81) was added to a stirred solution of sodium cyanoborohydride (0.2260 g, 3.596 
mmol) in 4.5 mL of dry MeCN. The solution was brought to reflux and stirred under N2 
for 48 h. The solvent was removed under aspirator pressure and 7 mL of a 25% HBr 
solution was added dropwise to the residue (the mono-HCl salt was found to be insoluble 
in H2O). 2 mL of MeOH were added and the solution was made strongly basic (pH=14, 
slow addition of KOH pellets). The resulting solution was extracted with toluene (5x10 
mL), the combined organic phases were dried over anhyd Na2SC>4, the solvent was 
removed under aspirator pressure, and the residual solvent was removed under vacuum to 
yield 82 (0.0332 g, 92% yield), which solidified upon standing: mp = 58-60 °C; *H NMR 
(C6D6, 500 MHz) 8 1.25-1.51 (m, 4H), 2.12 (ddd, 1H, J= 13.4, 3.7, 2.1 Hz), 2.15-2.28 
(m, 4H), 2.28-2.58 (m, 10H), 2.71-2.86 (m, 4H), 2.86 and 3.45 (AX, 2H, J = 14.3 Hz, 
benzylic CH2), 3.11-3.20 (m, 2H), 3.27 (td, 1H, J= 12.3, 3.9 Hz), 3.64 (td, 1H, J= 11.7, 
4.2 Hz), 4.09 (td, 1H, 7= 11.6, 4.2 Hz), 5.05-5.09 (dm, 1H, J= -10 Hz, CH2CH=CH//E), 
5.12-5.18 (dm, 1H, / = -17, CH2CH=CH#Z), 5.89 (dddd, 1H,7= 17.1, 10.3, 7.8, 4.9 Hz, 
CH2C#=CHH), 7.00-7.04 (m, 2H, aromatic H), 7.87-7.90 (m, 2H, aromatic H); 13C{]H} 
NMR (C6D6, 125.68 MHz) 5 28.42, 28.71, 51.89, 51.95, 54.26, 54.70, 57.14, 57.30, 
57.74, 57.82, 57.99, 58.01, 58.31, 59.60, 116.29, 123.46 (2C), 129.34 (2Q, 137.50, 
147.36, 148.49 (Although the JH NMR did not reveal significant impurities other than 
silicon grease, C{ H} NMR showed the presence of impurities at the < 5% level); IR 
(C6D6) 3417, 2959, 2917, 2849, 2800, 1606, 1520, 1456, 1344, 1260, 1115, 1020; 
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HRFABMS, m/z (M+H+) exact mass for C22H3602N5: 402.2869; Found: 402.2885 (error 
+1.6 mmu/+ 4.1 ppm). 
4-benzyl-l,4,8,ll-tetraazabicyclo[6.6.2]hexadecyl-ll-(methanephosphonic 
acid diethyl ester) (88). Triethyl phosphite (0.0354 g, 0.213 mmol) and 
paraformaldehyde (6.4 mg, 2.5 molar equivalents of CH2O) were added to a solution of 
4-benzyl-l,4,8,ll-tetraazabicyclo[6.6.2]hexadecane (0.0450 g, 0.142 mmol) (61) in 1.0 
mL of THF (freshly distilled from benzophenone ketyl) and the mixture was stirred under 
N2 for 4 days. The solvent was removed under aspirator pressure and excess triethyl 
phosphite was removed under vacuum. The residue was dissolved in H2O (10 mL), and 
the solution was made strongly basic (pH=14, slow addition of KOH pellets). The 
resulting solution was extracted with toluene (5x10 mL), the combined organic phases 
were dried over anhyd Na2S04, the solvent was removed under aspirator pressure, and 
the residual solvent was removed under vacuum to yield 0.0564 g (85%) of product as 
clear oil 88: JH NMR (CDC13, 400 MHz) 8 1.32 (t, 3H, 7 = 7.0 Hz, P(0)OCH2C#3), 1-33 
(t, 3H,7 = 7.0Hz,P(O)OCH2C7/3), 1.29-1.50 (m, 3H), 1.51-1.63 (m, 1H), 2.17-2.31 (m, 
2H), 2.32-2.50 (m, 9H), 2.60-2.81 (m, 4H), 2.82-2.95 (m, 3H), 3.09-3.27 (m, 2H), 3.15 
and 3.79 (AX, 2H, 7 = 13.4 Hz, benzylic CHZ), 3.76-3.86 (m, 1H), 3.92 (td-like, 1H, 7 = 
~ 11.5, 4.2 Hz), 4.05-4.71 (m, 4H, P(0)C//2CH3), 7.18-7.24 (m, 1H, aromatic H), 7.26-
7.35 (m, 4H, aromatic H)\ nC{xtt] NMR (CDC13, 125.68 MHz) 8 16.53 (d, 37PC = 5.8 
Hz, P(0)OCH2CH3), 16.58 (d, 37PC = 5.8 Hz, P(0)OCH2CH3, 16.53 and 16.58 overlap to 
give the appearance of a triplet), 28.02, 28.15, 50.33 (d, XJ?C = 162.2 Hz, NCH2P), 51.10, 
51.79, 54.35, 55.86 (d, 37PC = 15.4 Hz), 56.60, 56.76, 56.95, 57.23, 57.46, 59.92, 60.16, 
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61.28 (d, 27pC = 6.7 Hz, P(0)OCH2CH3), 61.51 (d, 27PC = 6.7 Hz, P(0)OCH2CH3), 
126.49, 127.98 (2C), 128.93 (2C), 140.95; ^Pl 'H} NMR (CDC13, 161.83 MHz) 8 27.24; 
IR (thin film) 3449, 2978, 2906, 2796, 1452, 1364, 1244, 1124, 1056, 1028, 962; 
HRFABMS, m/z (M+H)+ exact mass calcd for C24H44N4O3P: 467.3151; Found: 467.3135 
(error -1.6 mmu/ -3.4 ppm). 
4-benzyI-1,4,8,11 -tetraazabicy clo [6.6.2] hexadecyl-1 l-(methanephosphonic 
acid) (89). 4-benzyl-l,4,8,l l-tetraazabicyclo[6.6.2]hexadecyl-l l-(methanephosphonic 
acid diethyl ester) (88) (0.0511 g, 0.101 mmol) was dissolved in 4 mL of a 6M HC1 
solution prepared from TraceMetal™ grade hydrochloric acid (Fisher Scientific), and 
refluxed under N2 for 1 d. The solvent was removed and the crude solid was dissolved in 
10 mL H2O. This was repeated three times. Residual solvent was removed from the 
yellow solid under vacuum (0.0576 g, 88% yield); *H NMR (D20, 500 MHz, internal ref 
Ci/3CN set to 5 2.06) 8 1.75-1.86 (tm-like, 2H, J= -17.0 Hz), 2.21-2.33 (qm-like, 1H, J 
= -13 Hz), 2.38-2.50 (qm-like, 1H, / = -13 Hz), 2.56-2.70 (m, 3H), 2.72-2.78 (dm, 1H, J 
= 14.2 Hz), 2.88-2.95 (m, 1H), 2.96-3.10 (m, 3H), 3.11-3.40 (m, 8H), 3.41-3.54 (m, 3H), 
3.55-3.66 (m, 2H), 3.67-3.79 (m, 2H), 4.53 and 4.80 (AX, 2H, J = 13.9 Hz, benzylic 
CH2), 7.48-7.61 (m, 5H, aromatic H); ^Cj'H} NMR (D20, 100.52 MHz, internal ref 
CH3CN set to 8 1.47) 8 20.12 (2Q, 45.02, 48.38 49.04, 50.60 (2Q, 51.70 (d, 2JPC = 143.0 
Hz, NCH2P), 54.30, 55.35, 55.48, 57.67, 58.55, 58.89, 127.28, 129.79 (2Q, 131.02, 
133.05 (2Q; ^Pl 'H} NMR (D20, 161.83) 8 12.76 (major), 23.26 (minor) (The 'H, 
31P{1H} spectra and analysis indicated the presence of 0.08 ± 0.01 molar equivalents of 
4-benzyl-1,4,8,1 l-tetraazabicyclo[6.6.2]hexadecyl-l l-(methanephosphonic acid) 
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trihydrochloride relative to 1.0 molar equivalents of 89); IR (KBr) 3376, 3963, 2858, 
1634, 1494, 1456, 1208, 1096, 1044, 1002, 931, 733, 707; HRFABMS, m/z (M+H)+ 
exact mass calcd for C20H36N4O3P: 411.2525; Found: 411.2534 (error +0.9 mmu/ +2.1 
ppm); Anal. Calcd for Q o H s v N ^ P C l ^ Q o H s s N ^ C ^ o . o s t H Q ^ ^ ^ O ) ^ : C, 43.54; 
H, 7.77; N 10.15; CI, 17.13. Found: C, 43.18; H, 7.70; N, 10.38; CI, 17.13. 
(10ba,10ca)-Decahydro-3a-[(4-methoxyphenyl)methyl]-lH,6H-3a,5a,8a,10a-
tetraazapyrenium bromide (920.5H2O0.2CH3Ph). 4-Methoxybenzyl bromide (0.1387 
g, 0.6898 mmol) was added to a solution of 31 (0.1180 g, 0.5307 mmol) in 4 mL of 
toluene and stirred for 3 d under N2. The resultant mixture was vacuum filtered and the 
crude white solids were washed with 5 mL toluene, 10 mL of Et20 and 1.5 mL of ice 
cold MeCN and put under vacuum for 1 d to yield 0.1495 g (62% yield) of 
920.5H2O0.2CH3Ph: mp = 155-160 °C (dec); 2H NMR (D20, 500 MHz, internal ref 
CH3CN set to 5 2.06) 5 1.43-1.49 (dm, 1H, J= 14.2 Hz, NCH2CH#eqCH2N), 1.74-1.81 
(dm, 1H, J= 13.9 Hz, NCH2CHtfeqCH2N), 2.11-2.30 (m, 3H), 2.43-2.50 (m, 2H), 2.62 
(td, 1H, J= 12.3, 3.4 Hz), 2.97-3.13 (m, 7H), 3.22 (td, 1H, J= 13.6, 3.0 Hz), 3.28-3.34 
(dm, 1H, J= 12.9 Hz), 3.46-3.55 (m, 2H), 3.62-3.65 (s-like, 1H, CH), 3.88, (s, 3H, 
OC#3), 4.16 (td, 1H, J= 13.2, 3.9 Hz), 4.34 (d, 1H, J= 2.2 Hz, CH), 4.73 and 4.99 (AX, 
2H, / = 13.6 Hz), 7.09-7.13 (XX' of AA'XX', 2H), 7.46-7.50 (AA' of AA'XX', 2H); 
^C^H} NMR (D20, 125.68 MHz, internal ref CH3CN set to 5 1.47) 5 18.57, 18.95, 
42.55, 47.19, 48.92, 51.90, 52.58, 56.13, 60.12, 62.87, 70.13, 82.22, 115.28 (2Q, 118.40, 
135.43 (2C), 161.45; (The !H spectrum indicated the presence of 16% (+/- 4%) residual 
toluene.) IR (KBr) 3410, 3007, 2989, 2940, 2867, 2836, 2778, 1612, 1518, 1437, 1275, 
133 
1264, 1251, 1187; HRFABMS, m/z (M+) exact mass for C20H3iN4O: 343.2498; Found: 
343.2505 (error +0.7 mmu/+2.0 ppm); Anal. Calcd for C2oH3iN40Br(H20)o.5-(CH3Ph)o.2: 
C, 57.01; H, 7.51; N 12.43; Br, 17.72. Found: C, 57.42; H, 7.45; N, 12.28; Br, 17.31. 
4-(Allyl)-ll-[(4-aminophenyl)methyl]-l,4,8,ll-
tetraazabicyclo[6.6.2]hexadecane (93). 4-(Allyl)-l l-[(4-nitrophenyl)methyl]-l,4,8,l 1-
tetraazabicyclo[6.6.2]hexadecane (0.0707 g, 0.1761 mmol) (82) and mossy tin (0.1045 g, 
0.8803 mmol) were heated in 6M HC1 (6 mL) with a steam bath for 3 h under N2. The 
solvent was removed under reduced pressure and the crude solid was dissolved in H2O 
and made strongly basic (pH=14, slow addition of KOH pellets). The resulting solution 
was extracted with toluene (5x10 mL), the combined organic phases were dried over 
anhyd Na2SC>4, the solvent was removed under aspirator pressure, and the residual 
solvent was removed under vacuum to yield product 93 as a clear oil. (0.0510 g, 78%): 
2H NMR (C6D6, 500 MHz) 5 1.27-1.48 (m, 3H), 1.54-1.62 (m, 1H), 2.20-2.28 (m, 2H), 
2.35 (ddd, 1H, J= 13.7, 6.1, 2.0 Hz), 2.38-2.46 (m, 5H), 2.47-2.61 (m, 5H), 2.68-2.84 
(m, 3H), 2.80 (br s, 2H, NH2), 3.00 (ddd, 1H, J= 13.0, 12.1, 4.0 Hz), 3.06 (d, 2H, J = 
12.9 Hz, benzylic CHH), 3.16 (ddt, 1H, J= 13.92, 4.7, 1.5 Hz), 3.27 (td, 1H, J= 12.4, 3.8 
Hz), 3.38 (td, 1H, J = 12.3, 3.9 Hz), 3.76 (d, 1H, J = 12.9 Hz, benzylic CHH), 3.77 (td, 
1H, J= 11.7, 4.4 Hz), 4.01 (td, 1H, J= 11.7, 4.0 Hz), 5.01-5.05 (dm, 1H, J= ~ 10.1 Hz, 
CH2CH=CH#E), 5.10-5.16 (dm, 1H, / = ~ 17.1 Hz, CH2CH=CH//Z), 5.88 (dddd, 1H, J = 
17.3, 10.0, 7.6, 4.9 Hz, CH2C#=CHH), 6.38-6.41 (XX' of AA'XX', 2H), 7.18-7.22 (AA' 
of AA'XX', 2H); 13C{'H} NMR (C6D6, 125.68 MHz) 5 28.48, 28.79, 51.82, 52.07, 
54.26, 54.83, 57.22, 57.34, 57.82 (2Q, 57.86, 58.06, 58.28, 59.85, 114.85 (2Q, 116.04, 
134 
130.28 (2C), 130.50, 137.71, 145.90; IR (thin film) 3451, 3363, 3217, 3073, 2911, 2793, 
1622, 1516, 1458, 1363, 1279, 1126, 1060, 999, 916; HRFABMS, m/z (M+H+) exact 
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